[{"article": "Partial replacements, also known as unicompartmental replacements, are suitable for people who have arthritis in just one side of the knee, usually the inner.\nThose surgeons who carried out more partial replacements had better outcomes from them than surgeons who did fewer.\nMany more people facing surgery for knee problems would be better off with a partial rather than total knee replacement, which should allow them to recover faster, say experts.\n\u201cThis has allowed us to provide strong proof that partial knee replacements are both better for patients and cheaper for the NHS.\u201d\n\nWhether people had a partial or total replacement varied by surgeon, as did the success of the operation, the researchers discovered.\nResearchers from the Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences (NDORMS) publishing in the BMJ Open journal found that the less invasive procedure was being used less than it could be.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "What risks are associated with getting either surgery? The story simply doesn\u2019t tell us.\nWhen considering harms, one needs to keep in mind the side effects of surgery, the recovery from surgery, how they function after recovery and then whether there are differences in the need for subsequent procedures.", "answer": 0}, {"article": "Melanie Ashton continued, \"We found that people who had a better-quality diet, a diet with anti-inflammatory properties, or a lower BMI, showed better response to add-on nutraceutical treatment than did those who reported a low-quality diet, or a diet including foods that promote inflammation, or who were overweight.\nParticipants received the study medication in addition to any stable treatments they were already receiving.\nNow a group of Australian, German and American scientists have shown those who have a high quality diet, a less inflammatory diet, and/or a low BMI (Body Mass Index) may respond better to an add-on nutraceutical treatment provided as part of a clinical trial.\n\"If we can confirm these results, then it's good news for people with Bipolar Disorder, as there is a great need for better treatments for the depressive phase of Bipolar Disorder\" said lead researcher Melanie Ashton of Deakin University in Australia.\nThe fact that there are two opposite sets of symptoms means that finding an effective treatment is difficult.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The harms of NAC, according to Memorial Sloan Kettering Cancer Center, listed here,\u00a0are not mentioned.", "answer": 0}, {"article": "After her mother unexpectedly died from a tear in the wall of her heart at age 63, Patricia Walters talked to her doctor, Leslie Cho, about how to better monitor her own heart health.\n\nPregnant at the time with her own daughter, Ms. Walters, now 46, says she was \"a nervous wreck\" worrying that she, too, might face serious cardiac risk.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "This is another example of a story about a screening test that didn\u2019t provide any information about the potential harms associated.\u00a0 While there are those who believe that the hs-CRP alone warrants drug treatment, this is not a universally held view.\u00a0 While the statins are relatively safe, they are not without potential side effects and are relatively expensive for the twenty plus years of potentially unnecessary treatment", "answer": 0}, {"article": "\"The disc is made up of mostly water, and it get tears in it.\nHe says his intent was not to put some orthopedic surgeons out of business.\nBut no matter where you live, surgery is not necessarily the best or only option.\nWhether you have surgery often depends on where you live and what doctor you see.\n\"However what was really interesting is that patients who decided not to have surgery who could wait also did very well.\"\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Although harms of surgery are rare, the story should have mentioned\u00a0the possible complications such as wound infection or need for reoperation. The story also does not address potential harms of non-operative treatment, such as permanent nerve damage from cauda equina syndrome.", "answer": 0}, {"article": "\"That's where the money is,\" Malmgren said.\nHowever, she said, the study does not provide support for all women aged 40 to 49 to have routine mammograms.\nMalmgren, a breast cancer survivor, says more focus should be placed on the benefit of early diagnosis, because it often means less treatment is needed.\n\"The data from randomized trials and modeling show there is a very modest improvement in mortality with mammograms from 40 to 49,\" she said.\nIn 2009, the U.S. Preventive Services Task Force issued mammogram recommendations.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story did discuss why mammography in younger women is not always beneficial and described several of the harms that the US Preventive Services Task Force discussed.", "answer": 1}, {"article": "Some critics say Medicare would not be doing a review of a drug already approved by the F.D.A.\nHowever, the panel gave very low scores to evidence that the drug would help prostate cancer patients other than the type who participated in the clinical trial, which were men with advanced cancer, but no or minimal symptoms.\nThe drug was approved by the Food and Drug Administration in April after a clinical trial showed that those getting the drug had a median survival of about 26 months, four months longer than those in a control group.\nThat could give Medicare grounds for denying payment when the drug is used off-label, as cancer drugs often are.\nHowever, Dr. Smith said he doubted that was the case because there were signs the drug also controlled tumors outside the bones.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There was no mention of any possible harms associated with XL184 even though information available from the company indicates that fatigue, diarrhea, nausea, high blood pressure, rash, \u2018hand-foot syndrome\u2019, and cough have been seen in the small cohort of men treated with XL 184 for 6 weeks or more.\nAnd while indicating that Provenge helped men with advanced prostate cancer live 4 months longer, there was no mention of any harms associated with use of this drug.", "answer": 0}, {"article": "Amgen reported just $40 million in third-quarter sales.\nThe company said Repatha would be well on its way to becoming a $1 billion seller if all prescriptions written had been filled.\nNo new safety problems cropped up in the 27,500 patient study called Fourier, Amgen said.\n\u201cThese results show unequivocally the connection between lowering LDL cholesterol with Repatha and cardiovascular risk reduction, even in a population already treated with optimized statin therapy,\u201d Amgen research chief Sean Harper said in a statement.\nThe primary goal also included need for a new artery-clearing procedure and hospitalization for angina.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story says that \u201cNo new safety problems cropped up in the 27,500 patient study.\u201d The\u00a0news release issued by the drug manufacturer Amgen about the same clinical trial revealed what was not known about potential harms for the use of the drug, as well as a number of contraindications, adverse events and harms that arose during the trial. The story would have done well to reference these.\u00a0", "answer": 0}, {"article": "\u2022 Gaziano TA, Fonarow GC, et al.\n\"In addition to survival benefits, the study also recognizes other treatment effects of Entresto, particularly in reducing HF hospitalizations.1 Coupled with the recent Class I recommendation, the strongest endorsement, in the focused update to the US HF Guideline,2 these findings underscore the potential of Entresto as a standard therapy for chronic HFrEF patients.\"\nPatients should either take Entresto or breastfeed.\nPatients are not to take Entresto for at least 36 hours before or after they take an ACE inhibitor medicine.\nPatients are encouraged to report negative side effects of prescription drugs to the FDA.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release includes extensive information on harms, including this summary of side effects: \u201cEntresto may cause serious side effects including serious allergic reactions causing swelling of the face, lips, tongue, and throat (angioedema) that may cause trouble breathing and death.\u201d", "answer": 1}, {"article": "But in leg arteries, the active flexing can cause a stent to break.\nThomas Gunderson, a senior analyst for Piper Jaffray & Co., said the Covidien study could lead to greater use of atherectomy and a bigger market.\nThe study is the largest to look at the effectiveness of atherectomy, Covidien said, and enrolled 800 patients at 47 centers in the U.S. and Europe.\nThe company says this is a major step forward in treating PAD because, unlike stents, atherectomy \"leaves no metal behind.\"\nAlso of note, Garcia said, is that the procedure proved as effective at improving blood flow for patients with diabetes as those without diabetes.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "No discussion of potential harms from the approach.\nAny newly introduced device used in an interventional procedure has inherent risks both from the device itself and from the operator.\u00a0 The procedural complication rate is an important consideration especially since the new device is said to be as good as existing treatmemts.", "answer": 0}, {"article": "Nuts, seeds, whole grains, legumes and even dark chocolate are high in fiber\u2014as are vegetables.\n\u201cThat means if you\u2019re not eating dietary fiber, your immune system may be existing in kind of a simmering pro-inflammatory state,\u201d he says\u2014the very state that predisposes us to different Western diseases.\nYou can increase these bacterial populations by eating fiber, Cani\u2019s research suggests, which acts as a prebiotic in the gut and has a beneficial effect on some bacteria.\nLoading up on fiber-fortified processed foods isn\u2019t likely a good way to increase the kind of fiber that benefits the gut.\nSonnenburg was not involved with this study, but research from his lab also suggests that fiber plays a big role in promoting good bacteria.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does not discuss risks associated with increasing your intake of dietary fiber. However, that\u2019s likely because there are few (if any) health risks associated with increasing fiber in your diet. We\u2019ll rate this Not Applicable.", "answer": 2}, {"article": "The full article, \"OFF!\nClip-On caused high mosquito mortality and knockdown rates up to 0.3 meters from the device, enough to protect a single person wearing the device.\nA product called the OFF!\u00ae Clip-On\u2122 repellent device could be an effective tool for preventing bites from the Aedes aegypti mosquito -- the primary vector of Zika, chikungunya, dengue, and yellow fever -- according to an article in the Journal of Medical Entomology.\nThe effectiveness of the device came as a pleasant surprise to the researchers.\nSkepticism is inherent to the trade.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release doesn\u2019t give even a brief nod to harms. In addition to questions about the product\u2019s effectiveness, Consumer Reports pointed out that the active ingredient in the device is metofluthrin, a neurotoxin.\n\u201cThe label says, \u201cAvoid breathing vapor,\u201d but it\u2019s hard to imagine how, with the repellent swirling around you,\u201d according to Consumer Reports.\nThis seems to\u00a0be a critical oversight as the vapors will be inhaled by the people who are supposedly being protected as well as the mosquito.\nJohnson & Johnson\u2019s product website has a list of warnings buried under the topic, \u201cPrecautionary Statements.\u201d\n\u201cHAZARDS TO HUMANS AND DOMESTIC ANIMALS: CAUTION: Harmful if swallowed, inhaled, or absorbed through the skin. Avoid contacting skin, eyes, or clothing with treated refill cloth. Avoid breathing vapor. Wash thoroughly with soap and water after handling and before eating, drinking, chewing gum, or using tobacco. Remove and wash contaminated clothing before reuse. Store away from food, beverages and pet food. Do not use indoors or in enclosed spaces. Do not touch unit with metal instruments or wet hands. Do not allow materials of any kind to cover the unit while it is in use. Replace refill only when unit is off.\u201d ", "answer": 0}, {"article": "CT scanning uses X-rays and computers to produce a clearer image than traditional X-ray techniques, but CT also uses higher radiation doses to generate those images.\nThat\u2019s consistent with the findings of the National Lung Screening Trial in the U.S., which in November released data \u2014 published online in the New England Journal of Medicine last week \u2014 showing that 20 percent fewer middle-aged heavy smokers died of lung cancer when they were screened annually with a CT scan compared to a standard, less detailed chest X-ray.\nDr. Christine Berg, one of the leaders of the U.S. screening studies, said that generally about a quarter of chest CT scans show some kind of abnormality \u2014 but 96 percent of those abnormal scans turn out not to be lung cancer.\nBut experts say the findings likely don\u2019t apply in non-Asian countries, where the majority of all lung cancers are found in people who smoke \u2014 and where using computed tomography (CT) scans to screen for lung cancer in smokers has recently been a controversial topic.\nThe U.S. Preventive Services Task Force, a federally-supported expert panel, has said there isn\u2019t enough evidence for it to recommend screening for lung cancer in symptom-free people using CT scans or other methods.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "No quantification of what may have been observed in the study, but adequate general caveats were given:\n\u201c\u2026 each scan exposes a person to radiation, which also slightly increases cancer risks over time with repeated scans.\nAnd screening comes with an inherent risk of false-positives \u2014 scans which suggest a lung cancer that turns out not to be there.\nDr. Christine Berg, one of the leaders of the U.S. screening studies, said that generally about a quarter of chest CT scans show some kind of abnormality \u2014 but 96 percent of those abnormal scans turn out not to be lung cancer. While doctors ruled out cancer, those patients would have undergone further tests, sometimes including biopsies, which can cause complications including infection and bleeding.\nAnd for some patients, \u201cif you really weren\u2019t going to benefit from the screening\u2026that complication is something you may not have faced,\u201d Berg said. \u201cThose are some of the things I worry about.\u201d", "answer": 1}, {"article": "\u201cIt may provide more of a one-stop shop.\u201d\nAn experimental drug can reduce abdominal pain and increase bowel movements in people with irritable bowel syndrome, a condition that affects millions of Americans, the drug\u2019s developer said Monday.\nThe developer, Ironwood Pharmaceuticals, said the drug, linaclotide, met all the goals in the first late-stage trial testing it as a treatment for the type of irritable bowel syndrome accompanied by constipation.\nAbout one-third of the cases involve constipation, another third diarrhea and the rest both constipation and diarrhea, according to Dr. William D. Chey, an expert at the University of Michigan.\nLaxatives can relieve the constipation but often do not help with the pain, said Dr. Chey, who is a consultant to Ironwood.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "", "answer": 1}, {"article": "Learn more about type 1 diabetes from the American Diabetes Association.\nHow the highly hydrolyzed formula might reduce the risk of developing diabetes-predictive antibodies is unknown, but the researchers speculated that it might contribute to reduced gut permeability or changes in gut microflora, among other things.\nThe current study was randomized and double-blind (meaning neither the parents nor the researchers knew who was getting what), and compared regular baby formula to one that was made easier for babies to digest because the proteins were broken down (extensively hydrolyzed).\nPeople who have two or more type 1 antibodies have between a 50 and 100 percent risk of developing type 1 diabetes, according to background information in the study.\nBoth Lee and Harlan stressed that there is currently no definitive evidence to suggest that the use of standard cow's milk formulas leads to an increased incidence of diabetes compared to breastfeeding.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There are no real \u201charms\u201d with using formula, either cow\u2019s milk formula or extensively hydrolyzed formula.\u00a0 It appears the latter may be a better choice because there are fewer proteins broken down for digestion.", "answer": 1}, {"article": "I'll keep going as long as I can enjoy what's to be enjoyed.\u201d\nThe study shed new light on a question of prime interest to cardiologists: whether the injected stem cells actually transformed themselves into heart muscle, or improved heart function in some other way.\nThe trial was primarily about the safety of the procedure, and all eight patients came through without significant side effects, he said.\nBy implication, it almost certainly improves the patient's health, although that was not directly measured in the small, early study.\nIt worked in patients such as Eaton, whose heart attack was 11 years ago, Hare said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "As the story indicates, none of the participants experienced \u201csignificant side effects,\u201d but it would have been helpful to define what \u201csignificant\u201d means. For example, the study authors define serious side effects as death, non-fatal heart attack or stroke, hospitalization for worsening heart failure, blood flow compromise, or atrial fibrillation. While none of the subjects experienced these more serious side effects, the study did report that people had other issues such as premature ventricular complex, increased heart rhythm, and fluid buildup around the heart. Even when describing a study this small, the story should quantify the harms.\n", "answer": 0}, {"article": "The FASEB Journal, April 2017, vol.\nMore research is needed to determine if compounds in red raspberries play a role in human cardiometabolic pathways.\nBecause this study was limited to three meals, further research is needed to determine the factors that influenced outcomes.\nFurther research is needed to support the hypothesis that the consumption of raspberry puree may change the composition of the gut microbiota.\nFollow-up research explored the potential relationship between feeding freeze-dried whole raspberry powder and cardiometabolic risk in obesity prone rats.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The news release didn\u2019t mention any harms from eating raspberries, but that may be because there are no documented harms. Unless you are allergic, it seems safe to eat raspberries in moderation like any other fruit or vegetable.\nStill, out of eight studies it\u2019s reasonable to think one of them examined potential harms or made a statement about the lack of harms. Even noting \u201cthere were no observed harms\u201d would be helpful.", "answer": 2}, {"article": "Hernias occur when part of an internal organ, such as the intestines, bulges out through muscle.\nThe traditional approach may be appropriate when it's too risky to place patients under general anesthesia, Brunt said, such as in elderly patients and those with multiple health problems.\nThe other approach is older and is performed through a 2- to 2.5-inch incision in the groin, Brunt said.\nRecurrences decreased to 0.5 percent and 4 percent, respectively, if the procedures were performed by experienced surgeons.\nThe procedures are designed to reduce the bulge of the hernia and make a patch so it doesn't protrude again.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story explained that the less invasive surgery might not be appropriate for patients who face increased risk from general anesthesia, including the elderly or those with multiple health problems. We\u2019ll rule this satisfactory, but the story could also have noted that the less invasive procedure produced a higher rate of operative complications than the standard procedure (6% vs. 2%).", "answer": 1}, {"article": "Results are scheduled to be presented Sunday at the annual meeting of the Association for Research in Vision and Ophthalmology in Fort Lauderdale, Fla.\nIf this finding is considered valid, it could render the results of the National Eye Institute trial somewhat moot by raising safety questions about Avastin.\nA far less expensive alternative proved roughly as effective as Genentech\u2019s costly drug Lucentis in preserving or improving vision in elderly people with a common eye disease, according to two people familiar with the results of a closely watched clinical trial.\nHowever, experts say that with only 1,200 patients, the trial will be able to detect only major differences in safety.\nYet Medicare paid only $20 million for the Avastin compared to $537 million for the smaller number of Lucentis injections.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Potential harms in the NEI trial couldn\u2019t be quantified, as results weren\u2019t available. That may\u2019ve been excusable if the story had acknowledged that more information \u2014 potentially extremely important \u2014 would be available upon publication. We give it credit for noting that the trial\u2019s size could only detect major differences in safety, but it doesn\u2019t discuss whether any such differences were observed or might be; are we to assume from their silence that the two informants blessed the safety? Given the 57% increase in hemorrhagic stroke risk mentioned from the Genentech trial, one would think a major difference is a live concern, and the outcome was worth mentioning even qualitatively for balance.\n\n \nThe relative risks of the Roche Genentech study are presented, as well as a number of grains of salt.\u00a0 We wish the Times had given a bit more information as journalist Jim Edwards, in his Placebo Effect blog, wrote:\n", "answer": 0}, {"article": "Aug. 10, 2011 -- Two of three patients dying of chronic lymphocytic leukemia (CLL) appear cured and a third is in partial remission after infusions of genetically engineered T cells.\nBut the therapy worked vastly better than University of Pennsylvania researchers David L. Porter, MD, Carl H. June, MD, and colleagues had dared to hope.\nThis may be why relatively small infusions of the CAR T cells had such a profound effect.\nWhat's new about the current treatment is the addition of a special signaling molecule called 4-1BB.\nThe treatment success came in a pilot study that was only meant to find out whether the treatment was safe, and to determine the right dose to use in later studies.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "In a three-person study, it\u2019s difficult to quantify harms or benefits beyond just describing what happened to each patient. The WebMD story, though, did a better job of presenting the very real side effects of the study, even showing that the treatments for the side effects may have hampered the effectiveness of the cancer therapy. \u201cThe treatment was not a walk in the park for patients. One of the three patients became so ill from the treatment that steroids were needed to relieve his symptoms. The steroid rescue may be why this patient had only a partial remission.\u201d", "answer": 1}, {"article": "And for the test to be useful, \"you've got to find cancer that's going to otherwise be lethal, and not cancer that would otherwise be destined to do nothing,\" Prasad says.\nOf course, the ultimate goal of this test is to find cancer in people who haven't already been diagnosed.\nAn effective screening test would hold lots of potential for cancer patients, Prasad says.\nThen the researchers will need to show that the rate of false alarms remains very low, otherwise people will be sent on needless and expensive medical odysseys.\nFirst, he notes, the Hopkins team will need to demonstrate that the test will be useful in patients without symptoms.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does an excellent job of finding an independent source who explains that one of the potential risks of cancer screening tests is either identifying cancers that are not there, or are benign, and can lead to \u201cpointless and potentially dangerous treatments.\u201d\nThe opposite harm is also mentioned; that is, a screening test that erroneously gives a negative result, leading providers to falsely reassure a patient\u00a0that cancer is not there.", "answer": 1}, {"article": "[Seriously, why does anyone under 18 still have access to a tanning bed?]\nThat said, the agency warned Wednesday that the new drug can cause serious side effects, including trouble swallowing or nerve damage to the jaw that can result in an uneven smile or muscle weakness in the face.\nThe FDA warned, however, that the treatment also has the potential to kill other types of cells, such as skin cells, if injected improperly.\nPatients can receive as many as 50 injections of the drug in a single treatment, the agency said, with up to six treatments administered no less than a month apart.\nKeith Leonard, chief executive of Kythera, the California-based firm that developed Kybella, said at a conference last month that he believes the new treatment \"can drive a very large market and leave very satisfied patients.\"\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story notes the FDA\u2019s warning that \u201cthe new drug can cause serious side effects, including trouble swallowing or\u00a0nerve damage to the jaw that can result in an uneven smile or muscle weakness in the face.\u201d It then lists side effects, which\u00a0included \u201cswelling, bruising, pain, numbness, redness and areas of hardness in the vicinity of the injection.\u201d\nThis is sufficient for a Satisfactory rating. But the story could have could have mentioned a key concern cited by the FDA in the second sentence of its news release: \u201cUsing Kybella for the treatment of fat outside of the submental area is not approved and is not recommended.\u201d A reworded version of that warning is repeated twice more in the news release.", "answer": 1}, {"article": "\"If you have your choice, you want to get poked with a needle or you want to try this?\nGomaa's hope is that vaccine patches will cost less than vaccinations do now.\nA number of the people in the flu patch study applied it to themselves.\nAnd the patch can be administered by people who aren't trained health professionals.\nBut one version developed by Georgia Tech's Laboratory for Drug Delivery showed promising results in its first human clinical trial, according to a study published in The Lancet in June.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The focus of the article headline is convenience and comfort. It follows through on that focus by doing a fairly good job of addressing side effects of the various delivery mechanisms, though again, the information is somewhat uneven. The most thorough description of harms is provided in the flu patch section of the story, where we learn that participants in the clinical trial had\u00a0some redness, itching and tenderness but no serious side effects. About the jet injection we learn it is much less painful than when it was used for smallpox vaccination back in the 1960s. The story also informs us that nozzles are changed between patients so the former problem with infection from using the same equipment has been resolved. No other harms (like the redness and itching associated with the patch, for example) are mentioned. The section of the story on nasal spray vaccines is short, and it doesn\u2019t include any information about side effects or harms.", "answer": 1}, {"article": "It takes an hour or less,\" he said.\n\"That risk is much higher than we initially thought,\" said study co-author Dr. Andrew Krahn of the London Health Sciences Center in Ontario.\nSix percent of the 533 patients who decided to have their recalled defibrillators replaced over a 12-month period suffered major complications, including two deaths, according to a study published in Wednesday's Journal of the American Medical Association.\nIn contrast, the risk of failure among recently recalled defibrillators has been estimated by the manufacturers at just 0.009 percent to 2.6 percent.\nAll the patients had devices that were recalled by manufacturers, Canada's national health system or the FDA.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Article lists all harms noted in the study, both serious and less serious, and explains that the authors did not track what happened to patients who did not have devices replaced. The story did note that untreated abnormal rhythms can be \u2018potentially deadly\u2019. However, the article notes that manufacturers estimate the rate of failure for devices that are subject to safety advisories, and also lists both the minor and serious things that can go wrong with them. One big issue that is not dealt with well is that the initial decision threshold for putting these devices in place may change now, based on the higher failure rates and the higher rates of complications with replacement.", "answer": 1}, {"article": "\"There are a number of components that lead to a man having normal fertility potential,\" Brannigan said.\nAt-home sperm tests are a fairly new idea, Imler said, but SpermCheck Fertility is not the first one.\nMen tend to think they're perfectly healthy, especially when it comes to their sexuality, APA's Imler said.\nThe male reproductive system should not be oversimplified, Brannigan said.\nSpermCheck Fertility is the only FDA-approved home sperm test currently on the market and available in retail stores, Lopez said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story points out that the test might lull men into a false sense that they have no fertility problems. \u201cA positive result from the SpermCheck Fertility test could give men a false sense that everything is all right, APA\u2019s Imler said.\u00a0It might even cause some men to delay a necessary doctor\u2019s evaluation, Brannigan said.\u201d\nThe story waited a little too long to make this point, but we were glad to see it included.", "answer": 1}, {"article": "Oxidative stress refers to a situation where levels of reactive oxygen species or \u201cfree radicals\u201d \u2014 damaging byproducts of energy use in cells \u2014 rise beyond the body\u2019s capacity to neutralize them.\n\u201cBut,\u201d she added, \u201cit should be noted that yoga controlled the blood sugar levels which otherwise rose in the control group.\u201d\n\nIn addition to that, the study found, signs of so-called oxidative stress declined in the yoga group.\nThey found that, on average, the yoga group\u2019s levels of the chemicals dipped by 20 percent.\nThe yoga used in this study was a gentle form, Hegde said, and parts of the practice were adapted for people who had additional health problems; certain poses were avoided in people who had heart disease, for example.\nThe study, of 123 middle-aged and older adults, found that those who added yoga classes to standard diabetes care shed a handful of pounds over three months.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "This does not actually address what is known about any potential harms of the type of yoga reported on. \u00a0The story could have mentioned that the study mentioned that there were no adverse events reported during the 3 months of yoga classes but that about 5% of those assigned to the yoga classes dropped out and were not included in the final analysis.", "answer": 0}, {"article": "\"They got it completely wrong,\" he said.\nInitially regarded as a high-tech novelty, the new procedure has in recent months received key endorsements as a first-line screening test from influential medical groups, notably the American Cancer Society, after several large studies found it to be effective at finding large polyps.\nLike other mass screening tests including mammography, the overarching question is whether the benefits of virtual colonoscopy outweigh the risks.\nIts supporters, many of them radiologists who read CT scans, tout virtual colonoscopy as a more palatable alternative that has the potential to boost low rates of screening.\nCurrently about half of Americans over 50 are screened for the disease; some shun traditional colonoscopy, which is the only way to remove polyps, because of its invasive nature.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does a good job of describing the potential harms of the procedure, including radiation exposure (250 times that of a chest x-ray), missing small or flat polyps, and incidental findings that might lead to unnecessary treatments. The story could have also emphasized that about 20% will require a follow-up colonoscopy because of suspicious findings.", "answer": 1}, {"article": "CHICAGO (Reuters) - Two new drugs using very different scientific approaches can extend survival among patients with the deadliest form of skin cancer, offering the first new hope for real progress in many years.\nISI Group analyst Mark Schoenebaum said although the vemurafenib results look the most encouraging, the findings are unlikely to make a difference for current sales estimates, since virtually all eligible patients will be treated with both drugs, either in sequence or in combination.\nBristol-Myers\u2019 Yervoy was approved in March for patients with inoperable or metastatic melanoma, based on a previous study which showed the drug given alone extended survival by four months in patients who had failed other treatments.\n\u201cWe worried a lot that chemotherapy could be immunosuppressive,\u201d Wolchok said, noting that that might explain why the average survival benefit was two months instead of four.\nShe and others expect vemurafenib to be approved this year.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story mentioned only skin rashes and joint pain from vemurafenib, but the story didn\u2019t explain, as the New York Times did, that 38% of trial participants had to stop taking the drug or lower the dose because of side effects. And there wasn\u2019t a word about side effects from ipilimumab.", "answer": 0}, {"article": "Platelet-rich plasma (PRP) is blood that has been spun in a centrifuge to separate the blood cells.\n\u201cPRP is probably the best treatment for chronic refractory lateral epicondylitis if it is used after classical types of treatment like rest, braces, nonsteroidal anti inflammatory drugs, cortisone injections or physiotherapy have all failed,\u201d Thanasas said.\n\u201cThere is now a solution for patients suffering from unrelenting \u2018tennis elbow,\u2019\u201d said Christos Thanasas from Henry Dunant Hospital, Athens, who led the study.\n\u201cWhole blood treatment is a god alternative in remote areas or in health systems that do not support financially the use of PRP,\u201d he told Reuters Health in an email.\nNEW YORK (Reuters) - Blood injections, especially of platelet-rich blood, into the affected area help relieve the pain associated with \u201ctennis elbow\u201d where other treatment methods have failed, according to a Greek study.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There\u2019s no attempt to quantify harms here. After reading this story, one might assume that there\u2019s nothing risky about this procedure.", "answer": 0}, {"article": "In a related editor's note, Mitchell H. Katz, M.D., a deputy editor of JAMA Internal Medicine, writes: \"Of course, no study is perfect.\nMiguel A. Mart\u00ednez-Gonz\u00e1lez, M.D., of the University of Navarra in Pamplona and CIBEROBN in Madrid, Spain, and coauthors analyzed the effects of two interventions with the Mediterranean diet (supplemented with extra virgin olive oil [EVOO] or nuts) compared with advice to women to follow a low-fat diet.\nThe intervention paradigm implemented in the PREDIMED trial provides a useful scenario for breast cancer prevention because it is conducted in primary health care centers and also offers beneficial effects on a wide variety of health outcomes.\n\"The results of the PREDIMED trial suggest a beneficial effect of a MeDiet [Mediterranean diet] supplemented with EVOO in the primary prevention of breast cancer.\nThe study was conducted within the framework of the large PREDIMED (Prevenci\u00f3n con Dieta Mediterr\u00e1nea) trial, which was designed to test the effects of the Mediterranean diet on the primary prevention of cardiovascular disease.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Consuming both nuts and olive oil have been shown in numerous studies to be a positive asset to the regular diet. \u00a0And yet these foods are very calorie-dense, and so one wonders if consuming so much of them could increase the risk for weight gain, which is in turn associated with breast cancer risk. But the release\u2019s lack of discussion on that point shouldn\u2019t be enough for a Not Satisfactory rating \u2014 we\u2019ll rule it Not Applicable.", "answer": 2}, {"article": "When Ali Andrew Li was born on Jan. 7, he was gently placed on his mother's chest, where doctors cleaned and examined him and covered him with a warm blanket.\nNot only is the baby happier, she says, but his or her vitals are more stable.\nEven a little bit of kangaroo contact, he says, can be beneficial.\nThat \"magic\" can also happen between baby and father, too, says Gray, if there's skin-to-skin contact.\nBut doctors were surprised to see that babies whose mothers carried them close, skin to skin, not only survived but thrived.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There aren\u2019t any obvious harms from this intervention.", "answer": 1}, {"article": "Prediabetics are at increased risk for developing diabetes, which can damage the eyes, kidneys, nerves and blood vessels and often leads to cardiovascular disease.\nUsing a simple device for eight hours a night to treat sleep apnea can help people with prediabetes improve their blood sugar levels and may reduce the risk of progressing to diabetes, according to a new study published online in the April 21, 2015, issue of the American Journal of Respiratory and Critical Care Medicine.\n\"Assessment of sleep apnea should be considered in patients at high risk for diabetes and cardiovascular disease, since our study shows that treatment of sleep apnea can reduce these risks.\"\nBefore and after each treatment period, participants' glucose metabolism was assessed by oral and intravenous glucose-tolerance tests.\nAfter two weeks, blood sugar control, as measured by an oral glucose tolerance test, improved for those in the CPAP group compared to the oral placebo group.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "While the release does not mention any harms associated with CPAP, that is likely because there are no significant health risks associated with the use of CPAP devices. However, it would have been worth noting that CPAP devices can often cause significant discomfort for users (and their bedmates), particularly at first. Getting CPAP to work can also require a lot of tinkering with the device.", "answer": 1}, {"article": "For more information go to GetAwair.com.\nDry air can also exacerbate some illnesses and can be a problem as well.\u201d\n\nDifferent sources of air pollution in your home could include paints that release lead or volatile organic compounds (VOCs), carpets that harbor dirt, dust mites, and fungus and even nitrogen dioxide from gas stoves, but these aren\u2019t the worst culprits, Lahita said.\nIf you already have a smart device system for your home, Awair is working on partnerships with several connected devices like Nest thermostat and other smart appliances so you can manage the air quality in your home or office when you're not there.\nEvery room in your house could be susceptive to some form of an air pollutant, but now there is a new device and app that says it can help you breathe easier by tracking air quality.\nWhile breathing fresh, clean air can boost productivity, sleep and overall health, not everyone can live in the great outdoors and it\u2019s difficult to know just how clean the indoor air in your home or office is.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The concern here is that the story discusses a series of potential circumstances, many of which are either unlikely to harm human health or would only be potentially harmful to some people. For example, dry air is not a health concern for many people. This creates a potential \u201coverdiagnosis\u201d problem. In other words, using a product like Awair could potentially lead people to be concerned about circumstances that don\u2019t actually threaten their health. This may result in unnecessary worry, stress or anxiety, or in causing people to spend money on treatments or technologies \u2014 such as humidifiers or air filtration system \u2014 that they don\u2019t need. To be clear, there is a very real market for technologies like humidifiers and air filtration systems, but not everyone needs them. The story doesn\u2019t address these issues at all. Also, potential harm could come from false positives in the tracking device, but that isn\u2019t addressed, either.", "answer": 0}, {"article": "Wolters Kluwer N.V. (AEX: WKL) is a global leader in information services and solutions for professionals in the health, tax and accounting, risk and compliance, finance and legal sectors.\nDr. Moreira adds, \"In appropriately selected cases, DTI reconstruction is a viable alternative to staged techniques requiring multiple surgeries.\"\nDr. Moreira and colleagues write, \"These reported cases include our learning curve patients as we familiarized ourselves with appropriate patient selection and surgical technique.\"\n\"The DTI approach is a powerful tool for breast reconstruction in elderly patients,\" comments ASPS Member Surgeon Andrea Moreira, MD, of the Cleveland Clinic.\nThe researchers believe the DTI technique may expand the options for older women, who are less likely to undergo breast reconstruction.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "In framing this emerging technique as \u201csafe and effective,\u201d as well as highlighting complication rates that are no different from the standard approach, this news release may be minimizing the very real complication rates. The release states, \u201cComplication rates were similar between groups, including blood and fluid collections (hematoma and seroma), infection, unplanned surgery, and failed reconstruction.\u201d\nThe rates may not have been any different between the groups but that does not mean harms can be dismissed. It\u2019s not hard to find disquieting statistics on the rate of complications after mastectomy with reconstruction, for instance this study showing a 10.3% overall complication rate after mastectomy with implant \u2014 and 6% of implants being removed within 60 days.\nThe published study mentioned previous research had found greater complication rates with the direct-to-implant approach. These contradictory findings are not mentioned in the news release.", "answer": 0}, {"article": "Other texts might include something like, \"Hi, Elizabeth.\nIt's important to take them at the same time each day.\"\nAnd it worked to improve not just one risk factor for heart disease, but many.\n\"Everyone thinks it has a lot of potential, but there's actually very little evidence.\"\nYou don't have to have a smartphone to text.\"\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "As long as people aren\u2019t driving and checking their cell phones, there don\u2019t appear to be any harms associated with receiving well-meaning text messages four times a week, so we\u2019ll mark this one \u201cnot applicable.\u201d", "answer": 2}, {"article": "Older people tend to get less slow-wave sleep and are at greater risk for memory impairment.\nBut first, says Zee, larger and longer studies are needed to confirm the findings and show that there are benefits to long-term use, rather than on just one night.\n\u201cIt\u2019s just noticeable enough that the brain realizes it\u2019s there, but not enough to disturb sleep.\u201d The sounds were timed to match their slow-wave oscillations.\nCome morning, people who had listened to it performed three times better on memory tests than they had the other night.\nThe researchers hope to develop an affordable device that people can use at home.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The article does not mention harms at all. There may be no real harm to hearing these sounds as one sleeps, but we\u2019d like to see that question addressed.", "answer": 0}, {"article": "Drs.\nAsher and Burri, along with their co-investigators, now recommend that patients with one to three brain metastases should no longer receive routine whole brain radiation therapy, and should be treated with focused therapy alone to better preserve cognitive function and quality of life.\nThis is a very relevant finding, as over 200,000 patients still receive whole brain radiation in the United States each year, and the majority of patients with brain metastases have a limited number (typically three or less) of brain lesions.\nThe study, released on July 26, 2016, shows that patients with the most common form of brain tumor can be treated in an effective and substantially less toxic way by omitting a widely used portion of radiation therapy.\nAlong with Dr. Paul Brown at Mayo Clinic, they spearheaded an international, multi-institutional, randomized trial that will ultimately improve the standard of care for patients with a specific type of brain tumor, brain metastases, by reducing the toxicity of their treatment without reducing the effectiveness.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The main point of the release, emphasized in several statements, is that whole brain radiation is more toxic to the brain than focused (or stereotactic radiation) without improving survival outcomes. So, while one might expect that the more targeted approach might cause harm by \u201cmissing\u201d some of the cancer, the story does a good job of pointing out the\u00a0LACK of additional harm by targeting the tumor rather than irradiating the entire brain.", "answer": 1}, {"article": "A number of new multiple-sclerosis medications are beginning to hit the market that promise to make it easier for patients to control flare-ups of the disease and slow its progression.\n\nThe drugs, designed to be taken orally, represent a new generation of treatment for MS. Currently, people with the disease can choose from a range of drugs that are administered by injection.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "We get some valuable description of how other oral medications have come into question (even after FDA\u00a0approval) because of side effects, and this context allows the reader to judge that perhaps it is too soon to see the new drug \u2013 Gilenya \u2013 as a complete home run. Side effects mentioned for Gilenya include liver toxicity, infection risk and eye problems.\n\u00a0", "answer": 1}, {"article": "Why smokers are more susceptible is not known for sure, but some scientists believe it has to do with smoking-caused damage that allows the bacteria to more easily attach to the lungs and windpipe, said Dr. Pekka Nuorti, a medical epidemiologist with the Centers for Disease Control and Prevention.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The original AP story mentions that the vaccine may not be very effective and may be considered overtreatment in otherwise healthy younger smokers.\u00a0 But the NY Daily News cut out that part in what it published.\u00a0 Neither version mentioned potential side effects of the vaccine, which might include pain if adminstered via the muscle, and allergic reaction, though this is rare. ", "answer": 0}, {"article": "The company, which says gammaCore is already available in the European Union, expects to start selling it later this year in the U.S.\n\nVagus nerve stimulation is used to treat a range if disorders, including epilepsy, depression and overeating.\nBoth approaches are limited \u2014 it\u2019s not safe to use the injection more than twice a day \u2014 and inconvenient.\nA study in the journal Headache last September showed the treatment appeared to help just over a quarter of cluster headache patients who tried it, versus about 15 percent of those given a sham treatment.\nThis went up to about a third of patients with so-called episodic cluster headaches.\nRelated: New Migraine Drugs Would Treat Pain Before it Starts\n\nSilberstein helped test the device, which users press against the neck.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The side effects were considered to be temporary and relatively minor, but should have been mentioned.\nDr. Silberstein noted, \u201cIt does not have the side effects or dose limitations of commonly prescribed treatments\u2026\u201d \u00a0This is perhaps true but a closer examination of the research results reveals that 11 percent of the participants treated with the gammaCore device saw lip or facial dropping/pulling or twitching during the sham controlled trial and 7 percent experienced these side effects during the open label part of the trial (when both the researchers and volunteers knew which treatment was being administered). ", "answer": 0}, {"article": "\"This is pretty exciting,\" said Alycia Halladay, senior director for environmental and clinical sciences for Autism Speaks, an autism advocacy group.\nThe Norwegian study is the largest to date on the benefits of folic acid for autism prevention, and marks one of the first tangible things a woman can do to reduce her risk of giving birth to a child with the disorder.\nBut some experts aren't quite ready to tout the benefits of folic acid too loudly, particularly for autism prevention.\nDespite the fact that a link between taking folic acid and reducing autism risk isn't fully proven, Halladay says there's no harm in taking the supplement, and women should be taking it anyway to prevent birth defects.\nThe organization also recommends women of child-bearing age take 400 micrograms of folic acid daily before conceiving and 600 to 800 micrograms per day while pregnant.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There are hypothetical, but plausible concerns about harmful effects of getting too much folic acid, especially an increase in cancer risk. This is why many countries have not embraced mandatory folic acid fortification of the food supply. The story should have mentioned this.", "answer": 0}, {"article": "Bracing is one of a number of noninvasive ways to treat knee OA and/or delay the need for joint replacement surgery.\nNew research presented at a media briefing Tuesday in New York City suggests that Peterson is not the only one to find relief from knee bracing.\nThe study was also presented at the recent annual meeting of the American Academy of Orthopaedic Surgeons in New Orleans.\nThe brace used in the study was provided by Ossur, which also provided financial support to the study through a research grant and sponsored the media briefing.\nAll study participants led active lifestyles before they got sidelined by knee OA, and said they hoped to return to their previous level of activities.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "\u00a0There was no discussion of potential harms that might be associated with the use of the devices reported on. \u00a0Are there any short term or potentially longer term implications resulting from the use of a knee brace?", "answer": 0}, {"article": "\"To address inconsistencies in prior studies on vitamin D and to investigate associations in population subgroups, we analyzed participant-level data, collected before colorectal cancer diagnosis, from 17 prospective cohorts and used standardized criteria across the studies,\" said Stephanie Smith-Warner, PhD, an epidemiologist at the Harvard T.H.\n\"This study adds new information that agencies can use when reviewing evidence for vitamin D guidance and suggests that the concentrations recommended for bone health may be lower than would be optimal for colorectal cancer prevention.\"\nOptimal vitamin D concentrations for colorectal cancer prevention may be higher than the current National Academy of Medicine recommendations, which are based only on bone health.\nThese associations persisted even after adjusting for known colorectal cancer risk factors.\nHowever, risk did not continue to decline at the highest concentrations.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The news release indicates that vitamin D should ideally be obtained from the diet, and that there are no known harms to eating foods with vitamin D (an exception being when a mishap caused over-fortification of a local milk supply a few decades ago). Skin cancer risk associated with sun exposure was covered appropriately.", "answer": 1}, {"article": "Larry Holzman \u2014 avid mountain-biker, skier and guitarist in a band \u2014 plays hard.\nBishop says the benefit of the FlexBar, which costs between $16 and $33, over traditional hand weights is that it helps people strengthen without recreating the symptoms.\nBut he understands the appeal: The FlexBar is easy to use and you can do it at home.\nAnd the FlexBar makes it simple to do this kind of stretch.\nTurns out, lots of people who develop tennis elbow haven't played the game in years.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The FlexBar is probably safer than some other commonly used treatments for elbow pain such as steroid injections. However, the story doesn\u2019t really address safety, except to say that\u00a0traditional hand weights can sometimes make tennis elbow pain worse (and by implication, that the FlexBar won\u2019t). While this isn\u2019t a major concern of ours, we think\u00a0it\u2019s probably premature, based on a single 21-person\u00a0study,\u00a0to suggest that the FlexBar is safer than other noninvasive approaches to treating tennis elbow.", "answer": 0}, {"article": "They were divided in groups of 10.\nResearchers said that the lab results identify a class of existing drugs that are likely to treat Alzheimer\u2019s by blocking a particular part of the immune response.\nBrough, however, cautioned that further research is required to identify its impact on humans and the long-term implications.\n\u201cHowever, much more work needs to be done until we can say with certainty that it will tackle the disease in humans as mouse models don't always faithfully replicate the human disease.\nThe research was conducted when mice had developed memory problems.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "While the story does\u00a0allude to\u00a0harms, there are two problems. First, we are troubled that the explanation\u00a0was actually taken directly from the news release about the study. Second, we feel that it was too vague and not explored in any meaningful way. The story says only,\u00a0\u201cthey also warned that these \u2018drugs are not without side effects and should not be taken for Alzheimer\u2019s disease at this stage\u2013studies in people are needed first.'\u201d What are the side effects? We\u2019re not told.", "answer": 0}, {"article": "MORE: With Early Breast Cancer Treatment, Less May be More: Studies\n\nCertain fruits seemed to confer the biggest protection against breast cancer \u2014 apples, bananas and grapes were associated with the greatest reduction in risk while kale and oranges in adulthood also contributed to reduced breast cancer risk.\nThe findings are among the first to look at how diet during adolescence can affect health later, and highlights the importance of establishing healthy habits from a young age, especially since many of the chronic diseases occur over many years and get rooted early in life.\nAbout half of the 90,000 women who participated in the Nurses\u2019 Health Study also answered questions about their typical diet while they were teens.\n\u201cThis study also has an important message for schools and the need to provide students with the opportunity to consume more fruits and vegetables as part of the school meal program.\u201d\n\nFarvid wasn\u2019t able to document a strong relationship between vegetables and lower breast cancer risk, but says that may be because the study wasn\u2019t powered enough to detect an effect.\nIn the study, Farvid and her team could not find any significant relationship between fruit juice and breast cancer risk; that may be because fruit\u2019s anti-cancer effects may have to do with the fiber found in the whole fruit, which is stripped out of juice.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There are no significant risks with eating three servings of fruit per day during adolescence, so we\u2019ll rate this not applicable.", "answer": 2}, {"article": "There are many factors that cause obesity but there is a growing weight of evidence that shows obesity is not just caused by a behavioural disorder, such as a lack of self-control, but that many overweight people are physically addicted to foods rich in fat and sugar.\nThe drug, which is sold under a wide variety of brand names around the world, was one of two drugs tested by researchers, the other being Atomoxetine.\nThere is mounting evidence to show that there is a substantial number of obese people who are food addicts because they have an inability to control their impulsive actions and this drug has shown it can give them more control, which will help overweight people lose weight and so improve their health.\n\"It has been shown to reduce impulsiveness in a variety of disorders such as alcohol dependence, schizophrenia and ADHD.\n\"The drug improves self-control, which is a key factor in determining obesity, so our hypothesis is that this drug should help in treating the disease.\"\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Nowhere in the release is there any mention of possible harms from taking Modafinil, although a brief web search suggest there are numerous potential side effects associated with the drug including anxiety, backache, sleeping problems and potential heart complications.", "answer": 0}, {"article": "\"The goal is to create cells that are missing or defective in people.\nThe work was hailed as a welcome development even by critics of research involving embryonic stem cells, which can be coaxed to become any tissue in the body but are highly controversial because they are obtained by destroying embryos.\nMelton and other researchers cautioned that many years of research lay ahead to prove whether the development would translate into cures.\nResearchers in the field, who have become accustomed to rapid advances, said they, too, were surprised by the advance.\nAlthough the experiment involved mice, Melton and other researchers were optimistic that the approach would work in people.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There was no discussion of possible harms that might be associated with gene therapy even though there have been human deaths resulting from the use of viral vectors to alter gene expression.", "answer": 0}, {"article": "Having a large waistline, high blood pressure, high blood sugar, low levels of HDL (good) cholesterol and high levels of triglycerides, are among the factors that make up metabolic syndrome.\nSahebkar said most of the clinical benefits reported for curcumin have been achieved when curcumin was added to a standard drug therapy regimen, and patients should be careful not to replace their prescribed drugs with curcumin without prior consultation with their physician.\nThey found that the people who took curcumin had improved blood levels of all three biomarkers as well as reduced fasting blood sugar and hemoglobin A1c, a measure of long-term blood sugar levels.\n\u201cIn addition, patients with malabsorption syndrome, gall bladder problems, gastric ulcer, bleeding problems as well as those who are undergoing surgery, and those who have a history of hypersensitivity to herbal products should be cautious and consult with their physician before taking this supplement,\u201d Sahebkar said.\nHowever, owing to limited safety information, pregnant and lactating women should avoid using this supplement, Sahebkar said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does say that pregnant and lactating women should avoid using curcumin supplements, and quotes one of the study authors as saying that \u201cpatients with malabsorption syndrome, gall bladder problems, gastric ulcer, bleeding problems as well as those who are undergoing surgery, and those who have a history of hypersensitivity to herbal products should be cautious and consult with their physician before taking this supplement.\u201d\nWe\u2019ll rate this good enough for a satisfactory, although the story could have noted that many of these warnings seem to relate to the fact curcumin may interfere with iron metabolism (posing problems for those with iron deficiencies), and that curcumin can apparently also cause nausea, dizziness, or diarrhea in some people.", "answer": 1}, {"article": "Women who took hormones had an average of 24 fewer hot flashes per month, while those who took soy had 12 per month fewer.\nThat means that if women do take hormones, Bachmann told Reuters Health, it should be the lowest dose and for the shortest possible period of time.\nAnd not every woman needs treatment, notes Bachmann, who was not involved in the study.\nWomen with severe or frequent hot flashes or whose hot flashes keep them up at night, should consider treatment, she said.\nThe study did not look at whether eating soy in food has the same effect on hot flashes as supplements, Bolanos-Diaz said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Adequate job reminding readers of the risks reported from the 2002 Women\u2019s Health Inititiative study (although we wish it had given the absolute risk data).\u00a0 And it cited what the NIH reports as side effects of soy supplements \u2013 but again without numbers.\u00a0 Adequate nonetheless.", "answer": 1}, {"article": "Normally it's the very old or very young that die from flu, but every year there are deaths from influenza A,\" said Gilbert.\nThe vaccine would be an important step in treating seasonal flu, not just pandemics.\nThe initial results are positive, says Peter Palese, professor and chair of microbiology at Mount Sinai School of Medicine, New York, but more research is needed before the new treatment is approved.\nThe results, say Gilbert, are important in developing a new form of protection that researchers hope could spell the end of flu vaccination supply problems.\n\"Whether it's this vaccine or another one someone else develops, I don't think we'll be continuing with the type of flu vaccines that we have at the moment.\"\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "", "answer": 0}, {"article": "All of these study participants \u2014 largely people in their 70s, all with a diagnosis of either \"mild cognitive impairment\" or atypical dementia \u2014 are living with the unconfirmed suspicion that they have Alzheimer's. The study is underwritten by the Centers for Medicare & Medicaid Services and the Alzheimer's Assn. It set out to find out whether knowing \u2014 getting the costly test that would offer either confirmation or reprieve \u2014 would change the way that patients with cognitive troubles are treated, or the way that they plan their lives.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story discusses the frustration of having a diagnosis with no known treatments. However, when it comes to the intervention specifically\u2013the PET scan\u2013there are the risks of false-positives and false-negatives. As in, what\u2019s the risk someone is diagnosed when they don\u2019t have the disease, or they\u2019re not diagnosed when they do indeed have the disease? Every screening test has these risks\u2013it\u2019s important to know how likely they are.\nAnd, PET scans themselves expose people to radiation and can cause allergic reactions to the tracer.", "answer": 0}, {"article": "The F.D.A.\nDr. Gold said there were about 100,000 men who get such a diagnosis each year.\nAnd the drug failed to do that by a statistically significant measure.\ninstead said it wanted more proof that the drug worked and would await results from a trial that was then under way.\nBased on those results, an advisory panel to the F.D.A., meeting in March 2007, voted 13 to 4 that there was \"substantial evidence\" that the drug worked and 17-0 that the drug was safe.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story suggests the drug\u2019s side effects are milder than those of standard chemotherapy. But the source of this assessment is a member of the study team who is a consultant to the drug maker. \nThere is no description from an independent source of the drug\u2019s safety profile.\u00a0 ", "answer": 0}, {"article": "\u201cBut it does give us hope.\u201d\nThe research team surmises the disparity is due to antibiotics prescribed within the first three years of life.\nOne of the study\u2019s limitations is its small size, and researchers cautioned that families should not try to replicate the treatment at home.\nResearchers also asked the children\u2019s doctors to perform pre- and post-diagnostic evaluations, which suggested lasting benefits.\nChildren without autism were used as a control for the study, the news release reported.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There are risks to introducing a donor\u2019s stool into a recipient. No mention of risk was included. A donor could have undetected disease or infection before donating.", "answer": 0}, {"article": "Last year, 2.3 million young Europeans (aged 15 to 34) used cocaine, and the US National Institute on Drug Abuse estimates that 1.4 million Americans suffer from cocaine addiction1.\nAs far as we know, this work represents the first clinical report indicating that rTMS treatment results in significant reduction in cocaine use.\nThe study indicated the safety of rTMS in patients with cocaine addiction.\nThe results of this pilot study, published in the peer-reviewed journal European Neuropsychopharmacology, suggest that this may become an effective medical treatment for patients with cocaine addiction, although a larger trial is needed to confirm the initial findings.\nOur study suggests that rTMS may also represent a new treatment for patients with cocaine use disorder\".\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release states that the magnetic stimulation treatment is safe and non-invasive and is already in use to treat patients with depression and neuropathic pain.", "answer": 1}, {"article": "A new study shows women who drank the equivalent of a beer or small glass of wine each day were less likely to develop chronic diseases like heart disease, cancer, and diabetes as they got older compared to nondrinkers or those who drink four or more drinks at one time.\nIn the study, researchers looked at the effects of drinking alcohol at midlife on the risk of diseases commonly associated with aging in a group of 13,894 women enrolled in the Nurses' Health Study.\nResearchers then analyzed health status information collected after the women turned 70.\nAfter taking into account other factors that might affect health and disease risk, like smoking, researchers found women who drank light or moderate amounts of alcohol were less likely to develop chronic diseases as they aged.\nFor example, compared to nondrinkers, women who drank up to one alcoholic drink per day were 20% more likely to be disease-free at age 70 than nondrinkers.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Any story that discusses the potential benefits of alcohol consumption should say a word or two about the potential harms of overdoing it, since heavier drinking is unequivocally related to a host of health risks. This story didn\u2019t\u00a0include any such warning.", "answer": 0}, {"article": "What if doctors had a pill that prevents breast cancer and nobody wanted to take it? That has pretty much been the situation with tamoxifen, an estrogen-like drug that was proved in 1998 to cut in half the chance of developing breast cancer if taken for five years by women with increased risk of the malignancy. The trouble is, tamoxifen also triggers menopausal symptoms like hot flashes and slightly increases the chances that a woman will develop blood clots and uterine cancer. As a result, women haven't been too eager to take the medication--nor have many doctors been all that enthusiastic...", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Mentions harms of hormone therapy, such as an increased risk of blood clots and uterine cancers. Notes that there were \u201cfewer side effects\u201d (i.e. blood clots and uterine cancers) in the raloxifene group, but does not mention that the difference in side effects was not statistically significant for uterine cancer and blood clots. This information was not readily available on the National Cancer Institute (NCI) website or in reports of the study, but we give this a \u201csatisfactory\u201d score because the story presents caveats on the drugs. Mentions reduction in the risk of cataracts with raloxifene, which was statistically significant. Does mention that raloxifene, like tamoxifen, has bothersome side effects such as hot flashes and vaginal discharge, which are reported as comparable and mild to moderate in the NCI press release of the initial results of this trial. ", "answer": 1}, {"article": "As they age, people with elevated diastolic blood pressure are at a higher-than-average risk of developing elevated systolic blood pressure.\nThese evidence-based data demonstrate the effect of diet on cardiovascular disease outcomes, particularly diastolic blood pressure.\"\nAt the beginning and end of each diet period, participants spent three days undergoing metabolic testing in a clinical research setting.\nThe findings, published in the Journal of Nutrition today, suggest that whole grains can be a key regulator of blood pressure, and could provide an effective nutritional strategy to reduce cardiovascular-related deaths and disorders.\n\"Heart disease and strokes are a leading cause of death in the United States.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "There is no mention in the release of any harms arising from a diet rich in whole grains but we won\u2019t fault them from that. The benefits of whole grain foods have been well documented.\nProviding more detail on what the diets contained would have been helpful to readers.", "answer": 2}, {"article": "\"When people have serious injuries, whether from accidents or violence, and when they have severe hemorrhage they can bleed to death.\nIn fact, a trial to see whether TXA can reduce postpartum bleeding has started, the team noted.\nLevy however, cautioned that the results of this study apply only to TXA and do not mean that people should try similar drugs hoping for similar results.\nCurrently, TXA is not generally used in emergency rooms to treat trauma patients, but Roberts believes that this study could change that.\n\"I think people should consider it [TXA] following trauma on the basis of this study,\" he said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story correctly\u00a0states that the researchers observed no increase in clots in the patients receiving TXA, earning enough for a satisfactory. However, we wish it had included, as the AP did,\u00a0a caveat regarding the difficulty of identifying clots\u00a0in\u00a0trauma patients who subsequently die.", "answer": 1}, {"article": "Drug list (formulary): To see a list of covered drugs for the plan you\u2019re considering, use the drop-down menus below.\n\nIf your employer is offering coverage, contact HR for the pharmacy plan name.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Does not mention the increase in \ncholesterol and cardiovascular disease among the women in the aromatase inhibitor group. Tamoxifen may have a positive, \ncholesterol-lowering effect, which is also not mentioned. ", "answer": 0}, {"article": "WINSTON-SALEM, N.C. - Aug. 17, 2015 - Every year falls affect approximately one in three older adults living at home, with approximately one in 10 falls resulting in serious injury.\nThe study showed that the monthly vitamin D supplement was effective in increasing the concentrations of vitamin D in the blood from insufficient to sufficient levels in all but one of the 34 people who received it, and to optimal levels in all but five people.\nSixty-eight study participants received either a monthly vitamin D supplement of 100,000 international units or placebo delivered with their MOW meal.\nThe Wake Forest Baptist team currently is conducting a clinical trial to try to determine how vitamin D affects risk factors for falls such as balance and muscle strength and power.\nFunding for the study was provided by the Wake Forest Translational Science Institute and Center for Integrative Medicine and the Claude Pepper Older Americans Independence Center of Wake Forest Baptist.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release makes no mention of possible harms caused by Vitamin D supplements, though the\u00a0FDA website cites a laundry list of concerns that it attributes to the American Association of Family Physicians: Nausea, vomiting, poor appetite, constipation, weakness, weight loss, confusion, heart rhythm problems, deposits of calcium and phosphate in soft tissues.", "answer": 0}, {"article": "\u201cIt isn\u2019t \u2018grin and bear it for a few months\u2019 and it will all pass, as many women suffer severe symptoms for five-plus years,\u201d she said.\nThere is also, she said, a complete lack of understanding that for most women, these symptoms are not fleeting.\n\u201cExtrapolating our findings to 3.7 million Australian women aged 40 to 64 years, we found that 455,000 women are likely to have moderate to severe vasomotor symptoms, with most women (385,000) remaining untreated,\u201d they write.\nIn addition, very few women were receiving vaginal estrogen therapy for sexual symptoms.\nVaginal estrogen preparations are very safe and effective for this problem but were prescribed to less than 5 percent of the women, the authors say.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story states several times that alternative therapies for menopausal symptoms, including vaginally applied estrogen, are safe. But elsewhere it acknowledges that pill-based treatment with hormones is associated with increased cancer risk. It would have been reassuring to provide some evidence backing up the claim that these alternative treatments are, in fact, safe \u2014 since that seems to be a key reason why women are reluctant to use these therapies. And certainly some of the nonhormonal options for hot flashes (e.g. antidepressant medication) carry a risk for side effects that could have been mentioned.", "answer": 0}, {"article": "\"Many labs are looking at this.\nHis test is one of numerous such tests under study, says Heather Snyder, PhD, a spokesperson for the Alzheimer's Association, who reviewed the research results.\nThe only definitive way to diagnose the disease is by direct examination of brain tissue after the patient dies.\nNone are highly accurate, and some are costly and not practical to use on a widespread basis, experts say.\nThe research results on the new test are published online in PLoS ONE.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "\n\n\nThe story does not discuss the potential harms of this sort of test. As mentioned above, some healthy people would be told in error that they have signs of Alzheimer\u2019s Disease. Such a misdiagnosis could have profoundly grave consequences.", "answer": 0}, {"article": "\"The challenge now is to determine if humans benefit the same way,\" said Gerdes.\n\"Thus, T3 treatment inhibited the major cause of stiffening of the heart in hypertension.\nI predict the same will eventually be true for thyroid hormones in a large subpopulation of cardiac patients.\nGerdes has long argued that medical opinion on thyroid treatment for patients with heart disease is largely shaped by outdated studies that used toxic doses of thyroid hormones.\nEarlier, a study in the Journal of Cardiac Failure found that thyroid hormone replacement therapy in rats significantly reduced the incidence of atrial fibrillation.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release does not adequately discuss potential harms. Thyroid hormone treatment for other conditions, such as hypothyroidism, has been around for years. And, in those cases, it\u2019s known that such treatment can cause side effects such as heart palpitations and insomnia. But there are other risks as well, which the release itself points out in a very roundabout way. The release says that the study\u2019s lead author \u201chas long argued that medical opinion on thyroid treatment for patients with heart disease is largely shaped by outdated studies that used toxic doses of thyroid hormones.\u201d This sentence manages to highlight that there can be significant risks associated with the use of thyroid hormones (the \u201ctoxic doses\u201d reference), but it isn\u2019t clear what these risks are, and it\u2019s not made clear that there may be risks (even lesser risks) associated with the undefined \u201clow-dose\u201d applications of thyroid hormone used in this study.", "answer": 0}, {"article": "In general, the risk of developing colorectal cancer varies with age, race, ethnicity and lifestyle.\nDr. Friis emphasized that people should not start taking aspirin or NSAIDs on the basis of the new findings.\nNonaspirin NSAIDs were also protective against colorectal cancer with consistent long-term use, \u201cand there was some indication that even non-continuous use of these agents may be (marginally) effective for the prevention of colorectal cancer,\u201d Dr. Friis said.\nOn the other hand, merely having taken aspirin did not alter the colorectal cancer risk, they reported in Annals of Internal Medicine.\nLong-term use can cause gastrointestinal bleeding, for example, so the potential reduction in colon cancer risk needs to be balanced against potential side effects, the authors warn.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story is straightforward in saying that all NSAIDs carry risks.\n\u201cLong-term use can cause gastrointestinal bleeding, for example, so the potential reduction in colon cancer risk needs to be balanced against potential side effects, the authors warn.\u201d\nIt would have been easy to also mention cerebral vascular bleeds, but that\u2019s a minor point.", "answer": 1}, {"article": "\"We didn't expect that at all,\" Dackis says.\nAddiction specialists gave it a look because even though modafinil isn't a classic stimulant, it triggered something in the brain to also improve patients' mood, energy levels and ability to concentrate _ effects that might counter cocaine withdrawal.\nThe prospect of that double-whammy has the National Institutes of Health spending $10.8 million researching modafinil as a potential cocaine treatment.\nHundreds of cocaine users are testing whether that legal pill, called modafinil, could help them kick the addiction, and there's early evidence that it may.\nIn a small safety study to ensure that modafinil didn't make cocaine worse, some users found the once-a-day pill blocked that high.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story doesn\u2019t mention the incidence of side effects in the pilot study or from other trials. Insomnia is mentioned in the story, but we\u2019re not told how common this is in people who take the drug for withdrawal symptoms of cocaine dependence. Side effects were twice as common in the treatment group in the pilot study and included nausea, anxiety, tachycardia, loss of appetite and urinary tract infection. ", "answer": 0}, {"article": "March 15, 2010 -- A common pain reliever may help people with type 2 diabetes control their blood sugar levels.\nThat prompted researchers to take another look at salsalate in reducing blood sugar levels.\nHowever, it also has been shown to increase protein in the urine and its long-term safety will need further investigation.\nDue to the small size of the study and short follow-up time, researchers say it's too soon to recommend use of salsalate for the treatment of type 2 diabetes.\nOther markers of glycemic control and heart disease risk also improved in the three salsalate groups compared with the placebo group.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "While harms were not quantified, we give the story the benefit of the doubt for discussing potential safety issues prominently in the study, including a very early mention of proteinuria and the need for more long-term safety data.", "answer": 1}, {"article": "If the child said a word, the parent repeated it and added something.\n\u201cThese results at follow-up are pretty consistent in showing the benefit of this early intervention for autism across a range of measures.\nMy impression is that this is an intervention that reduces the severity of autistic symptoms, rather than curing autism.\nNevertheless, for parents of children with autism, even a modest reduction would be worthwhile.\u201d\n\nDr Max Davie, of the Royal College of Paediatrics and Child Health, said it offered \u201ca hugely cheering message for families\u201d, while Uta Frith, emeritus professor of cognitive development at University College London, called it \u201ca remarkably positive story, because the intervention itself was neither intensive nor invasive\u201d.\nThe success of the preschool autism communication trial (Pact) has surprised even the researchers who designed it.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The article quotes\u00a0an outside expert\u00a0who notes that the training intervention was non-invasive and non-intensive.", "answer": 1}, {"article": "A new study offers a fresh strategy for treating patients suffering from both coronary artery disease and heart failure, afflictions linked to poor quality of life and high risk of death that affect as many as two million Americans.\n\nThe 1,212-patient study calls into question the need for immediate bypass surgery in these patients\u2014an approach commonly recommended by doctors. The study, called Stich, found benefits in treating people with medication only, and in treating people with a combination of bypass surgery and medication....", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "", "answer": 1}, {"article": "What to do?\nHowever, the study also found that those risk factors -- a small body frame, a history of fractures, or taking medications that could thin bones -- had only a slight effect on a woman's decision to get her bones tested.\nOver seven years, more than 42 percent of eligible women aged 65 to 74 were not screened, Amarath's team found, nor were nearly 57 percent of those older than 75.\nThe result: Osteoporosis screening rates jumped sharply at age 50, despite guidelines suggesting that screening only begin at age 65, unless a woman has certain risk factors.\n\"DXA screening was underused in women at increased fracture risk, including women aged 65 years and older.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does not mention a potential harm common to all screening tests \u2014 the risk of a false-positive result that can lead to more tests and unnecessary treatment. And while the dose they provide is small, DXA tests do involve\u00a0radiation exposure. The story makes no mention of any possible downside to that exposure.", "answer": 0}, {"article": ".\nDespite the adverse effects, more than 75 percent of participants reported being willing to use this method of contraception at the conclusion of the trial.\nOnly four pregnancies occurred among the men's partners during the efficacy phase of the study.\nResearchers stopped enrolling new participants in the study in 2011 due to the rate of adverse events, particularly depression and other mood disorders, reported by the participants.\n\"The study found it is possible to have a hormonal contraceptive for men that reduces the risk of unplanned pregnancies in the partners of men who use it,\" said one of the study's authors, Mario Philip Reyes Festin, MD, of the World Health Organization in Geneva, Switzerland.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The news release discusses adverse effects. It says researchers stopped enrolling new participants in 2011 due to the rate of reported side events, particularly depression and other mood disorders. It also mentions that men reported having injection site pain, muscle pain, increased libido and acne, and that 20 men dropped out due to adverse effects. It also says serious adverse events that were assessed as probably or possibly related to the study included one case of depression, one intentional overdose of acetaminophen, and a man who experienced an abnormally fast and irregular heartbeat after he stopped receiving the injections.\nFurther, it quotes a researcher saying that \u201cthe combination of hormones needs to be studied more to consider a good balance between efficacy and safety.\u201d\nDespite the attention to side effects there were a few gaps. The release didn\u2019t quantify the number of men who developed depression. It noted there was one suicide among the study group, but stated it was determined not related to the hormones. How was it determined that the injection did not contribute to the suicide when the hormone shots did contribute to mood disorders? The release doesn\u2019t say.\nThe news release also doesn\u2019t adequately explain the need to cancel the study due to harms. When compared to the side effects of other hormonal contraceptives used by women it appears to be safer.", "answer": 1}, {"article": "Details of the cases are documented in the paper \"Artemisia annua dried leaf tablets treated malaria resistant to ACT and i.v.\nACT, the current recommended therapy, is expensive to produce and is in short supply in areas hit hardest by the disease.\nWeathers says the superior performance of DLA in comparison to ACT, as well as its ability to kill drug-resistant parasites and avoid the resistance trap, itself, is likely due to the synergistic effects of a complex array of phytochemicals contained in the plant's leaves, several of which are also known to have antimalarial properties and others of which may act both to enhance the absorption of artemisinin into the bloodstream and bolster its effectiveness against malaria.\n(Weathers noted more than 100 other drug-resistant patients also have been successfully treated with DLA tablets.)\nIn effect, the dried leaves constitute a robust natural combination therapy, one whose benefits far surpass those of ACT and other combination drugs.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "We expect releases to state \u201cthere are no known harms\u201d if that is the case, but this story does not mention potential harms at all. The story speculates that the stronger value of the dried-leaf product may come from other phytochemicals (not named) that are in the leaves. What if one or more of those have other impacts on patients months from now? Just because a drug is \u201cnatural\u201d\u00a0doesn\u2019t mean it is free of side effects.\nMemorial Sloan Kettering has studied artemisia annua and states that people taking antiseizure medications should avoid artemisia since it can induce seizures and make these medications less effective.", "answer": 0}, {"article": "Flu season has already begun, and last year\u2019s was one of the most lethal in decades; about 80,000 Americans died of flu or its consequences, the Centers for Disease Control and Prevention said earlier this month .\nThe pill will cost $150, according to a spokeswoman for Genentech, which will sell Xofluza in this country.\nstill strongly recommends that every American over the age of six months get a flu shot as soon as possible.\nGenentech will offer coupons that lower the price to $30 for patients with health insurance and to about $90 for the uninsured.\nThe first new flu drug in 20 years won approval Wednesday from the Food and Drug Administration.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story addresses this issue head on, earning it a solid satisfactory rating from us. One point that would have made it even stronger would have been to note that the company selling Xofluza\u00a0warns that pregnant women and nursing mothers may want to avoid the drug, as it is not known whether the drug may harm the fetus or if it would pass into breastmilk for nursing mothers.", "answer": 1}, {"article": "WASHINGTON\u2014People with mild Alzheimer\u2019s disease who started taking an experimental Eli Lilly & Co. drug earlier in the course of their disease fared better than patients who started later in a clinical trial.\n\nThe outcome may bolster the company\u2019s case that the drug, solanezumab, can slow the decline of memory and function in mild Alzheimer\u2019s patients, despite prior studies with negative results. But the new data aren\u2019t final proof of the drug\u2019s benefit\u2014a separate, continuing study due to end in late 2016 is designed to...", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story doesn\u2019t address harms at all. One of the most important aspects of clinical trials is determining whether an experimental drug causes significant side effects. And at least one of these drugs is associated with brain swelling associated with headache and confusion. To be clear, this is not about asking reporters to paint a grisly picture of potential harms. If a drug had no adverse side effects, that\u2019s great \u2014 but tell readers that. And if a drug does have adverse side effects, tell readers that too.\n[Editor\u2019s note: An updated version of the story now includes the following line:\u00a0\u201cSome patients receiving solanezumab experienced swelling in the brain and other adverse events, but researchers said the drug was generally well tolerated.\u201d This line was not in the version of the story that we originally reviewed. We applaud any effort to get better, more complete information to readers. But such updates do miss readers like us who only saw the original version of the story.]", "answer": 0}, {"article": "\u2022 The percentage of days with full asthma control were virtually the same for acetaminophen and ibuprofen: 85.8 and 86.8 percent, respectively.\n(The asthma therapies were given in varying order as part of a concurrent randomized trial, making this, in effect, a \"trial within a trial.\")\nThe study enrolled 300 children 1 to 5 years old with mild persistent asthma.\nWhile the study was modest in size, it was powered to detect any clinically significant differences, more so than past retrospective studies, Phipatanakul notes.\nThe 18-site study should settle a debate that originated when several retrospective studies seemed to indicate that children had exacerbations of their asthma when receiving Tylenol for pain and/or fever.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Another major study question was whether frequent acetaminophen use in children with mild persistent asthma worsens symptoms. This was measured by the number of asthma exacerbations, percentage of days with full asthma control, use of \u201crescue\u201d medication and unscheduled healthcare visits for asthma. As mentioned in the \u201cQuantify Benefits\u201d section, this release\u00a0includes quantitative data from the original study in easy-to-read bullet form. Furthermore, the headline and quotations used in the news release reinforce the study\u2019s findings, making it clear that acetaminophen does not worsen asthma symptoms in children.\nFor these reasons, we give the news release a Satisfactory rating.", "answer": 1}, {"article": "In devising their models, the researchers updated assumptions that have cast doubt on the relevance of existing breast-cancer risk calculators, which relied on the experiences of women who got an earlier generation of screening mammograms and were more likely to die of breast cancer than is currently the case. Here, teams of modelers from Erasmus University in the Netherlands, Albert Einstein College of Medicine in New York and Harvard Pilgrim Healthcare assumed that women were getting digital mammograms, which offer improved cancer detection rates at lower radiation dosages than earlier mammographic methods. They took into account improved rates of breast cancer treatment effectiveness, and changing causes of mortality for women older than 50. They also took account of the fact that breast density decreases in older women.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The article mentions overdiagnosis and a couple of its consequences.\nTo better communicate harms, it could have used some outside expert commentary about the numerous risk factors and comfort levels women and their physicians have when considering the frequency of mammography; and about the fact that there are no definitive answers about the ideal screening protocol for any individual woman.\nThe article also should have included specific information from the journal article about the economic costs of biopsies and other enhanced screening. While it\u2019s hard to quantify the emotional and psychological costs to women who undergo biopsies that are found to be negative, it is possible to quantify the economic costs to a person and to the larger healthcare system.", "answer": 1}, {"article": "\u201cI really cannot overstate the size of this effect.\u201d\n\nThe key finding is that there is often more time than doctors realized in which brain cells can still be rescued by a procedure to remove the clot.\nHowever, the findings do not apply to every stroke victim.\nThe researchers used a special type of brain imaging to identify the patients who still had live brain tissue that could be saved if the blood supply was restored.\nOnly about half the patients who were screened qualified for treatment, known as thrombectomy, which uses a mechanical device to pull clots out of a blood vessel.\nMany more stroke victims than previously thought can be saved from disability or death if doctors remove blood clots that are choking off circulation to the brain, a new study has shown.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Aside from acknowledging that not all stroke patients who fall in the extended time frame are eligible for this procedure, no harms were discussed. What are the harms of standard medical therapy for stroke, therapy plus thrombectomy surgery, and the special brain imaging?", "answer": 0}, {"article": "Check it out if you're interested in finding a trial for yourself or someone you care about.\nThat suggests that a five-year follow-up period is not long enough to determine how well biomarkers can predict which patients will develop Alzheimer's disease, researchers say.\nKnowing which patient with mild cognitive impairment patients may go on to develop Alzheimer's is vital information for researchers, who are looking for treatments for the fatal brain disease.\nThe current thinking is that interventions will be most effective when given to a patient as early as possible, Brickman said.\nClinical trials can better focus their efforts if patients are known to be in the early stages of Alzheimer's.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story did make several stabs at touching on harms, reporting:\n\u201cSome of the participants, who were originally found to be stable with mild cognitive impairment after about five years, went on to develop Alzheimer\u2019s disease during the longer follow-up.\u00a0 That suggests that a five-year follow-up period is not long enough to determine how well biomarkers can predict which patients will develop Alzheimer\u2019s disease, researchers say.\u201d\nAnd it did end with this:\n\u201cAs scientists gain more insight into predicting Alzheimer\u2019s, aging adults may struggle with the question of whether they want to know their risk,\u00a0 especially since there\u2019s still no cure.\u00a0 Some people want to enroll in clinical trials as soon as they start showing symptoms; others would rather be ignorant of their status since there is no cure.\u201d\nWe think these could have been framed more clearly as potential harms, but we\u2019ll give the story the benefit of the doubt on this one.", "answer": 1}, {"article": "For example, the U.S. Preventive Services Task Force, a federal expert panel, currently doesn\u2019t recommend routine cholesterol screening in any children.\n\u201cUnfortunately, there is no evidence that starting a ten-year-old on cholesterol-lowering drugs will prevent heart disease 40 years later,\u201d said Dr. Michael L. LeFevre, a member of the task force.\n\u201cIt is therefore prudent to implement universal screening in the pediatric population independent of family history,\u201d the researchers conclude.\nIn a report published in the journal Pediatrics, they call for screening of all children, expanding one set of current recommendations that target only those whose parents or grandparents have heart disease or high cholesterol.\nHe said statin treatment in children was still controversial, and that no long-term safety data existed.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "1clip_filelist.xml\" rel=\"File-List\"/>\n\n\n\nThe story points out that cholesterol-lowering drug treatment in children is controversial and the safety of such treatment has not been studied in children. However, the story does not mention any of the specific harms of statin treatment that have been identified in studies of adults.", "answer": 1}, {"article": "\"We have been trying as doctors for centuries to find a treatment that actually reverses heart injury,\" Eduardo Marban, MD, PhD, tells WebMD.\nMarban, director of the Cedars-Sinai Heart Institute in Los Angeles, led the study.\nIt's the first completed, controlled clinical trial showing that scarred heart tissue can be repaired.\nHe invented the \"cardiosphere\" culture technique used to create the stem cells and founded the company developing the treatment.\nIf so, this could change the nature of medicine.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There is no mention of harms in the story. Bloomberg BusinessWeek reported on the same study and said, \u201cA year after the procedure, six patients in the stem cell group had serious side effects, including a heart attack, chest pain, a coronary bypass, implantation of a defibrillator, and two other events unrelated to the heart.\u201d\n\u00a0", "answer": 0}, {"article": "Editor's note: Tune in as Dr. Sanjay Gupta explores the signs, tests and lifestyle changes that could make cardiac problems a thing of the past on \"The Last Heart Attack,\" Saturday, August 27, 8 and 11 p.m.\nThe 351 participants in the study suffered from high cholesterol but were not on a cholesterol-lowering statin medication.\nJenkins said participants achieved these results even though compliance to the whole grain, vegetarian diet was only about 40%.\nLead author Dr. David Jenkins, Canada research chair in nutrition and metabolism at the University of Toronto and St. Michael's Hospital, had previously shown the effectiveness of a cholesterol-lowering diet when all the meals were provided to participants.\nIn addition to the soy protein, nuts and whole grains, participants in the diet were encouraged to eat peas, beans and lentils.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There was no discussion of the safety of the diet. The study paper notes that there were some potential allergic reactions in the portfolio diet group.", "answer": 0}, {"article": "Many pregnant women who have symptoms of depression worry that taking antidepressants might harm their unborn babies -- so they stop taking their medications, say researchers at the Stanford University School of Medicine.\nAcupuncture might be a useful alternative, they say, because a study of pregnant women shows that the procedure works in reducing depressive symptoms better than other non-pharmacological techniques.\nThe researchers say up to 14% of pregnant women may suffer from depression.\nThe study included 150 pregnant women diagnosed with major depressive disorder.\nRemission rates were not significantly lower in the depression-specific acupuncture group compared to the other two groups.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "While acupuncture is generally safe, the story should have mentioned that 21 women in the study reported transient pain at the site of needle insertion and 1 woman experienced bleeding. ", "answer": 0}, {"article": "And finally, this is a very real world study.\u201d\n\nThe study was received well by the audience.\nOne of the caveats of the study was that participants were highly motivated people looking for ways to cope with and decrease their blood pressure.\nParticipants were also largely white and well-educated, with most having a postsecondary education, so the results of the study might not be generalize well to other groups.\nEngaging patients in such a way could be a very powerful tool in promoting behavioral change, Nolan said.\nThese tools were carefully chosen to increase in knowledge about and motivation to maintain a heart-healthy lifestyle.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story makes no mention of harms that might arise from the use of web-based tools and videos, but it\u2019s hard to envision how they could harm study participants.", "answer": 2}, {"article": "Commenting on the next stage of the research, she said: \u201cIn the larger phase II trial we\u2019ve recruited 140 women with relapsed ovarian cancer across the U.K. to standard chemotherapy (paclitaxel) or paclitaxel in combination with vistusertib.\nDr. Dean A. Fennell, professor and consultant in thoracic medical oncology at the University of Leicester, who was not involved in the study, told Newsweek the study presents an \u201cexciting result.\u201d\n\nHe was particularly surprised by the magnitude of the response triggered by vistusertib combined with paclitaxel, which is closely related to standard chemotherapy.\nThe U.K.-based researchers used a new drug along with chemotherapy medication known as paclitaxel on 25 women with high-grade, serous ovarian cancer, and 40 participants with squamous non-small cell lung cancer.\nThe cocktail also stopped the cancer growing for almost six months, which is unexpected for patients with advanced-stage cancers who were unresponsive to currently available treatments, including chemotherapy, the authors said.\nCombined with paclitaxel chemotherapy, the scientists were able to block cancer cells from harnessing p-S6K.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Potential harms were not mentioned. According to the study, the most common side effects were fatigue, nausea, anemia, and diarrhea.", "answer": 0}, {"article": "It also shrank waistlines and resulted in weight loss, both in total body fat and trunk fat, but not in muscle mass.\nThe researchers said further investigation will determine whether the benefits of the diet can continue for several months.\nPeople in the second group were placed on a three-month test of the fasting-mimicking diet.\nThe research team found that the beneficial effects -- from weight loss, smaller waistlines and lower glucose, blood pressure and IGF-1 levels -- were sustained.\nThe phase II trial, conducted by researchers at the USC Leonard Davis School of Gerontology, demonstrated a host of benefits from the regimen.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "There is no mention of any potential side effects. Certain people may not be ideal candidates for an extreme low-calorie diet, even intermittently. The release does not comment on this.", "answer": 0}, {"article": "In rural or underserved areas, doctors sometimes must rely on a patient's symptoms or use their own judgement in looking at test sample color results to determine whether a patient has an infection.\nThe researchers tested the device, which is about the size of a hand, with 771 patient samples at Hospital of University of Pennsylvania and found that it provided false positives only about one percent of the time (was 97. to 99.9 percent accurate).\nThe WSU researchers found that their portable smartphone reader worked nearly as well as standard lab testing in detecting 12 common viral and bacterial infectious diseases, such as mumps, measles, herpes, and Lyme Disease.\nCollaboration with Ping Wang, associate professor of Pathology and Laboratory Medicine at the University of Pennsylvania's Perelman School of Medicine, enabled the design and implementation of the key clinical validation study.\nThe work could lead to faster and lower-cost lab results for fast-moving viral and bacterial epidemics, especially in rural or lower-resource regions where laboratory equipment and medical personnel are sometimes not readily available.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Tests, even accurate ones, have downsides which were not mentioned in this release. The release stated that the device \u201cprovided false positives only about one percent of the time.\u201d If field workers fanned out across a city and tested 100,000 people, that 1% false positive rate would mean that about a thousand people would be told they were infected when they actually were not. The release did not mention false negatives (telling an infected person that he or she is not infected).", "answer": 0}, {"article": "\"The work by [first author] Price et al.\nTesting the effect of resveratrol on SIRT1 in mice was difficult, Sinclair said.\nWe should be very careful about claiming the importance of resveratrol for medical purposes.\nstrongly supports the basic rationale being pursued at Sirtris, which focuses on the development of small-molecule compounds that directly activate the enzymatic activity of SIRT1 as a new therapeutic approach to many diseases of aging,\" Vlasuk wrote in an email to the journal.\nInstead, the goal is to develop synthetic resveratrol compounds that activate SIRT1 and could be taken as medication.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There was no discussion of potential harms, nor of the concern for potential harms in the leap from mice to humans, nor of how long and widely a substance would need to be tested in people before its safety could be projected.", "answer": 0}, {"article": "A viral vector is a virus that has been modified to deliver foreign genetic material into a cell.\nThe boy is currently on chemotherapy, the study authors noted.\nIn fact, the experiment was largely successful, with cells now able to produce WAS protein, resulting in increased platelet counts and improvement of some immune-system cells.\nHowever, one of the 10 kids in the study developed acute T-cell leukemia, apparently as a result of the viral vector that was used to insert the healthy gene.\nThe National Marrow Donor Program has more on Wiskott-Aldrich syndrome.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story acknowledged early on and prominently that one of the study participants developed leukemia, which may have been related to the new treatment. The story probably should have mentioned that other harms might become apparent as these patients are followed further or as more patients are studied. However, we think the study went far enough to earn a satisfactory.", "answer": 1}, {"article": "In deep brain stimulation, surgeons insert wires into the brain that allows a specific region to be continuously hit with an electronic pulse.\nAnd for now, the research is preliminary, so it's too early to know for sure if the treatment is appropriate to be used for any kind of depression.\nDr. Samuel James Collier, an assistant professor of psychiatry at the University of Texas Southwestern Medical Center at Austin, predicted that even if deep brain stimulation turns out to be an effective treatment for depression, it'll be far from the first line of defense.\nThe cost of the surgery is about $50,000, she said.\nMost of the patients continued to receive the treatment over two years, although researchers temporarily turned it off in three of them as part of the study before realizing that doing so caused their depression to return.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There\u2019s just one line in the story about harms: \u201cPatients didn\u2019t suffer from side effects, she noted.\u201d The story also says, \u201cThe workings of deep brain stimulation as a whole are a mystery, although Mayberg said it may work by changing the brain\u2019s rhythms.\u201d If how it works is a mystery, we think a little more space should have been devoted to potential harms. There were a total of 8 adverse events related to either the surgery or the device, two of which were deemed serious (infection). The story misses these events entirely.", "answer": 0}, {"article": "Worse, Anderson says, \"I could feel the tumors getting bigger.\nResearchers linked 14 deaths to the study drugs, half caused by immune-system reactions.\nStill, the study stands as \"a major landmark in cancer immunotherapy,\" says Dr. Bernard Fox, president of the International Society for Biological Therapy of Cancer.\nMore than 600 melanoma patients took part in the ipilimumab clinical trial at 125 cancer centers in 13 countries.\nWhile far from a cure, the treatment is the first to improve survival in people with melanoma that has spread, or metastasized, says Dr. Walter Urba, director of cancer research at the Providence Cancer Center.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Good job on harms as well \u2013 \"Serious side effects also became clear. Nearly two-thirds of patients on ipilimumab experienced side effects caused by over-active immunity, such as severe itching, intestinal irritation and diarrhea. Researchers linked 14 deaths to the study drugs, half caused by immune-system reactions.\"", "answer": 1}, {"article": "\"Obviously that's very exciting,\" Spira said.\nWorking on the theory that cigarettes harm not only the lungs but a \"field of injury\" extending to other areas of the respiratory tract, the study authors surmised that evidence of existing or soon-to-develop lung cancer might be available further up in the airway.\nThe minimally invasive procedure involves using a small brush to collect a smattering of cells from the windpipe (a bronchoscopy), explained study co-author Andrea Bild, an assistant professor of pharmacology and toxicology at the University of Utah in Salt Lake City.\nCurrently, there is no good way to detect lung cancer -- the number one cancer killer -- in its early stages when it's most treatable.\nMaybe one day, screening could be done using an even simpler nasal or sputum test, the researchers said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "No potential harms are discussed. Bronchoscopy can be risky, especially in those with already compromised lung function such as smokers.", "answer": 0}, {"article": "In the increasingly popular \"no-scalpel vasectomy,\" a doctor uses an instrument called a dissecting forceps to poke a very small hole in the skin of the testicles to reach the vas deferens.\nOne for the Guys Men, too, have an option for a faster, less painful procedure than vasectomy to tie the vas deferens -- the tubes that carry sperm from the testicles to the penis.\nThe biggest drawback, Whitaker says, is the need for X-rays three months after the procedure to confirm the fallopian tubes are blocked.\nUntil then, the patient must use another form of birth control.\nEven the IUD can't stay in place for more than 10 years.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does a good job of describing the possible harms of Essure. The story should have pointed out that, because the procedure is new, long-term safety is not known.", "answer": 1}, {"article": "Doppler ultrasound, done in the third trimester, is an established way to monitor high-risk pregnancies \u2014 those complicated by problems like poor fetal growth or health conditions in the mother, such as high blood pressure and heart and kidney diseases.\nAnother question, Alfirevic said, is whether ultrasounds of blood vessels other than the umbilical artery might improve pregnancy outcomes.\nOne thing that is clear, the researcher stressed, is that Doppler ultrasound is not necessary for women with average, healthy pregnancies.\nThe review assessed a technology called Doppler ultrasound, which measures blood flow through the umbilical cord.\nBut in the new review, researchers found that across 16 studies of more than 10,000 high-risk pregnancies, Doppler ultrasound testing was linked to a 29 percent reduction in fetal and newborn deaths.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "1clip_filelist.xml\" rel=\"File-List\"/>\n\n\n\nThe story notes that there has been concern that the use of Doppler ultrasound might increase unnecessary interventions, including cesarean section deliveries in cases where it is not actually needed. It says the studies indicated that Doppler ultrasound appeared to lead to better decisions about cesarean sections and inductions of labor. ", "answer": 1}, {"article": ": Link will be live at the embargo time http://jamanetwork.\nAuthors: Andrew K. Chang, M.D., M.S., of Albany Medical College, Albany, New York, and coauthors\n\nResults: After 2 hours pain was less in all participants, without any important difference in effect between the four groups.\nStudy Limitations: The results apply only to pain after two hours.\nBottom Line: For adults coming to the emergency department for arm or leg pain due to sprain, strain, or fracture, there was no difference in pain reduction after 2 hours with ibuprofen-acetaminophen vs three comparison opioid-acetaminophen (paracetamol) combinations.\nWho: 416 patients (ages 21 to 64 years) with moderate to severe acute extremity pain in two urban emergency departments were randomly assigned to receive\n\nWhat (Study Measures): The between-group difference in decline in pain two hours after taking the study drugs.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release does address the harms associated with the use (or misuse) of opioid analgesics. However, the release doesn\u2019t address the potential harms from ibuprofen or acetaminophen in a meaningful way. The closest it comes is a sentence noting that \u201cfurther research to assess longer-term effect, adverse events and dosing is warranted.\u201d But there are some things we already know. As the Mayo Clinic notes, ibuprofen use may increase risk of heart attack or stroke, and may also cause stomach or intestinal bleeding. And acetaminophen can harm the liver if taken in too large a quantity. Granted, the risk of these things is low \u2014 particularly if it is used only in the short term to address acute pain \u2014 but it would have been relatively easy to address.\nThe JAMA study didn\u2019t assess harms either; still a statement to this effect could have been made.", "answer": 0}, {"article": "About 2.2 million Americans currently live with an irregular heartbeat condition, known as atrial fibrillation.\nThis, they said, is due to the procedure's use of a slender medical device called an endoscope, which when inserted into the target region provides a continuous real-time image of the culprit cells.\nIn fact, with this new approach, the study team found that physicians could destroy such cells with 100 percent accuracy.\nThe findings are reported by study author Dr. Vivek Y. Reddy, a senior faculty member in medicine and cardiology at the Mount Sinai Medical Center in New York City, and colleagues in the May 26 online edition of Circulation: Arrhythmia and Electrophysiology.\nThe current study focused on 27 patients (66 percent men), all of whom were diagnosed with a form of atrial fibrillation.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "No discussion of harms. ", "answer": 0}, {"article": "The potential use of psilocybin in patients diagnosed with life-threatening diseases comes at a moment when medical care at the end of life is a subject of growing concern among patients and physicians. Research finds it's still common for dying patients to get painful and futile procedures. Palliative and hospice care, both aimed at easing the discomfort of the seriously ill, are growing specialties in American hospitals. An increasing number of patients, meanwhile, are demanding the right to die with a physician's help.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story addresses this issue thoroughly. Well done.", "answer": 1}, {"article": "So this is like a teaser.\"\nThere are studies based on symptomatic things such as pain, and I think there's pretty good evidence that it does have benefit in that respect.\nChildren, however, often have trouble adhering to patch therapy, the treatment can bring emotional issues for some and a reverse form of lazy eye can also take root, the researchers said.\nThe team nonetheless pointed out that their study's tracking period was relatively short, and that acupuncture is a complicated system that may lend itself to different success rates, depending on the skills of the particular acupuncturist.\nMONDAY, Dec. 13, 2010 (HealthDay News) -- Acupuncture may be an effective way to treat older children struggling with a certain form of lazy eye, new research from China suggests, although experts say more studies are needed.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story states that neither treatment produced significant side effects in the study, which is accurate.\u00a0It also\u00a0goes into some detail about the potential adverse effects reported previously with\u00a0patch treatment, but it doesn\u2019t mention any of the drawbacks of acupuncture that\u00a0patients might encounter outside of a study.\u00a0Notably, the\u00a0frequent treatments required by the study protocol might require taking children out of school\u00a0and cause\u00a0disruption to their education as well as the parent\u2019s employment.\u00a0The researchers\u00a0were able to\u00a0avoid\u00a0this by scheduling all appointments after school,\u00a0but parents outside of a study might not have this\u00a0much flexibility. We\u2019ll call this a satisfactory, but more detail would have been useful.", "answer": 1}, {"article": "In early September, the FDA held scientific meetings to clarify how to regulate such practices.\nNone of these techniques have been studied because clinics maintain that use of a patient\u2019s own cells is not a drug.\nHe adds that these findings are important because while use of a patient\u2019s own stem cells for regenerative therapy is extraordinarily popular, the treatments may be untested and are often poorly regulated.\nThe researchers say such testing is needed because there are at least 600 stem cell clinics in the U.S. offering one form of stem cell therapy or another to an estimated 100,000-plus patients, who pay thousands of dollars, out of pocket, for the treatment, which has not undergone demanding clinical study.\nThey are only able to conclude the procedure is safe to undergo as an option for knee pain, but they cannot yet recommend it for routine arthritis care.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Descriptions of BMAC treatments note that there are minimal side effects, mostly pain at the injection site that lasts a few days and can be treated with painkillers. But there are potential short- and long-term complications (including infection) of bone marrow aspiration and injections into a joint which were not addressed.", "answer": 0}, {"article": "Researchers are developing decision aids to guide physicians and consumers beginning to struggle with lung cancer screening.\nBut it is worth remembering that however effective it is, screening can\u2019t ward off disease.\nResearchers call it \u201ccompeting mortality.\u201d Finding lung cancer is a hollow victory if patients endure testing and treatment, then die of another illness before the cancer would have killed them.\nIn fact, if screening finds cancer, some seniors won\u2019t withstand the surgery, usually a lobectomy, that may cure it.\nThe post-surgical death rate in the national trial was just 1 percent, but that involved major medical centers with specialized radiologists and surgeons \u2014 the ideal setting.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "This story devotes considerable space to explaining the potential problems invoked by false positives, again with facile use of numbers. The one narrative offered in the story elaborates on this element by focusing on an elderly retiree whose scan unearths a \u201chot spot\u201d on her lung that, after considerable angst and pain caused by diagnostic procedures, was found to contain no cancer.\nAnother harm that could have been added is that the screening x-ray involves radiation, which may cause cancer itself. Though the scan is \u201clow dose\u201d, it isn\u2019t \u201cno dose,\u201d and we know that screening not only will prevent death from cancer, but it will in fact be the cause of some of the cancers.", "answer": 1}, {"article": "New vertebral fractures occurred less frequently in the active treatment groups vs placebo: in 0.58 percent (n = 4) of participants in the abaloparatide group; in 0.84 percent (n = 6) of participants in the teriparatide group; and in 4.22 percent (n = 30) of those in the placebo group.\n\u201cFurther research is needed to understand the clinical importance of risk difference, the risks and benefits of abaloparatide treatment, and the efficacy of abaloparatide vs other osteoporosis treatments,\u201d the authors write.\n: This study was funded by Radius Health.\nOverall, there were no differences in serious adverse events between the treatment groups.\nEditorial: Osteoporosis Therapy in Postmenopausal Women With High Risk of Fracture\n\n\u201cUltimately, which therapy is selected for osteoporosis treatment may be less important than identifying and initiating an approved treatment,\u201d write Anne R. Cappola, M.D., Sc.M., of the Perelman School of Medicine at the University of Pennsylvania, Philadelphia, and Associate Editor, JAMA, and Dolores M. Shoback, M.D., of the University of California, San Francisco, in an accompanying editorial.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release says that there were no significant differences in harms seen between the drugs and the placebo without describing all the side effects. But it also mentions that hypercalcemia (elevated calcium level) was lower with the new agent compared to the existing comparator drug. While this was not explained in depth, we\u2019ll give the release the benefit of the doubt for this brief mention of harms.", "answer": 1}, {"article": "Cancer is the No.\nThe test is a long way from being used to screen for cancer, but the study shows a way to get there, the team reported in the journal Science Translational Medicine.\nThe blood test detected the majority of cancers in people with four of the biggest cancer killers: breast, colon, lung and ovarian cancer, the team at Johns Hopkins University said.\nWyndham said it will be important to study such tests in large groups of people who have not had cancer diagnosed, to see if it can truly be used to screen asymptomatic people for cancer.\nResearchers say they have taken a big step towards developing a test that can tell people if they have cancer long before the first symptoms show up.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story is dealing with a proposed new blood test for early-stage cancer, so it would require a blood draw.\u00a0 While the risks of problems with that is small, the larger risk is from false positives or false negatives from the test.\u00a0 The story says, \u201cThere were no false positives in 44 people who did not have cancer, they said.\u201d\u00a0 It also points our that the test didn\u2019t detect the cancer in all cases, giving readers a reasonable expectation of risk of harms from wrong results.\nIdeally the story would have included comments from a researcher not involved with the study about the sensitivity and specificity of such tests (factors that determine false-positive and false-negative rates), and how they would perform in a larger population. \u00a0The other risk here is overdiagnosis\u2013finding cancers that don\u2019t need to be treated.", "answer": 1}, {"article": "Like all laparoscopic procedures, a camera is inserted through a tiny incision to see into the abdomen; two other small incisions are made so that tools can be inserted to perform the surgery.\n\"You would want them to have the least invasive procedure possible.\"\nThe surgery she's upset about may be archaic - but it's very common.\nIt's all over in about an hour, and patients are usually home within a day and back to normal within a week or two.\nWhat's happening now is that the vast majority, about 70 percent, are done the old-fashioned way, with a large surgical incision, lots of pain, and a six-to-eight-week recovery.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does not mention the harms of surgery.", "answer": 0}, {"article": "AMHERST, Mass.\nBoutot and Bertone-Johnson add, \"Though relatively few women in our study consumed very high levels of vegetable protein and our power for analyses of more extreme intake levels was limited, women consuming 9 or more percent of their calories from vegetable protein had a hazard ratio of 0.41 (95 percent confidence interval = 0.19-0.88)\" compared to those eating less than 4 percent.\nParticipants in the study contributed more than 1 million person-years of follow-up, during which 2,041 women experienced early menopause.\nBoutot and Bertone-Johnson suggest that more prospective studies of their findings are warranted, including studies that compare soy-based and non-soy vegetable proteins.\nDiet was assessed five times over the 20-year study, allowing the researchers to capture within-person variation in changes in food and nutrient intake over times, Boutot explains.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The news release doesn\u2019t discuss harms such as allergic reactions or other adverse effects from eating certain plant foods such as soy, wheat, and nuts. However, a discussion of harms doesn\u2019t seem to be warranted since the news release does not advocate consumption of a specific foods, but rather suggests that a moderate increase in a range of plant foods might offer a benefit.", "answer": 1}, {"article": "In Belgium, engineer and nuclear physicist Yves Jongen is pioneering a new therapy that targets cancers with proton radiation; a therapy that offers precision and minimal side effects.\nWhile proton therapy is a giant step forward, it's not yet the magic bullet that clinicians are looking for.\nSo far, it is not effective against all types of cancer.\nOther centers, however, are currently in development.\n\"If you look at leukemia, which is cancer of the blood cells, there is nowhere to shoot -- it's all through the body.\"\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The only harm that is suggested is the lack of availability of the treatment.", "answer": 0}, {"article": "\"Started looking in the cupboard and I saw pie pans and I said, 'These are perfect.\nThe last thing John Kanzius thought he'd ever do was try to cure cancer.\nIt was the worst kind of luck that gave Kanzius the idea to use radio waves to kill cancer cells: six years ago, he was diagnosed with terminal leukemia and since then has undergone 36 rounds of toxic chemotherapy.\nHere's the important part: if clinical trials pan out - and there's still a long way to go - the Kanzius machine will zap cancer cells all through your body without the need for drugs or surgery and without side effects.\nThat's what 60 Minutes wanted to know, so Stahl went to his garage laboratory to find out.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The segment repeatedly states that the treatment has no side effects. This is at least premature, at worst deceptive.\nThe segment should have stated that meaningful clinical outcomes (such as death and quality of life) even in animals have not been demonstrated, that little is known about the long-term effects of the treatment on surrounding tissues, and that the use of nanoparticles in cancer treatment is so new that it\u2019s premature to declare that their use in cancer treatment is without side effects. \nOne researcher interviewed makes clear that the inference that the technique does no harm to surrounding tissue is based only on \"gross inspection\" of that tissue.\u00a0 But the story simplistically states at one point, \"Kanzius put his hand in the field to demonstrate that radio waves are harmless to humans.\"\u00a0 That\u2019s not proof of anything. ", "answer": 0}, {"article": "Dennis Halmi, a member of the Bluepoint Surgical Group in Woodbridge, says that in 2002 \"we did a handful\" of second operations on obesity patients, \"maybe five, six.\nOf course, a second obesity surgery comes with increased risk.\nThat's an often frightening attack of sweating, nausea, faintness, diarrhea, cramps and rapid pulse that bypass patients sometimes suffer after eating just a bite of a sugary food -- a deterrent to consuming certain calorie-dense items.\nIf the patient doesn't go in for adjustments, the whole thing won't work.\nAlong with the risk comes the uncertainty of how well people will be able to lose -- and keep off -- weight the second time around.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story did mention the gastric banding following gastric bypass could be complicated by adhesion of organs to one another resulting from scarring from the first surgery. \u00a0And while mentioning that this might result in a longer time needed for the surgery, there was no discussion about what ramifications there might be for the patient or how often this scenario was encountered. \u00a0There was no discussion of other complication rates. ", "answer": 0}, {"article": "When his heart disease was first diagnosed four and a half years ago, Mr. Del Sontro, now 50, told his cardiologist he wanted to run one more Bay to Breakers race, a century-old 12-kilometer race in San Francisco.\nDr. Biesecker acknowledged that there was no guarantee of success.\nThat strategy alone, Dr. Biesecker said, has eliminated the vast majority of candidate genes.\nResearchers\u2019 ignorance of these control regions and what many of them do might doom the effort.\nStill, Mr. Del Sontro is preparing for the worst.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There are several \u201charms\u201d embedded in this story in the way it is framed \u2013 worry, anxiety, and a sense of foreboding. Yet those harms are mostly unexplored in a meaningful way.\u00a0 \u201cBetter\u201d tests won\u2019t help unless they also identify better treatments, and there is little or no critical attention paid to potential interventions here \u2013 just a tossed off one-liner about the women who gets a stent after the first episode of stable angina, and the implied sense that stenting and bypass are used to prevent heart attacks and death.", "answer": 0}, {"article": "Philadelphia, PA, August 14, 2017 - Stanford University scientists have described a new type of test that can detect genetic mutations in minute amounts of DNA released from cancer cells into the blood.\nAccording to the report in The Journal of Molecular Diagnostics, this highly sensitive test has the potential to be personalized to recognize mutations unique to any individual cancer.\nIn contrast, molecular tests like the one we have developed will enable patients to be monitored at every visit, and thus have the potential for quickly tracking cancer growth and spread.\n\"For monitoring patient tumors, only a handful of blood tests are available which are limited to only several types of cancers.\nAfter generation of customized mutation detection assays, the researchers were able to identify tumor-derived circulating DNA from three out of six patients.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "There is no mention of harms. The assumption here is that more regular monitoring of patients via blood samples will lead to better outcomes, when we actually know from repeated studies that more monitoring for disorders leads to more unnecessary treatments and surgeries.\nWhat is the false positive rate? The false negative rate? What are the possible clinical harms that can result from either of these scenarios?", "answer": 0}, {"article": "\"When parents have a child diagnosed with an autism spectrum disorder, one of the first questions they often ask is 'how did this happen?'\nBetween 10 percent and 15 percent of autism cases can be traced to a known genetic cause, the researchers noted.\nStandard practice is to offer children with autism two tests as a first-line genetic work-up: karyotype and fragile X testing, the researchers said.\nBut that leaves 85 percent or more families with little explanation for the disorder, Marion said.\n\"CMA should be added to first-tier genetic testing for autism spectrum disorders.\"\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There was no discussion regarding the emotional or social ramifications associated with receiving genetic testing results.\u00a0 ", "answer": 0}, {"article": "\u201cIt\u2019s a tricky thing to get your mind around,\u201d Whitlock said.\nAt that time, the task force recommended that sexually active women get regular Pap tests to screen for cervical cancer.\nAnd no one knows yet whether HPV testing actually catches cervical cancer at an earlier stage, or reduces deaths from the disease, compared with Pap tests.\nBut many women still do not get regular Pap screening, Whitlock pointed out.\nIn general, Whitlock\u2019s team found, HPV tests were more sensitive than conventional Pap tests, but they were less specific, meaning they had a higher false-positive rate.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story explained the impact that false-positive tests might have if the HPV testing became routine. More women could have unnecessary biopsies to remove tissue that was not cancerous.", "answer": 1}, {"article": "In a study suggesting that red wine might be the next big thing in breast cancer prevention, a study has found that women who drank just under two servings of red wine daily experienced hormonal changes that mimic the effects of a drug used to prevent malignant breast tumors from coming back.\n\nThe study, published Friday in the Journal of Women's Health, found that consuming the same amount of white wine did not have the same effect in premenopausal women participating in the study.\n\nWomen intent on warding off breast cancer have been warned about alcohol consumption: as recently as November, a study found that women who consumed as few as three servings of alcohol a week increased their risk of developing the disease, which strikes one in eight American women at some point in life.\n\nWhite wine and other alcoholic beverages are believed to promote the conversion of androgens--\"male hormones\" such as testosterone, which circulate in all women's blood--into estrogen. And the greater a woman's lifetime exposure to estrogen--whether her own or estrogen that comes from medication or environmental sources--the higher her risk of developing breast cancer.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story included past warnings about alcohol consumption for \u201cwomen intent on warding off breast cancer.\u201d", "answer": 1}, {"article": "Patients taking briakinumab had more serious infections and more cancers than those taking methotrexate.\nReich, a partner at Dermatologikum Hamburg and professor of dermatology, venerology, and allergology at Georg-August-University in Gottingen, Germany, says that after a year of therapy, roughly 60% of the 154 patients in the briakinumab group had near or complete clearance of their skin lesions.\nGordon was not involved in the current study, but he has been involved in research of the drug and has been a paid consultant and investigator for Abbott.\nBut as successful as the drug appears to be for some patients, it may come with a significant risk.\n\"This drug has had, in this trial, the highest efficacy we have ever seen with any biologic in psoriasis before,\" says study researcher Kristian Reich, MD.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Weaker than the competing HealthDay story on this point.\u00a0 This story only reported \u201cpatients taking briakinumab had more serious infections and more cancers than those taking methotrexate.\u201d\u00a0 Then, in the second last sentence of the story, it added that serious adverse events occured in 9/1% of briakinumab group and 6.1% of methotrexate group.\u00a0 But HealthDay actually quantified what they were \u2013 the number of serious infections and the number of cancers.\nIt\u2019s inadequate for WebMD to throw in a line \u201cmore cancers\u201d while failing to provide any numbers or details.", "answer": 0}, {"article": "\u201cRemember this day.\nAnd when given with two older chemotherapy drugs in non-selected patients, it was almost twice as likely to shrink tumors as chemotherapy alone.\nThe second trial, mixing Keytruda with chemotherapy, was much smaller but was notable because it was the first time that a combination of immunotherapy and chemotherapy has been shown to work in a randomized Phase II study.\nRival drugmaker Bristol-Myers Squibb had tried a catch-all approach with its Opdivo drug but it failed to help previously untreated patients when given on its own in a trial that included people with low levels of a protein called PD-L1.\nAnother similar drug from Roche also demonstrated broad efficacy as a so-called second-line option in patients who had received prior treatment.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Both chemotherapy and immunotherapy carry risks. But the story doesn\u2019t discuss the general potential harms of either, nor what was reported\u00a0in the study.\nAs the NEJM study offered up, \u201cserious treatment-related adverse events occurred in a similar percentage of patients in the pembrolizumab (Keytruda) group and the chemotherapy group (21.4% and 20.7%, respectively).\u201d And, \u201cdiscontinuation of treatment because of treatment-related adverse events occurred in 7.1% of patients in the pembrolizumab group and in 10.7% of patients in the chemotherapy group.\u201d\nThese serious adverse events included diarrhea and pneumonitis in the Keytruda group, and anemia, fatigue, and decreased appetite in the chemo group (among other events).\nSome independent\u00a0commentary on how these drugs impact quality of life\u2013especially for very sick patients with advanced cancer\u2013would have been very useful.", "answer": 0}, {"article": "They did so to offer support, but also to spread awareness, because they say too often life and death for someone having a cardiac arrest comes down to chance. If a bystander performs CPR while medics are on their way, survival rates more than double, doctors say.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "CPR, when performed by training medical personnel or bystanders, carries risk including broken ribs, internal organ damage and cognitive deficits. These risks are especially high for those with chronic or terminal diseases, or whose arrests already have lasted long enough to cause brain damage. The urge to \u201chelp\u201d among bystanders is powerful and praiseworthy; and Good Samaritan laws not only recognize the impulse as humane but also protect those who give aid. But a story so positive about \u00a0CPR\u2019s benefits has some obligation to alert victims and potential helpers alike of the risks as well as the benefits.", "answer": 0}, {"article": "\"One caveat is that other agents that have shown clear efficacy in this model of PD have subsequently failed to show benefit in clinical studies in PD (e.g.\nThis study, published online in Brain Research, involved Parkinsonian mice that were given Carbidopa/Levodopa (sold as Sinemet\u00ae), a drug used to boost levels of the neurotransmitter dopamine, which is lost in PD.\nPlans for a clinical trial of low-dose lithium for PD patients are in early stages.\nThe third in a series of studies from the Andersen lab involving PD and low-dose lithium, the results add to mounting evidence that low-doses of the psychotropic drug could benefit patients suffering from the incurable, degenerative condition.\nLow-dose lithium reduced involuntary motor movements - the troubling side effect of the medication most commonly used to treat Parkinson's disease (PD) - in a mouse model of the condition that is diagnosed in about 60,000 Americans each year.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The news release is silent on the issue of the potential for toxicity with lithium augmentation. \u00a0Although the research was conducted in mice, the researchers did note the potential for toxicity in their publication, \u201c\u2026in a few reported cases lithium treat- ment was suggested to be detrimental to PD patients and to cause side effects\u2026\u201d Since lithium is also used in the treatment of psychiatric disorders, it\u2019s possible the release could have pulled from the literature on this use to discuss potential side effects.", "answer": 0}, {"article": "A study shows that not all good fats are the same when it comes to protecting your health\n\nA study shows that not all good fats are the same when it comes to protecting your health.\nReviewing the dietary advice as a whole is important, says Alice Lichtenstein, a spokesperson for the association, since changes in one area could have unexpected, and potentially harmful, effects on other eating habits.\nRamsden says the findings provide some refined understanding of unsaturated fats, which come in different chemical forms that may have varying benefits or risks.\nThe latest results, however, raise questions about that advice.\n\u201cWhat happened is that in the 1960s all polyunsaturated fats were considered the same.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The overall thrust of the story was about harms of linoleic acid, so we\u2019ll call this satisfactory.", "answer": 1}, {"article": "Eating more fiber during adolescence was linked to a 16 percent lower risk of breast cancer overall, and a 24 percent lower risk of breast cancer before menopause.\n\"The results of this study emphasize the role of an early life high-fiber diet on prevention of breast cancer in later life.\nEating more fruits and vegetables was especially beneficial, the researchers said.\n\"Having the recommended 25 to 30 grams of fiber daily would decrease the risk by 30 percent and potentially even greater with higher fiber intake,\" Farvid said.\nShe said that recently more evidence has come to light suggesting a relationship between dietary fiber and breast cancer risk, and that eating more fiber would be a simple way to reduce risk.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "We\u2019re not aware of any harms from incorporating additional fiber into one\u2019s diet by eating more fruits and vegetables. We\u2019ll rate this Not Applicable.", "answer": 2}, {"article": "BioZorb has received 510(k) clearance from the U.S. Food and Drug Administration.\nThe study also noted that the device provides a helpful guide for post-treatment mammograms and other long-term follow-up to check for any cancer recurrence in these patients.\nThe article reports that the device provides clear visualization of the surgical site where the tumor was removed, thereby improving communication between the surgeon and radiation oncologist.\nBy providing better targeting, they said, the marker could also play a role in facilitating the use of external beam partial breast irradiation.\nThe authors said use of the marker facilitated their shift toward these shorter courses of radiotherapy.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "There was no indication of harms in the news release. However, the original article did note side effects that arose in two patients. It would have been good to note them in the release. The published study also acknowledged that skin changes and dermal lymphedema (swelling) were a concern among patients but were not specifically tracked. Again, a mention of that in the release would have been helpful to patients.", "answer": 0}, {"article": "A drug-coated stent made by Abbott Laboratories that is awaiting U.S. regulatory approval is as safe as, and potentially more effective than, the market-leading version of the heart device made by Boston Scientific Corp., according to findings presented Tuesday at the EuroPCR conference in Barcelona.\n\nClinical-trial data analyzed by Abbott two years after its Xience V stents were implanted in patients are likely to reassure investors and regulators about the product's long-term safety and could restore some investor confidence...", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story provided quantitative data indicating that the rate at which blood clot formation occurred after implanting the new stent was comparable to the rate with one of the currently available drug-eluting stents. \u00a0However there was no information about how the harms with this new stent compared with bare metal stents or no stent at all.", "answer": 0}, {"article": "Kite Pharma is racing to get the first FDA approval of an experimental gene therapy to fight cancer.\n\nAn experimental gene therapy that turns a patient\u2019s own blood cells into cancer killers worked in a major study, with more than one-third of very sick lymphoma patients showing no sign of disease six months after a single treatment, its maker said Tuesday.\n\nIn all, 82 percent of patients had their cancer shrink at least by half at some point in the study.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "This is a major\u00a0strength of this article. It makes it clear CAR-T treatment is not without major risks which include: treatable anemia, brain toxicity, and a \u201cdangerous condition where the immune system overreacts in fighting the cancer\u201d (likely, \u201ccytokine release syndrome\u201d). Deaths directly caused by CAR-T therapy in this and other trials are\u00a0mentioned.", "answer": 1}, {"article": "Anderson Cancer Center in Houston.\nThis targeted form of treatment takes advantage of a weakness in the BRCA gene to further cripple the cancer cell's ability to repair itself, grow and spread, said Weiss, who was not involved with the study.\nIn addition, several ongoing studies are looking at combinations with PARP inhibitors \"to try to expand who may benefit or lengthen how long they may work,\" Litton said.\nSimilar drugs have already been used to treat advanced, BRCA-mutated ovarian cancer, according to the agency.\n\"For women with metastatic breast cancer and a BRCA mutation, PARP inhibitors may be considered for their treatment,\" said lead researcher Dr. Jennifer Litton, an associate professor of breast medical oncology at the University of Texas M.D.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story explained some of the harms, notably blood disorders, and included the rate of harms in both the treatment group and the control group, which is a useful comparison to include.\nOne detail that also would have been useful to include: The rate of severe adverse events was similar in both the treatment and control groups. The drop-out rate (how many women dropped out of the study due to side effects) was slightly higher in the talazoparib group.", "answer": 1}, {"article": "\"Everyone heals differently.\nThere also isn't a great deal of information on how effective medications or home exercise programs are for treating neck pain, the researchers noted.\nThere are different pathways to healing, and whether you feel you're better off with chiropractic, home exercises or medications, this study shows that all three are basically just as effective.\nAll three experts said anyone experiencing neck pain needs to have it evaluated to make sure there isn't a serious or correctable cause of the pain.\nHe also noted that it's important for anyone receiving spinal manipulation to know that there are rare, but serious risks that can occur with neck manipulations.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "This rating is a close call. The story does warn readers that spinal manipulation can pose \u201crare, but serious risks.\u201d Also, none of the trial participants reported a serious adverse event. But the story could have been more specific and reported that, as the editorial accompanying the research article pointed out, \u201cneck manipulation has a rare but potentially catastrophic risk for vertebral artery stroke.\u201d Also, the story should have at least briefly mentioned some of the harms that can be caused by the pain medications (including acetaminophen, narcotics and muscle relaxants) that were prescribed to some participants.", "answer": 0}, {"article": "No question,\u201d he said.\nThe Phase II study included 173 women whose cancer had spread and who had received other treatments.\nThe best overall tumor response rate, of 20 percent, was in those given Erbitux.\nIt is the first time researchers have shown that a drug like Erbitux, which targets a protein called epidermal growth factor involved in cancer cell growth, can provide substantial benefit in difficult-to-treat \u201ctriple negative\u201d breast cancer.\nDr. Fabrice Andre from Institut Gustave Roussy in Villejuif, France, who was not involved in the research, said the results were \u201cextremely important\u201d but echoed the view that the findings now had to be confirmed in larger-scale clinical tests.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "", "answer": 0}, {"article": "Among those 40 to 49 who had regular screening, for every 1,000 women tested, 121.2 had a false positive.\nFor every 10,000 women screened repeatedly over 10 years, four lives are saved in women 40 to 49; eight in women 50 to 59; 21 in women 60 to 69; and 13 in women 70 to 74, the task force found.\nThe guidelines relied in part on a study of records from 405,191 women who had digital mammograms from 2003 to 2011, which found that false positives were common, especially in younger women.\nDr. Constance Lehman, a professor of radiology at Harvard Medical School and director of breast imaging at Massachusetts General Hospital, who is not on the task force, said she was pleased to see that although its advice had not changed, the group had placed more of an emphasis than before on the importance of women\u2019s having the freedom to decide how often to be screened and when to start.\nThe task force said it concluded \u201cwith moderate certainty\u201d that the benefit was moderate in women 50 to 74 and small in women 40 to 49.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "This is really a strong point for the story. The story devotes several paragraphs to explaining \u2014 and quantifying \u2014 the potential harms of false positives and overdiagnosis. It then spends an additional two paragraphs trying to place these harms in context. For example, citing a cancer expert\u2019s position that the potential harms are significantly outweighed by the potential benefits. The story also made clear that there was an emphasis in the recommendations that women be able to decide for themselves on when to begin screening, and how often to be screened. That\u2019s an important point \u2014 women should know that they have a role to play in weighing risks against potential benefits and \u2014 ultimately \u2014 making decisions about their health.", "answer": 1}, {"article": "\u201cAnd you need all hands on deck.\u201d\nWhen the injections stopped, many in the study relapsed.\nDr. Joshua Lee, of New York University\u2019s medical school, said more evidence is needed to determine whether the medication can help substantial numbers of people and whether it\u2019s worth paying for, but the early results are encouraging.\nThe results, published in March in the New England Journal of Medicine, have been promoted by the drugmaker, Ireland-based Alkermes, as it markets Vivitrol to U.S. correctional systems.\nThe drug\u2019s manufacturer hopes prisons will be the gateway to a larger market.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Although the story does make clear that evidence so far suggests that short-term use of Vivitrol does not eliminate overdoses in the longer term, it does not reflect on adverse events reported in the NEJM article as a result of the trial, which included such issues as reactions at the injection site, headaches and nausea.", "answer": 0}, {"article": "Dr. Len Lichtenfeld, deputy chief medical officer of the American Cancer Society, said it's clear that \"some women with metastatic breast cancer have benefited from Avastin, but others not only have not benefited, they've been harmed.\nThe results of those studies were a bitter pill for patients thriving on Avastin and researchers excited by the promise of the early data.\n\"Survival was consistently better at one year in all of the studies, indicating that this is a safe and effective option.\nBased on the new data, an FDA advisory panel voted 12-1 to reverse the accelerated approval in July.\nThe announcement does not affect Avastin's status as an approved therapy for lung cancer, kidney cancer, colorectal cancer and brain cancer.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Harms are not quantified, and it would\u2019ve been very helpful to know how frequently these serious side effects occurred in the trials. Were they exceptionally rare? Utterly rampant? The point of our criterion is that without quantifying the harms, readers can\u2019t evaluate the risk/benefit trade-off for themselves.\nThat said, we could almost award\u00a0the story credit on the spirit of this criterion because it gives the serious harms, and their implications in the FDA decision, a solid amount of time in this article. The point from the ACS medical officer that some women \u201chave not only not benefited, they\u2019ve been harmed,\u201d conveys the big picture.\nHowever, true to the definition of this criterion, we must grade this as unsatisfactory.", "answer": 0}, {"article": "\u201cWe do not know for sure, and we do not know which particular aspect of olive oil is the most relevant to stroke,\u201d he says.\n\u201cMaybe olive oil improves vascular risk factors such as hypertension, dyslipidemia, diabetes, heart disease, obesity, which may in turn reduce stroke risk, or it may be that olive oil is anti-inflammatory or an antioxidant.\u201d Scarmeas writes an accompanying editorial.\nShe calls the findings \u201cintriguing\u201d but says they \u201cdo not equate a randomized clinical trial and should be used with appropriate caution in making broad recommendations.\u201d\n\nSuzanne Steinbaum, MD, director of women and heart disease at Lenox Hill Hospital in New York, says moderate use of olive oil in cooking and on bread may help protect against stroke in people older than 65.\n\u201cOlive oil is a healthy fat and it can reduce cholesterol and inflammation, and has been shown to help reduce the incidence of heart disease,\u201d she says.\nKeeping blood pressure controlled, not smoking, exercising regularly, and eating a healthy diet that is low in salt and rich in fruits and vegetables can also help reduce stroke risk, she says.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Not applicable.", "answer": 2}, {"article": "Radiation oncologist Dr. Richard Stock, of Mt.\n\"With four treatments left, I have 98 percent of my vision left,\" Rianta said.\n\"There is no good evidence, medical evidence that it is better than the current state of the art intensity modular radiation therapy,\" Stock said.\nJust weeks later, Rianta was getting the therapy and the tumor was shrinking.\nThe technology is two decades old, but Mass.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does not mention any harms of proton beam therapy.", "answer": 0}, {"article": "With advanced heart failure, a leading cause of hospitalizations, blood-pumping ability is diminished as the heart\u2019s left ventricle becomes enlarged and weakened.\nAfter one year, the Vericel treatment led to a 37 percent reduction versus placebo in a composite of adverse events, including death, heart-related hospitalizations and unplanned clinic visits related to heart failure.\nHowever, the treatment failed to improve secondary goals of the trial, such as heart-pumping efficiency and six-minute walking distance, and Vericel shares fell more than 31 percent by afternoon trading on Monday.\n\u201cFor patients, this is a really hopeful thing.\u201d\n\nHenry, who presented the data at the ACC meeting, stressed the need for larger trials to prove the benefit of ixmyelocel-T\n\nFor the treatment, bone marrow is taken from the patient and enhanced over two weeks to increase two types of cells associated with healing.\n\u201cThis is strong evidence in a well-designed trial that we can decrease events,\u201d said Dr. Timothy Henry, the study\u2019s lead investigator and chief of cardiology at Cedars Sinai Heart Institute in Los Angeles.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Harms were not discussed, although they are important, especially considering the failure of the therapy to improve secondary outcomes.", "answer": 0}, {"article": "Tai chi is a mind-body exercise that originated as a martial art in China, utilizing slow, gentle movements to build strength and flexibility, as well as deep breathing and relaxation, to move qi, or vital energy, throughout the body.\nThe controlled breathing and movements may promote \"mental tranquility,\" according to the study, which could help with pain.\nWhile larger studies are needed to confirm the findings, tai chi looks promising as an alternative treatment, Yeh said.\nMost patients, according to background information in the article, remain in pain years after the diagnosis, are aerobically unfit, have poor muscle strength and flexibility, and need medications to control symptoms.\n\"This could represent an ideal exercise for fibromyalgia sufferers.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does not identify any possible harms. It is difficult to imagine that twice-weekly tai chi, like any other form of moderate exercise, would be harmful, but, at a minimum, the story could have reported upon the study\u2019s adverse events registry. The NEJM authors clearly state: \"No adverse events were noted during the study interventions.\" The study did not consider worse muscle soreness to be an adverse event so long as it resolved before 3 days\u2019 time, so we don\u2019t know how much of that occurred in either arm of the study. So why not drop in a line about the lack of adverse events? Wouldn\u2019t a reader be interested that this exercise appears safe?", "answer": 0}, {"article": "A popular new type of prenatal test intended to find genetic flaws in a fetus can in rare cases also reveal previously undiagnosed cancer in the mother.\n\nThe unexpected finding emerged in a study involving eight women who initially had abnormal results from the prenatal blood test, but for whom a subsequent assessment showed their babies were normal. When the mothers\u2019 DNA was reanalyzed, researchers said, the anomalies were linked to cancer in each of the women.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The WSJ article very explicitly notes that there are harms from invasive prenatal tests, although it does not give rates of miscarriage; and it goes into welcome detail about the challenges of giving women genetic risk information for themselves or their infants based on the noninvasive blood test, noting \u201cthere is no consensus on when or how to inform\u201d patients of such findings. On the other hand, the story explains, if maternal tumor DNA is detected, the need to inform the mother may be urgent and life saving.", "answer": 1}, {"article": "Although TEPI patch remains highly tacky and adheres well to skin, it is not uncomfortable to peel off, unlike many traditional plasters.\nThe team says that popular ibuprofen gels make it difficult to control dosage and can be easily rubbed off.\nHe said Medherant\u2019s technology would eliminate most side effects created by oral medication.\nHaddleton says the technology has exciting potential for other medications, such as opioid painkillers.\nWe\u2019re controlling the dosage and we\u2019re keeping it there for a prolonged period of time.\u201d\n\nThe patches could help treat conditions like chronic back pain, neuralgia and arthritis without the need to take potentially damaging doses of the drug orally.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story provides no information on the potential side effects of this method of drug delivery. Ibuprofen is a drug and all drugs have side effects. It sounds like the TEPI patches will have the same possible side effects as topical gels or other patches, which are mostly limited to irritation on the skin and other minor issues. It is claimed that the TEPI patches cause little discomfort, but how was this assessed?", "answer": 0}, {"article": "In nonblood-based tumors, such as melanoma, only about one-half of patients have T cells in their tumors that can be harvested, and only about one-half of those harvested cells can be grown.\nFor the clinical trial, the Johns Hopkins team enrolled 25 patients with newly diagnosed or relapsed multiple myeloma, although three of the patients relapsed before they could receive the MILs therapy.\nOne year after receiving the MILs therapy, 13 of the 22 patients had at least a partial response to the therapy, meaning that their cancers had shrunk by at least 50 percent.\nNoonan says the research team has used these data to guide two other ongoing MILs clinical trials.\nNoonan says the small trial helped her and her colleagues learn more about which patients may benefit from MILs therapy.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "We\u2019ll give this criterion a satisfactory rating since the release specifically spells out, \u201cNone of the participants had serious side effects from the MILs therapy.\u201d However, the study is really too small, and the time\u00a0span too short, to comment substantively on the possible harms that might be seen if and when the treatment is more widely used. The research paper actually makes the point that the new procedure doesn\u2019t require the \u201csurgical removal of tissue,\u201d and the procedure can be done at bedside rather than an operating suite. But\u00a0the removal of cells from the bone marrow is still an invasive procedure that carries its own risk of infection or other problems. The release would have benefited from at least mentioning this aspect.", "answer": 1}, {"article": "Airways became less likely to close off after exposure to an allergen.\nThe drug also improved overall airway function, an effect researchers hadn't expected, Israel said.\nBut, this powerful cancer drug can't be recommended for them on the basis of this small study, Israel and other specialists noted.\nTwo generic versions of the drug were launched last year, which could make it less pricey than new-wave asthma drugs headed for the market, Israel added.\nPhysical examinations showed that people taking Gleevec actually experienced a slight overall widening of their airways, Israel added.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story just barely passes the bar on this one, reporting that side-effects \u201cwere not as severe as expected.\u201d It adds: \u201cOne person dropped out because of a sharp decline in white blood cells, which bounced back after the drug was discontinued. Another person dropped out because of leg cramps associated with the drug.\u201d\nIt also quotes an independent expert saying the drug is \u201ctoxic.\u201d For lay readers, that might be a confusing term.\nAlso, there\u2019s no mention of the general risks of imatinib, which include infections, bleeding, liver problems, and heart problems. The fact that this is a type of chemotherapy could have been mentioned, too.", "answer": 1}, {"article": "The stool was more solid, the diarrhea goes away, and the bloating is much less.\"\nWith the drug treatment, Pimentel says, those with the IBS ''can enjoy social outings without the worry of having to run to the bathroom and having diarrhea.\"\nThat can translate to big changes in the lives of those with IBS, estimated to affect about 15% of adult Americans.\nThe study looked only at those IBS patients with the non-constipation form, he tells WebMD.\nExisting treatment options -- diet and lifestyle modification, psychological therapy, and other drugs -- do not help all people with the condition.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The main problem is that there was no explicit statement about presence or absence of side effects. Readers want to know, and since researchers have studied and reported on adverse effects, there should be an explicit mention in a news report. In this case, there was no difference in side effects between the drug group and the placebo group.", "answer": 0}, {"article": "We could not find the requested page.\n\nPlease visit our home page to explore our services.", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release says the test\u2019s ability to diagnose normal moles was 36 percent, \u201capproaching the levels achieved by expert dermatologists performing visual examinations of suspect moles under the microscope.\u201d\nBut as noted above, that statement downplays the fact that the test will result in a very high number of false-positives. A 36% specificity means that nearly two thirds of non-malignant moles will test positive and require additional follow-up. A test that correctly identifies nearly all melanomas, but also flags more than half of normal growths as melanomas, isn\u2019t all that useful.", "answer": 0}, {"article": "When it comes to health, I\u2019m skeptical of willpower. Sure, I talk to my students about personal responsibility, but when it comes to the health of populations, I look for big fixes more than for small acts of will.\n\nThat\u2019s why my ears perked up when I heard that two old physician friends had decided to start taking, as a preventive measure, some of the medications often included in what the field has dubbed the \u201cpolypill.\u201d My friends are both top doctors in their 60s, with good diet and lifestyle, and this is now part of their...", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story doesn\u2019t mention important harms of the various medications that might go into the pill. We\u2019re told only that \u201cthe doses are low, so it\u2019s relatively safe.\u201d We wanted to see a nod to side effects, risks and trade-offs of using these drugs\u00a0in a broad preventive manner.\u00a0Taking a baby aspirin every day, for example, can increase the risk of serious gastrointestinal bleeding, which is why guidelines don\u2019t recommend that everyone over 50 take them.\nThe story does state that a polypill might actually backfire by causing people to think it will protect them, and therefore they exercise less and eat worse.", "answer": 0}, {"article": "Smith also embarked on a new diet, cutting out dairy and red meat.\nBut the report doesn\u2019t note that just 1 percent of women have that condition in the first place, making the odds still overwhelmingly in her favor.\nAnd even the company\u2019s founder and CEO acknowledges the test can\u2019t provide clear and definitive answers on which treatments women should try next if they\u2019re struggling with infertility.\nBut others caution that Fertilome is just the latest genetic test promising more than it can deliver \u2014 and, in this case, playing to the fears of women who are anxious about becoming a mother.\nCelmatix is mostly marketing the test to reproductive specialists, who are largely using it in the toughest infertility cases, Beim said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "One of the strengths of this story is its explanation of the actual risk to a woman with a particular genetic variant identified by the test.\u00a0 The test results cast risk in terms of relative likelihood (i.e., they determine if a woman is more likely, as a result of a genetic variant, to develop a specific condition that could affect her ability to get pregnant) while the story supplements that with numbers characterizing the \u201cabsolute\u201d risk (that condition is rare in the first place, so even an increased risk is small in absolute terms). \u00a0Sources in the story also identify another harm: misinterpretation of results can heighten anxiety. The story could have gone further, to contemplate the possibility that women may make wrong decisions based on the incomplete information provided by the test.", "answer": 1}, {"article": "\"However, if your child is overweight or obese I recommend that you consult your primary care physician for advice, and consider having their vitamin D levels tested.\"\n\"Although these initial findings indicate that vitamin D could be used in the treatment of obesity, there remains a lack of evidence on the safety and long-term effects of supplementation, particularly if there is no vitamin D deficiency,\u201d said Charmandari.\nIn their next investigation, the team will study whether vitamin D supplements can improve the health of obese children and adolescents who have been diagnosed with disorders linked to obesity, such as high cholesterol, high blood sugar levels, and high blood pressure.\n\"Future studies should explore what the underlying mechanisms are that explain this specific relationship between vitamin D and visceral adipose tissue.\"\nChildren who took vitamin D had a significantly lower BMI, the researchers found.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The possible harms of taking too much vitamin D are fairly well-known for adults, less is known about how it affects kids. Nevertheless the harms are\u00a0numerous and significant. At least a small sample of those risks should have been included in the story, e.g. putting too much calcium in the blood, a greater risk of forming kidney stones, and a greater risk of developing kidney diseases.\nThe story did at least point out \u201cthere remains a lack of evidence on the safety and long-term effects of supplementation, particularly if there is no vitamin D deficiency.\u201d", "answer": 0}, {"article": "\"Those stem cells are given back to the patient where they can go back to the bone marrow and make the blood cells for the rest of the patient's life,\" Kohn said.\nIt's a genetic disorder that leaves the body with a weakened immune system, making infants extremely vulnerable to illness.\nDr. Kohn said of an experimental treatment for SCID, \"It's gone from a 'one day, maybe' to a real clinical reality.\"\nDr. Kohn is currently working with the FDA to make his treatment available nationwide.\nThat means an actual cure for the disease, said Kohn, who is also director of the Human Gene Medicine Program at UCLA.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Harms were not discussed in any way. With such a serious disease, harms would have to be significant to outweigh the potential benefits, but they should still be mentioned.\nThe story\u2019s depiction of the procedure doesn\u2019t convey the full scope of what\u2019s involved. It states, \u201c\u2026.the\u00a0treatment involves taking bone marrow from the patient to gather stem cells. A cloned gene is then added to correct what was missing at birth\u2026\u201dThose stem cells are given back to the patient where they can go back to the bone marrow and make the blood cells for the rest of the patient\u2019s life.\u201d Although it sounds pretty straightforward, a look at the actual procedure as listed at ClinicalTrials.Gov\u00a0provides a more complete picture. The stem cells are collected under general anesthesia and treatment with busulfan (which can cause significant side effects) to reduce bone marrow cell production in preparation for the stem cell infusion.", "answer": 0}, {"article": "The requested URL /2011-08-30/business/29945941_1_mark-kris-cancer-cases-lung was not found on this server.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story quotes sources claiming \u201cYou\u2019re going to be sparing individuals side effects\u201d and it describes Xalkori as \u201ca pill with relatively minor side effects compared to the hair loss and nausea that chemotherapy can cause\u201d. The drug label and FDA news release are less dismissive of the problems experienced by patients in the preliminary trials so far.\nWhile few trial participants reported symptoms severe enough to cause serious harm, hospitalization or symptoms so bad they couldn\u2019t carry on routine activities, most of the patients did report problems with vision and more than half reported nausea, diarrhea, vomiting or other gastrointestinal symptoms, including some that may have required treatment. Treatment was interrupted in 36 percent of the patients in one of the trials and 45 percent of the patients in the other trial. Five percent of patients had neutropenia, abnormally low white blood cell counts. (See http://labeling.pfizer.com/showlabeling.aspx?id=676) \nThe FDA news release included a list of side effects and warned of potentially life-threatening reactions. \u201cThe most common side effects reported in patients receiving Xalkori included vision disorders, nausea, diarrhea, vomiting, swelling (edema), and constipation. Vision disorders included visual impairment, flashes of light, blurred vision, floaters, double vision, sensitivity to light, and visual field defects. Xalkori use has also been associated with inflammation of the lung tissue (pneumonitis), which can be life-threatening. Patients with treatment-related pneumonitis should permanently stop treatment with Xalkori. The drug should not be used in pregnant women.\u201d (See http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm269856.htm)\nThe story should have summarized these side effects and warnings. It should have also noted that since the trials reported by Pfizer included only 255 patients, little is known about the potential risk of rare, but serious, side effects.", "answer": 0}, {"article": "He walks about 50,000 steps a week, golfs, works out and tap dances and consumes about 1,800 daily calories.\nThe study, known as DPPOS, puts science behind Mr. Held's success.\nThat means lifestyle changes were twice as effective as medicine in delaying or preventing diabetes.\nJohn Held, with a family history of type 2 diabetes, watched as his own blood-sugar levels crept over the normal range, identifying him as a prime candidate for the disease.\nThe study is published online today in the The Lancet, a medical journal.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story fails to mention the side effects of metformin, which include gastro-intestinal side effects that can inhibit compliance. A serious condition, lactic acidosis, is a rare but significant side effect.\n\u00a0", "answer": 0}, {"article": "\"Transfer between hospitals takes a lot of time,\" said Turner.\nThe VIPS device requires very little training to operate compared to that required to learn standard emergency examination skills, thereby reducing the possibility of human error during emergency diagnosis.\nThe researchers hope that the device will save valuable time -- especially important in stroke where time is brain -- when it is deployed with emergency medical personnel in the field.\nIf so, the VIPS device could have widespread clinical implications, helping emergency personnel decide whether to take a patient to a comprehensive stroke center or a primary stroke center for treatment.\nThis places the VIPS device above standard physical examination tools used by emergency personnel that display specificity scores between 40 and 89 percent.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "There are no harms mentioned in this news release. One big concern with both diagnostic and screening tests is the consequence of a false negative test result which could lead to a patient receiving the wrong, unnecessary or no treatment.", "answer": 0}, {"article": "But not a whole lot.\nThe bottom line: After seven days of treatment, those taking the supplements had less than half the chance of still being sick.\nThey add it is currently unclear what dose and particular formulation of the supplement will be most helpful.\n\u201cBut giving zinc over a long period of time for prevention should be done very carefully,\u201d she told Reuters Health.\nAnother two trials found that zinc helped stave off colds, but the quality of that research was low.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story didn\u2019t quantify the potential harms, but did discuss the side effects. This story says, \u201cSingh said the side effects of zinc lozenges, which can be bought for a few dollars in any drug store in the U.S., come down to bad taste and some cases of nausea.\u201d\u00a0The full listing in the article includes constipation, diarrhea, abdominal pain, dry mouth and oral irritation. Because the story downplayed the side effects in a story that is essentially encouraging long-term zinc use, we rate this unsatisfactory.", "answer": 0}, {"article": "American veterans coping with PTSD are traveling to lodges in the Amazon that offer ayahuasca, a hallucinogenic brew. Some say it has helped them manage emotional trauma from war, but others say it\u2019s not worth the journey. Photo: Ryan Dube/WSJ\n\nAfter surviving firefights and a roadside bomb in Afghanistan, U.S. Army veteran Asa Barrett tried antidepressant drugs and therapy to overcome depression and bouts of anger. Nothing worked.\n\nBut then, like many other foreigners, he journeyed to Peru\u2019s remote Amazonian jungle to drink ayahuasca, a centuries-old, sacred indigenous brew that some Western scientists think can help to heal psychological traumas.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Potential harms are called out clearly starting with the headline, which reads: \u201cIs Peru\u2019s Psychedelic Potion a Cure or a Curse? Foreigners are flocking to try a traditional brew called ayahuasca that some say eases psychological distress \u2014 but it has dangers, too.\u201d\nThe story mentions vomiting as a common reaction in the third paragraph. More serious risks are addressed in paragraph nine, which says \u201csome scientists \u2014 and users \u2014 warn that ayahuasca can be dangerous. It can be fatal when mixed with other drugs, such as antidepressants, and should be avoided by those who are bipolar or schizophrenic, since it has been known to trigger psychotic episodes.\u201d\nThe story also tells of purported deaths related to ayahuasca use, but these incidents are not flushed out in detail, leaving the reader to wonder about their significance. It paraphrases comments from a U.S. Navy official who says DMT can cause seizures, comas and respiratory arrests and lead to hallucinations that \u201ccan be so traumatic that they can worsen medical conditions such as PTSD.\u201d Another user mentions \u201cnightmarish hallucinations.\u201d\nHowever, there are no firsthand accounts of these known harms,\u00a0unlike the many accounts of positive experiences.", "answer": 1}, {"article": "The armpits, palms, and soles are often affected.\nThe study was small and the findings are preliminary.\nAll had hyperhidrosis, a condition where a person sweats much more than the body needs to cool itself.\nIt works, he says, by heating and destroying the sweat glands under the arm.\nHe presented the findings here at the annual meeting of the American Academy of Dermatology.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story states that \u201csome in the study reported temporary tenderness, redness, numbness and bruising.\u201d That\u2019s all it said.\nThat raises more questions than it provides answers.", "answer": 0}, {"article": "\u201cIf out of 10 years the patients have left to live we can keep them at home in a relatively mild state of the disease for three, four, five years, it\u2019s a lot.\u201d\n\nAccording to Alvaro Pascual-Leone, director of the hospital\u2019s Berenson-Allen Centre for Non-invasive Brain Stimulation, brain stimulation - or transcranial magnetic stimulation - involves a very low current applied to a specific part of the brain and is approved by the FDA for treatment of a variety of ailments and diagnostic applications.\n\u201cWe see improvement lasting for 9-12 months and the good thing is that patients can return and undergo treatment again,\u201d Baror said.\n\u201cYou stimulate the brain on a biological level as well as on a cognitive level,\u201d Neuronix CEO Eyal Baror told Reuters, saying this double approach created longer-lasting benefits.\nThe device, which combines electromagnetic stimulation with computer-based cognitive training, is already approved for use in Europe, Israel and several Asian countries such as Singapore.\nThe device, which consists of a chair containing an electronic system and software in the back and a coil placed at the head, has been tested on mild to moderate Alzheimer\u2019s patients who suffer from dementia but are not totally dependent.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "We can\u2019t know how complete is the list of complications reported when the data haven\u2019t been published yet and we\u2019re hearing this only from the company and/or a company-supported investigator.\u00a0 The story stated that \u201cabout 20 percent of patients experience a mild headache but there are no long-term negative effects.\u201d Why would this approach cause headaches?\u00a0 How can you discuss \u201cno long-term negative effects\u201d after short-term results in 6 people?\nThe story should have painted a picture of how incomplete the harms picture is at this point.", "answer": 0}, {"article": "Minimally invasive procedures increased to 31 percent of all radical prostatectomies in 2005 from 12.2 percent in 2003.\nBut the surgery increases the chance for longer term problems that require further therapy, the research says.\nThe widely advertised procedure is becoming more popular, said Dr. Jim C. Hu, the lead author of the study and an instructor in surgery at Harvard.\n\u201cThis paper,\u201d Dr. Hu said, \u201cdemonstrates that there are hidden risks for patients who opt for laparoscopic or robotic surgery.\u201d\n\nIn laparoscopy, a surgeon inserts instruments through small cuts in the skin instead of making large incisions to expose the organs.\nThe study, published on May 10 in The Journal of Clinical Oncology, examined a sample of 2,702 Medicare patients undergoing radical prostatectomy, the complete removal of the prostate, from 2003 to 2005.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story explictly compares the harms of the two surgical approaches in terms of short-term complications and longer-term consequences. ", "answer": 1}, {"article": "Everyone loses some bone with aging - women abruptly at menopause when estrogen levels decline, men more slowly as male hormones decline over time.\nWalking has not been shown to restore bone that is already lost to osteoporosis, but it can help preserve the bone density that a person has, said Dr. Carol Hartigan, a spine specialist at New England Baptist Hospital.\nBut remember: Not exercising also puts you at risk.\nIf a person simply stands, the muscles accommodate and do most of the work, he said - with no benefit to the bone.\nOther exercises - such as front and lateral raises with free weights - focus on the spine at chest level.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does note that that fractures can occur as a result of weight lifting.\u00a0 But the focus of the column was on walking, and it didn\u2019t discuss the possibility of falling during walking and the importance of good footwear and a clear walking area.\u00a0 \nIt also concludes with the following statement: \u2018Not exercising also puts you at risk\u2019 \u00a0\u00a0This raises questions such as \u2013 at risk of what, and how great a chance is there of that happening, and to what extent it that chance diminished by exercising?\u00a0\n\u00a0", "answer": 0}, {"article": "A sticky mucus clogs organs, particularly the lungs and liver.\nIn an editorial accompanying the study, Dr. Pamela Davis, of Case Western University paraphrased Winston Churchill, \u201cThis study is also a great victory in the war against genetic diseases and marks the end of the beginning for the treatment of the cystic fibrosis defect.\u201d\n\nIvacaftor has been submitted to the FDA for approval, and could be available next year, according to Konstan.\nThat trial is ongoing and the treatment is at least four or five years away from approval, but if it works, Beall says, it could help 90% of the people with cystic fibrosis.\nHe points to other research under way with ivacaftor combined with another drug that could help people with the most common mutation of cystic fibrosis.\nOn average, patients taking the drug grew more and put on more weight than the placebo group, according to the study, and had lower sweat chloride \u2013 an indicator of the disease.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "\n\n\nThe story does not make any reference to harms. Although the journal article reporting the trial findings says that the patients receiving the active drug generally had fewer problems than those in the placebo group and that the adverse effects were not serious enough to cause people to stop taking the drug for more than a short period, the editorial points out that this trial does not prove that long term use of this drug is safe. The story should have told readers that patients will probably need to take the drug their entire lives and that further tests are needed before long term safety questions can be answered.", "answer": 0}, {"article": "LONDON -- Sanofi-Aventis SA's obesity drug Acomplia can improve blood-sugar levels and weight loss in diabetic patients, according to a study presented at the World Diabetes Congress in South Africa.\n\nThe findings from the clinical trial have shown newly diagnosed patients with type-two diabetes who weren't taking antidiabetic drugs had significantly improved blood-sugar levels and lost more weight with Acomplia, compared with a dummy pill over a period of six months. In addition, Acomplia -- also known as rimonabant -- helped...", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story did an incomplete job on side effects.\u00a0 It did mention nausea, depressed mood and skin tingling \"which led to a discontiuation rate of 9.4%.\" But the FDA has raised major concerns\u00a0about this drug and rates of depression, and that is not clear from the story.", "answer": 0}, {"article": "Try to eat a pound of vegetables each day, half of which are cooked and the other half eaten raw, as well as half a pound of raw fruit.\nBut while certain common foods \u2014 like raw onions, garlic, citrus juices, coffee and chocolate \u2014 are likely to cause reflux in most people with the condition, Dr. Aviv and other experts emphasize that everyone is different, and trial and error is the most effective way to determine an individual\u2019s trigger foods and drinks.\nLosing weight is one of the best ways to find relief without having to rely on medication.\nIf adopting the above measures fails to fully control acid reflux, taking a proton pump inhibitor may also be needed.\nQuitting smoking, limiting alcohol and avoiding carbonated drinks are also important protective measures.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does not address potential harms. However, it\u2019s difficult to think of harms associated with quitting smoking, reducing alcohol intake or eating a healthier diet. There may be harms associated with not addressing GERD if lifestyle changes are not adequate, but the story does note that patients may need to take PPIs if lifestyle changes are insufficient. Ergo, the story earns a satisfactory rating here.", "answer": 1}, {"article": "\"Aim for an average of three, 8-ounce cups of coffee per day in the morning after eating breakfast.\"\nAbout 15% of people with MCI develop full-blown Alzheimer's disease each year.\nPeople whose memory loss did not progress all had blood caffeine levels higher than this level, the study shows.\nAccording to the findings, people older than 65 who had higher blood levels of caffeine developed Alzheimer's disease two to four years later than their counterparts with lower caffeine levels.\nNo one with mild memory loss who later developed Alzheimer's had initial blood caffeine levels above 1,200 ng/ml.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Caffeine can cause anxiety, poor sleep, irritative bladder symptoms, palpitations, and even arrythmia. \u00a0Older people are at greater risk for each of these problems and should be aware of the adverse effects of caffeine, even at lower levels of intake.", "answer": 0}, {"article": "But from other research \"we know it's safe to place an electrode in the nucleus accumbens, it's safe to stimulate it electrically, and we expect to be able to tune [the electrode] as we already do with DBS.\nTrouble is, the moderation wore off in a few days, and the DBS also interfered with the animals' social behavior.\nThat got Halpern thinking about a newer system \u2014 one that doesn't stimulate continuously, like DBS, but switches on briefly only after sensing a trouble signal, much like a pacemaker monitors and responds to abnormal heart rhythms.\nFiguring out if this biomarker would also work in people is challenging.\nThe intermittent system controlled overeating much better than the continuous or random protocols \u2014 and nearly as well as in a separate group of mice that got zapped manually by a researcher watching their behavior on video.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The article didn\u2019t discuss harms. Bleeding in the brain, infection, and device failure are all known risks. This would have helped balance out the researcher\u2019s unchallenged assertion that this procedure is \u201csafe.\u201d This is especially important to balance when talking about medical devices, which are not as regulated as drugs.", "answer": 0}, {"article": "For more information on asthma, visit the U.S. National Library of Medicine.\nHowever, the study authors and an outside expert stressed that these are early findings and much longer, larger clinical trials are needed.\nHowever, at this stage there is no definitive answer whether Spiriva should or shouldn't be used in asthma, she said.\nIn addition, Spiriva's safety profile among asthmatics still needs to be studied, he said.\nThese drugs carry a note on their labels warning of the possibility of severe adverse events, including death, he noted.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Harms in the study aren\u2019t quantified. How often did they occur? It tells us that the long-term safety needs to be studied, and it gives us good points about safety concerns that have been raised about Severent. (The AP article we reviewed mentions the safety concerns that have been raised about Spiriva.) We think safety information from this study, including the rates of serious events, could\u2019ve been mentioned if not quantified.", "answer": 0}, {"article": "\"It's very exciting,\" Klein says.\nAt the current recommended prescription dose -- 120 milligrams taken up to three times per day, for example up to 360 milligrams daily -- about 70 percent of users experience gastrointestinal complications, Klein says.\nThe company says that 22 million people in 145 countries have taken the drug.\nAnd many consumers may be put off by the drug's significant gastrointestinal side effects, including flatulence, diarrhea and anal leakage.\nWhile Americans spend an estimated $1 billion on nonprescription weight loss products, few if any of those products have undergone the rigorous testing that is required by the FDA for prescription medications.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story explains that about 70% of users experience gastrointestinal \ncomplications and lists some. ", "answer": 1}, {"article": "We've found a way to block CatK only in bone tissue that we think will prevent these other negative effects.\"\nThe study builds on previous research by Br\u00f6mme and his team that looked at the effectiveness of red sage, known as Danshen in Chinese and used to treat bone ailments, in stopping the activity of CatK in limited ways.\nThe treatment could also potentially be used to treat a variety of other bone and cartilage diseases such as arthritis and certain bone cancers.\nThey found that it prevented bone loss and increased the bone mineral density of the mice treated with the compound by 35 per cent, when compared with the control group.\nAn herb widely used in traditional Chinese medicine might hold the key to a new osteoporosis therapy that could prevent bone loss without causing side effects.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "No potential harms are mentioned. According to WebMD, red sage: \u201ccan cause some side effects, including itching, upset stomach, and reduced appetite. There is some concern that it might also cause drowsiness, dizziness, and a blood condition called thrombocytopenia.\u201d The safety of long-term use hasn\u2019t been rigorously studied.", "answer": 0}, {"article": "A pack year means smoking one pack a day for 30 years, or a variation like two packs daily for 15 years.\nLike the previous experiences, the Augusta area screening that started in 2014, also reiterated the ability of LDCT to find lung cancer early, said Schroeder, corresponding author of the study in Southern Medical Journal.\nThe pioneering National Lung Screening Trial, which began in 2002 and included 33 largely urban centers, found 292 cases of lung cancer among the 26,722 high-risk individuals screened in the first year, for a rate of 1.1 percent.\nFollowing the trial, the National Comprehensive Cancer Network, a nonprofit organization of cancer centers that develop guidelines for cancer diagnosis and treatment, along with the United States Preventive Services Task Force, which makes recommendations for preventive medicine, recommended screening high-risk individuals on a slightly broader scale, which the Lahey and Augusta area screening used.\nAlso, about half of patients screened continue to smoke so screening might also be a logical point for smoking intervention, Schroeder said.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "CT scans expose a patient to a significant amount of radiation, which this release doesn\u2019t address at all. Do the benefits of a potential early diagnosis outweigh the risks associated with radiation exposure? That\u2019s for each patient (and his or her physician) to decide. But a patient needs to be aware of those risks in order to make an informed decision.\nIn addition, an important limitation was not addressed in the release (nor was it spelled out in the study abstract). According to a 2017 article in the journal Chest, \u201cA significant limitation of lung cancer screening is the false-positive rate. One of the major concerns with the NLST [National Lung Screening Trial] has been the high false-positive rate of screening with LDCT (27.3%).\u201d", "answer": 0}, {"article": "\u201cThere\u2019s some danger of kids getting a rash, and it would be inadvisable to give it to women in the early stages of pregnancy,\u201d he said.\nSome might not have a large enough sample to find a small but statistically significant effect.\nThe authors acknowledged certain weaknesses in their study.\nDr. Barrett said there was probably little harm in using echinacea, and he was cautiously optimistic that the herb does have a very small positive effect.\nThere are more than 200 species of virus that cause colds, Dr. Coleman said, and a study could test one species against which echinacea proves ineffective, while leaving open the question of whether it works for others.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The article\u00a0points out\u00a0that the herb has some side effects, and quotes a physician mentioning the most common one (a rash, especially in children) and the most important contraindication (pregnancy).\u00a0It also points out that the study did not take potential harms into account, alerting readers to the possiblity of others\u00a0not mentioned here.", "answer": 1}, {"article": ".\nAs part of the PARTNER-I trial, Vinod H. Thourani, MD, from Emory University in Atlanta, and colleagues from 12 other institutions in the United States found that transcatheter aortic valve replacement (TAVR) is a safe and effective way to treat aortic stenosis in nonagenarians who qualify for the surgical technique.\nThe study also showed that the 30-day stroke risk was 3.6% in TF-TAVR patients and 2.0% in TA-TAVR patients.\n\u2022 Both transfemoral and transapical approaches to TAVR appear to be safe and effective for treatment of aortic stenosis in select patients age 90 years and older.\n\"Compared with an age-sex-race-matched US population, the TAVR patients had a comparable risk of mortality, and quality of life improved within 6 months of the procedure.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "This is a close one. The release (and related study) looks at both TF-TAVR and TA-TAVR patients. It\u00a0notes the frequency of adverse health outcomes associated with the two procedures. For example 30-day stroke risk for TF-TAVR was 3.6 percent, and 35 percent of TF-TAVR patients had \u201cmajor complications, such as bleeding or vascular issues.\u201d Stroke risk for TA-TAVR was 2.0 percent and 32 percent of TA-TAVR patients had major complications.\nThat\u2019s useful information, but the release neglects to mention the higher mortality rate observed in the TA-TAVR group compared with TF-TAVR \u2014 a difference that was not trivial. Overall, 4.6% of patients in the TF-TAVR died within 30 days or as a complication of the procedure. Among the TA-TAVR, the rate was 13%.\nOverall, we think the lack of any mention of death rates related to the procedure unbalances the discussion of harms. We also think it\u2019s problematic that the headline of the release describes TAVR as \u201csafe,\u201d when the second half of the release makes clear that there are substantial health risks associated with the procedures. Since the patients in this study were not randomly assigned to the valve treatment or conservative care, it is difficult to know for sure how the risks compare. The release could have done more to highlight that these patients are at high risk based upon age and their valve disease, and that it isn\u2019t clear whether the complications and deaths associated with these procedures are greater than what would be expected with conservative care.", "answer": 0}, {"article": "Drs.\nThis study suggests that IV fluids could help women maintain hydration at appropriate levels, reduce the likelihood of c-section, and decrease length of labor,\" says Dr. Berghella.\nThis study and others are providing evidence for changes in obstetric practice that could help safely reduce c-section rates.\n\"The results are compelling and strongly argue for a change in practice,\" says Vincenzo Berghella, M.D., the Director of Maternal Fetal Medicine and Professor in the Department of Obstetrics and Gynecology at the Sidney Kimmel Medical College at Thomas Jefferson University.\nDr. Berghella and colleagues compiled data from seven small clinical trials that collectively included a total of 1,215 women.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "An important potential risk of pulmonary edema (fluid build-up in the lungs) due to higher levels of intravenous hydration is not mentioned in the release, although it was reported in the article.\nAdditionally, the release neglects to explain that the only studies pooled for this analysis were those performed on low-risk, first-time mothers whose labor was not induced. The original research report notes that the effectiveness and safety of giving increased fluids to women who had given birth previously, whose labor was induced or who have other medical issues, is unclear. This is an important caveat that belongs in the news release.", "answer": 0}, {"article": "Dr. David E. Neal, a professor of surgical oncology at the University of Cambridge in the U.K. and author of an accompanying editorial, believes that, \"PSA testing detects prostate cancer early in its natural history when it causes no symptoms.\nOf the men in the screened group diagnosed with prostate cancer, nearly 79 percent were diagnosed because they took part in the study, the researchers noted.\nHowever, since the benefit of PSA screening requires at least 10 years to be borne out, it still seems questionable to test PSA for men over 70, the researchers noted.\nMoreover, the risk of over-diagnosis was less than previously thought, with just 12 men needed to be diagnosed to save one life.\nThis study adds to previous evidence that PSA testing and screening for prostate cancer saves lives, he said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Although reporting that \u2018just 12 men would need to be diagnosed with prostate cancer in order to save one life\u2019 the story neglected to follow though and examine the harm done to the other 11 men. \u00a0There are psychological consequences of a cancer diagnosis. \u00a0In addition, it wasn\u2019t just that men were diagnosed with prostate cancer that affected the chance that they would die from prostate cancer \u00a0\u2013 at least some of these men also received treatment for prostate cancer. \u00a0There was no discussion of the possible harms that are a consequence of prostate cancer treatment.\nThese are not easy issues, but the story did not mention that the number needed to screen to prevent one cancer death was 293.\u00a0 Those who were screened and got a false positive, perhaps leading to unnecessary followup testing like a biopsy, experienced harms. ", "answer": 0}, {"article": "Alcohol is known to activate some of the same receptors in the brain that opioids do, and studies find that by tempering the pleasure from alcohol, naltrexone can help people drink less.\nNaltrexone is certainly not a cure-all, researchers say.\nAnd it won't help everyone who has a drinking problem \u2014 especially if the disorder is severe.\nHe says that when used alone the medicines are only modestly effective.\nMany physicians are \"unaware that there are medications to treat alcohol use disorders,\" says Koob.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story briefly mentions the drug is \u201csafe,\u201d but does not discuss any side effects of the drug, nor notable interactions or contraindications. For example, this drug can\u2019t be used if the person is prescribed or otherwise taking opioids, too, or has certain types of liver damage.", "answer": 0}, {"article": "Diffuse large B-cell lymphoma is the most common type of non-Hodgkin lymphoma in adults.\nEven so, Yescarta's cost is likely to stoke the ongoing debate about high drug prices.\nArmin Ghobadi, an oncologist at Siteman who was an investigator in the Kite trial, said the new treatment is \u201cjust the first step\u201d and that researchers are working to make it safer and more effective.\nBecause of the side effects, the treatment will carry a boxed warning, the FDA's most serious.\nThe group numbers about 7,500 patients a year in the United States.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story wisely documents the harms found in the trials for the drug, including patient deaths. This is important, and helps balance the glowing patient anecdote from a woman whose cancer went into remission.", "answer": 1}, {"article": "Strawberries have the potential to prevent esophageal cancer, according to a preliminary study released Wednesday.\n\nResearchers, led by Ohio State University, were able to show that freeze-dried strawberries slowed the growth of dysplastic, or precancerous, lesions in about 30 people who consumed the fruit for six months.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Not applicable.\u00a0 We don\u2019t know what the harms of strawberry consumption would be.", "answer": 2}, {"article": "\"Remember that increasing omega-3 intakes is basically just improving the quality of one's diet slightly, like reducing the amount of sodium or increasing your dietary fiber.\n\"The 6 percent reduced risk among RCTs, coupled with an 18 percent risk reduction in prospective cohort studies -- which tend to include more real-life dietary scenarios over longer periods -- tell a compelling story about the importance of EPA and DHA omega-3s for cardiovascular health.\"\nStudy authors did point out that further clinical trials looking specifically at CHD outcomes may continue to provide a better understanding of the promising beneficial relationship between EPA/DHA and CHD risk.\n\"There are important public health implications related to reducing the risk of coronary heart disease, and therefore we are encouraged by the results of this comprehensive analysis,\" said Dr. Harry Rice, Vice President of Regulatory and Scientific Affairs for the Global Organization for EPA and DHA Omega-3s (GOED), which funded the study.\n\"The meta-analyses of Alexander and colleagues suggests that omega-3 fatty acid intake may reduce risk of adverse CHD events, especially among people with elevated levels of TGs or LDL-C....omega-3 fatty acid intake of at least 1 gram of EPA+DHA per day, either from seafood or supplementation (as recommended by the American Heart Association), continues to be a reasonable strategy,\" said the authors.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release does not mention any potential problems associated with omega-3s. And there are potential harms. For example, the University of Maryland Medical Center notes that patients should consult with their doctors about potential interactions with prescription drugs before taking omega-3 supplements, and adds that \u201cHigh doses of omega-3 fatty acids may increase the risk of bleeding, even in people without a history of bleeding disorders, and even in those who are not taking other medications.\u201d There are concerns about other potential harms as well, such as whether fish oil supplements may increase risk for prostate cancer. We don\u2019t expect a news release to include an exhaustive summary of all the possible harms associated with a particular intervention. But we do expect a news release to at least acknowledge that the potential for harms exists, when appropriate.", "answer": 0}, {"article": "\"We can't say this research is definitive,\" Dr. Senay said.\nThey are the first studies to examine the association between the Mediterranean Diet and neurological diseases \u2013 specifically Alzheimer's.\n\"Those who most closely adhered to the Mediterranean diet had a 68 percent reduction in the risk of Alzheimer's disease.\n\"Those who moderately adhered to the diet had a 53 percent reduction in risk of developing Alzheimer's disease,\" The Early Show medical contributor Dr. Emily Senay.\nDr. Senay said another study done in Stockholm, Sweden observed that the decline of patients with a very mild form of Alzheimer's Disease after they began taking supplements that contained two Omega-3 fatty acids.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story claims that there is \u201cno harm in doing the Mediterranean diet\u201d. However, people still need to maintain appropriate caloric consumption, regardless of the type of diet. Excess calories, even from healthy food, can cause weight gain. What is not discussed in the news story, but is mentioned in the source article is that greater adherence to the Mediterranean diet was associated with lower caloric intake. Also, the addition of daily moderate consumption of wine may be problematic for those who cannot drink alcohol. One to two alcoholic drinks per day has been shown to slightly increase the risk of breast cancer in women. ", "answer": 0}, {"article": "\u201cThis is great science,\u201d says J. Stephen Jones, MD, chairman of the department of regional urology at the Cleveland Clinic in Ohio.\nTo increase the accuracy of the test, researchers also looked for another gene, called prostate cancer antigen 3, or PCA3, which is also found in urine.\nResearchers then narrowed their analysis to see how the urine test scores matched the men\u2019s Gleason score, which helps doctors gauge how aggressive a cancer may be.\nThe company that developed the test, Gen-Probe, helped to pay for the study, and several authors said they had a personal financial interest in the technology.\n\u201cWhat we\u2019ve found is that your risk of having an aggressive cancer if you\u2019re in the high group is about 40%, and if you\u2019re in the low group, the risk of having an aggressive cancer is only about 7%,\u201d Tomlins says.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "While alluding to problems with the PSA test, the story did not cover any potential problems that might arise with the experimental test. \u00a0Although this test may potentially improve the accuracy of a man\u2019s risk estimate, there was still a fair amount of overlap and uncertainity. \u00a0The story did not report the proportions of cancers that were low and high risk. \u00a0Finding a low risk cancer could be considered a harm because many are considered overdiagnosed. \u00a0Missing a high risk cancer also causes harm.\nThis new test was suggested to eliminate the problem that arises because \u2018it\u2019s up to the patients and their doctors to figure out what to do next\u2019 when an elevated PSA level is detected. \u00a0However \u2013 even if this new test were available \u2013 it would still be up to patients and their doctors to determine what next steps to take.", "answer": 0}, {"article": "New Jersey and Ohio were the first to participate statewide in the program.\nThe boxes aren\u2019t the only option for safe sleeping, of course, but health officials say they\u2019re a useful part of a broader safe-sleep education program.\nThe boxes are a new idea for many Americans.\nShe said the program was eye-opening for how much information she learned about how to prevent sudden unexpected infant death.\nThe boxes provide a clutter-free sleep space that has been shown to reduce accidental and unexpected deaths, she said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does not include any mention of harms. Just because something doesn\u2019t seem harmful, we would still like a story to note \u201cThere are no known harms\u201d because that means they\u2019ve given it some thought.", "answer": 2}, {"article": "His own previous research indicates that cannabis was used as early as 1800 B.C.\nBased on the overall results, Devinsky believes CBD should be evaluated for epilepsy types beyond Dravet syndrome, which is caused by a genetic mutation and affects about one in 20,000 to 40,000 children in the United States.\nThe study was a randomized, double-blind, placebo-controlled human trial, which is considered the gold standard test for any new medicine.\nHe noted that generating more evidence of effective use is \"a good thing.\"\nGW Pharmaceuticals, a company that is developing cannabidiol medicines, helped subsidize the study.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story nicely refers to the harms up high and then returns to them in greater detail later in the piece. It also does something we see too rarely, which is mention how many patients dropped out of the study.", "answer": 1}, {"article": "A growing number of doctors who treat the estimated 6.4 million American children diagnosed with A.D.H.D.\nYet Dr. Bertin has recently changed the way he talks about medication, offering parents a powerful argument.\nThe question is whether these effects can last once the drugs have left the bloodstream.\nexperts challenge this conclusion.\nDr. F. Xavier Castellanos, director of research at the New York University Child Study Center, called assertions that stimulants are neuroprotective \u201cexaggerated,\u201d adding: \u201cThe best inference is that there is no evidence of harm from medications \u2013 normalization is a possibility, but far from demonstrated.\u201d\n\nA.D.H.D.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story cries out for some details about the downsides of medication. It includes a statement that most children quit taking their medicine. Why? Again, the story seems to assume that readers are ADHD aficianados.", "answer": 0}, {"article": "But don't rush out to adopt a furry friend just yet.\nWhat's more, Kozyrskyj's study suggested that the presence of pets in the house reduced the likelihood of the transmission of vaginal GBS (group B Strep) during birth, which causes pneumonia in newborns and is prevented by giving mothers antibiotics during delivery.\n\"The abundance of these two bacteria were increased twofold when there was a pet in the house,\" said Kozyrskyj, adding that the pet exposure was shown to affect the gut microbiome indirectly--from dog to mother to unborn baby--during pregnancy as well as during the first three months of the baby's life.\nHer team of 12, including study co-author and U of A post-doctoral fellow Hein Min Tun, take the science one step closer to understanding the connection by identifying that exposure to pets in the womb or up to three months after birth increases the abundance of two bacteria, Ruminococcus and Oscillospira, which have been linked with reduced childhood allergies and obesity, respectively.\nThe latest findings from Kozyrskyj and her team's work on fecal samples collected from infants registered in the Canadian Healthy Infant Longitudinal Development study build on two decades of research that show children who grow up with dogs have lower rates of asthma.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "There are no harms mentioned in the release release. Presumably there are some dangers of exposing babies in the womb and newborns to pet dogs and cats but we aren\u2019t given any hint that they exist or what they are. One of the most common \u201charms\u201d associated with furry pets is allergies, the very condition this study purports to lessen or prevent.", "answer": 0}, {"article": "\"Our thinking is similar to how you might approach a battle against two enemies,\" said Dr. Soran.\nThe study received scientific advisement from UPMC and assistance with statistical analysis from epidemiologists at the University of Pittsburgh Graduate School of Public Health.\nDr. Soran began the trial in 2007, ultimately recruiting a total of 274 women newly diagnosed with stage IV breast cancer from 25 institutions.\nThe study was selected for the society's \"Best of ASCO,\" an effort to condense the research \"most relevant and significant to oncology\" into a two-day program to increase global access to cutting-edge science.\nThis research was primarily funded by the Turkish Federation of Societies for Breast Diseases.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "There is no mention in the release of the risks associated with surgery. It\u2019s unclear from the abstract whether the study captured the risks involved in the surgeries.", "answer": 0}, {"article": "Impaired insulin sensitivity is one risk factor for type 2 diabetes, which is associated with age and obesity and happens when the body can\u2019t properly convert blood sugar into energy.\nAnd it doesn\u2019t prove that catching up on sleep will prevent diabetes.\nBut then, when they let the men get extra sleep for the next two nights, their blood tests returned to normal, countering the effect of the short-term sleep deprivation.\n\u201cBy catching up on sleep on the weekends, people are reducing average extent and severity of the effects of sleep deprivation,\u201d Gangwisch added by email.\n\u201cIt gives us some hope that if there is no way to extend sleep during the week, people should try very hard to protect their sleep when they do get an opportunity to sleep in and sleep as much as possible to pay back the sleep debt,\u201d said lead study author Josaine Broussard of the University of Colorado Boulder.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Hard to imagine the \u201charms\u201d of getting more sleep, so we\u2019ll rate this Not Applicable.", "answer": 2}, {"article": "They then matched each statin user \u2014 who was aged over 40 when first prescribed a statin between 1995 and 2006 \u2014 with up to five non-statin users for comparison.\nDouglas noted that since this study looked at patients who were already taking statins when they developed pneumonia, a full randomized clinical trial was needed to find out whether starting a statin at the time of diagnosis has a similar effect.\n\u201cGiven the potential low number needed to treat to prevent a death suggested by this study, we believe that a strong case exists for randomized trials of statins in people with serious infection to determine if a simple and practical intervention at the point of diagnosis of pneumonia has a beneficial effect.\u201d\n\nDouglas\u2019s team, whose research was published in the British Medical Journal, used data from computerized medical records of doctors\u2019 practices in Britain to identify statin users.\nPrevious studies have suggested statins, which are also available as cheaper generics, may be linked to better outcomes after bacterial infection.\n\u201cStatins are safe, cheap, and an easy intervention in terms of delivery,\u201d said Ian Douglas, a lecturer in epidemiology at the LSHTM who led the research.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story glosses over potential harms when it unquestioningly accepts one of the researcher\u2019s claims that statins are \u201csafe, cheap, and an easy intervention in terms of delivery.\u201d Even if we accept that this is true for patients who take statins to prevent heart disease, it might not be true for patients who start taking the drug once they contract pneumonia. The story should have mentioned this, as well as the other common adverse effects of statin medication, which include muscle pain and gastrointestinal upset.", "answer": 0}, {"article": "Macular edema can arise during any stage of diabetic retinopathy and is the most common cause of diabetes-related vision loss.\nBy two years, 41 percent of participants in the Eylea group received laser treatment to treat their macular edema, compared with 64 percent of participants in the Avastin group and 52 percent in the Lucentis group.\nThe risk of heart attack, stroke, or death from a cardiovascular condition or an unknown cause by end of the trial was higher among participants in the Lucentis group.\nThe three drugs yielded similar gains in vision for patients with 20/32 or 20/40 vision at the start of treatment.\nAmong participants with 20/40 or better vision at the trial\u2019s start, all three drugs improved vision similarly on an eye chart.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release notes that \u201cThe risk of heart attack, stroke, or death from a cardiovascular condition or an unknown cause by the end of the trial was higher among patients in the Lucentis group. Twelve percent of Lucentis participants had at least one event, compared with five percent of the participants in the Eylea group and eight percent of the participants in the Avantis group.\u201d \u00a0This is useful information. The release also points out that more study is needed to determine if these treatments affect the rate of heart problems or if this observation was due to chance.", "answer": 1}, {"article": "Penn Medicine is committed to improving lives and health through a variety of community-based programs and activities.\nAlso, future studies are needed to include a more comprehensive assessment of potential predictors of treatment outcome to identify those patients most likely to benefit from sleep deprivation.\nThe authors note that further research is needed to identify precisely how sleep deprivation causes rapid and significant reductions in depression severity.\nPrevious studies have shown rapid antidepressant effects from sleep deprivation for roughly 40-60 percent of individuals, yet this response rate has not been analyzed to obtain a more precise percentage since 1990 despite more than 75 studies since then on the subject.\nReviewing more than 2,000 studies, the team pulled data from a final group of 66 studies executed over a 36 year period to determine how response may be affected by the type and timing of sleep deprivation performed (total vs early or late partial sleep deprivation), the clinical sample (having depressive or manic episodes, or a combination of both), medication status, and age and gender of the sample.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "There are many harms associated with sleep deprivation and these are not mentioned. Johns Hopkins has an info-graphic identifying some of them which include adverse effects on mood, memory and health.", "answer": 0}, {"article": "Patients with untreatable angina who received the injections of CD34+ stem cells in key areas of the heart had significantly fewer chest pain episodes and significantly better performance on exercise tests than patients who got placebo injections.\nThe patients received 10 such injections during a single catheterization procedure.\nPatients were given a drug for several days to increase the number of CD34+ stem cells in the blood.\nResults from a pivotal study of the treatment were reported today in the American Heart Association (AHA) journal Circulation Research.\nThe newly reported study included 167 patients with severe angina treated at 26 medical centers across the country.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "We\u2019ll give the story credit for the following \u2013 although we think it was incomplete:\n\u201cAbout one in three patients had elevations of a cardiac enzyme that is associated with heart attacks. While the elevations did not appear to be clinically significant, Losordo says the researchers will continue to closely monitor cardiac enzymes in patients who receive the treatment.\u201d\nWhat does that mean?\u00a0 \u201cAssociated with heart attacks\u201d?\u00a0 How? Why? How often? In what past research?\u00a0 And what does \u201cdid not appear to be clinically significant\u201d mean?\u00a0 Did it cause any problems or didn\u2019t it?", "answer": 1}, {"article": "Andrew Keaveney, now 73, shattered his ankle in a fall from a truck while hanging flags as an American Legion volunteer.\nAnkle replacement has been around for three decades, but it has been slow to catch on.\nThe procedure is among the most difficult that foot and ankle surgeons perform, and one of the biggest challenges is getting proper alignment of the replacement joint.\nEach year about two million Americans visit the doctor for ankle pain from arthritis or fracture.\nThe operation is complex, and many foot and ankle surgeons lack experience.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story presents some risks, i.e. replacement failure, loosening, slow healing, infection\u00a0and amputation.\u00a0 It\u00a0also mentions that not all individuals are appropriate candidates for surgery.\u00a0 It could have provided numbers for how often these harms occur.\u00a0 Nonetheless. we\u2019ll give it the benefit of the doubt on this criterion and grade it barely satisfactory. ", "answer": 1}, {"article": "LONDON -- AstraZeneca PLC said Monday its experimental heart pill Brilinta was more effective at preventing heart attacks and strokes in a large clinical trial than the blockbuster pill Plavix, boosting commercial prospects for the U.K. drug maker's still unmarketed treatment.\n\nPlavix, which is marketed by Sanofi-Aventis SA and Bristol-Myers Squibb Co., was the second-biggest-selling drug in the world last year, with global revenue of $8.6 billion, according to IMS Health. Any competitor to it could have a shot at big sales.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story fails to mention the potential harms of Brilinta. \nGiven the questions about risks of the reigning anti-platelet blockbuster Plavix it intends to replace, this is a significant omission.\nThe risks linked to Plavix could therefore arguably demonstrate a need for a drug that reduces heart risk without introducing other potential harms. \nThis should have been mentioned, as should have any potential risks early data link to Brilinta.", "answer": 0}, {"article": "With the FDA's announcement, drugs like pembrolizumab have also begun to change the way that physicians, patients and government regulators think of cancer. No longer will they see all cancers of the lung, breast, colon, brain, liver, pancreas and prostate as distinct from one another. Instead, they will look for the common genetic mutations that give rise to cancers no matter where they're found. And they'll treat those cancers with a drug that uses that common signature as a homing beacon, either for the immune system or for targeted cancer drugs to attack.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does not alert readers to the serious risks of immunotherapy for cancer. The drug label begins with this alert: \u201cKEYTRUDA can cause your immune system to attack normal organs and tissues in many areas of your body and can affect the way they work. These problems can sometimes become serious or life-threatening and can lead to death.\u201d\nThe story also quotes a researcher gushing about the potential benefits of pembrolizumab, but does not report that this same researcher recently reported the case of a patient who suffered a severe case of scleroderma while taking the drug.\nNot covering the downsides of immunotherapy is something we see a lot\u2013for tips on how to write more accurately about this, see:\u00a0Too many stories ignore or under-report the harms of cancer immunotherapies. Here\u2019s what the public needs to know.", "answer": 0}, {"article": "Visit http://www.\nThis study suggests that in the future, stroke patients can bypass the CT scan or emergency department and go directly to the angiosuite for imaging and proper care.\nThe study, New Multiple CT Assessment of Acute Stroke Patients: Are We Ready for Prime Time?, shows that recent advances in imaging software in the angiosuite give neurointerventionalists the essential details required to diagnose a patient with large vessel occlusion (LVO) for an endovascular thrombectomy (EVT).\nThe lead PI on this study, Professor Vitor Mendes Pereira, concluded by saying, \"By reducing intra-facility transfer times, patients can receive EVT treatment sooner, which can significantly impact patient outcomes\".\nPreliminary results show that the cone beam imaging software compares favorably with baseline and follow-up CT scans.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Harms aren\u2019t discussed. Are there potential risks associated with using the new software? The release doesn\u2019t say one way or the other. As noted previously, the study involved adding the new technology to standard care. So it may have actually harmed study patients. More broadly, the study was not designed to assess the relative benefits/harms of this new technique compared to the current standard.", "answer": 0}, {"article": "\u201cBut it is definitely a breakthrough.\nThe study\u2019s authors noted that patients would need to stay on the drug in order to receive protection against the allergy.\n\u201cReactions from the oral challenges at the end of the study were much milder than prior to treatment,\u201d Tilles said, according to EurekAlert.\n\u201cThis is not a quick fix, and it doesn\u2019t mean people with peanut allergy will be able to eat peanuts whenever they want,\u201d Jay Lieberman, MD, vice chair of the ACAAI Food Allergy Committee and study co-author, said, according to EurekAlert.\n\u201cOn average, the participants were able to tolerate a 100-fold higher dose of peanut at the end of the study than they did at the beginning.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does not mention harms \u2014 and harms were significant. The CNN story reported that 11% of participants dropped out of the study as a result of untoward effects of treatment, and other participants (who completed the study) had allergic reactions requiring treatment.\nIt also left out important issues such as the high dropout rate among those who received the treatment, and unknown long-term effects.", "answer": 0}, {"article": "The average age of people in both groups was 73.\nWhen the researchers focused on specific parts of the brain most likely to show damage, the accuracy rose to 95 percent.\nThe findings, presented Sunday, Nov. 25 at the Radiological Society of North America meeting in Chicago, suggest that doctors may one day be able to use widely available tests to tell people their risk of developing dementia before symptoms arise.\nThe researchers found that people who went on to experience cognitive decline had significantly more signs of damage to their white matter.\nAlthough there are no drugs available yet to prevent or delay the onset of Alzheimer's disease, identifying those at high risk of developing dementia within the next few years could still be beneficial, the researchers said.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The news release did not delve into potential harms, including anxiety and false results. If a test is accurate 95% of the time, five out of 100 people will get either a false positive, which can lead to more tests and anxiety, or a false negative, which can be wrongly reassuring.", "answer": 0}, {"article": "About Milken Institute School of Public Health at the George Washington University: Established in July 1997 as the School of Public Health and Health Services, Milken Institute School of Public Health is the only school of public health in the nation's capital.\nThe more intensive intervention did seem to help two subgroups quit smoking at least in the short run, Abroms says.\nVery little help is provided to pregnant smokers who want to quit so the study's findings are important, especially if the strategy can be adjusted to be more effective, Abroms says.\nAbroms and her team wanted to find out if a more intensive mobile phone program called Quit4baby would be more effective.\nThe researchers recruited pregnant women who were already enrolled in an established text messaging program called Text4baby.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "There is no mention of harms but it\u2019s hard to imagine there are any harms from voluntarily receiving from 1 to 8 text messages a day. We\u2019ll rate this Not Applicable.", "answer": 2}, {"article": "He is president and chair of the department of public health sciences at the University of Li\u00e8ge in Belgium.\nNearly one in 100 people have evidence of knee osteoarthritis on an X-ray.\nNov. 12, 2012 -- A drug used outside the U.S. to treat osteoporosis may not only lessen the everyday pain associated with knee osteoarthritis, but may even slow down the progression of osteoarthritis, researchers say.\nIn people with osteoarthritis, the cartilage in a joint wears away in some areas.\nThe wearing away of cartilage leads to pain and other symptoms.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story notes that strontium can increase the risk for deep vein thrombosis, but doesn\u2019t indicate whether the drug was associated with any adverse effects in the study.", "answer": 0}, {"article": "\u201cObviously it\u2019s something we need to worry about, but if you apply it to a population that\u2019s suitable for diagnosis you wouldn\u2019t run that risk,\u201d he said.\nDr. Sumit Majumdar, who wrote an editorial accompanying the new study, said a lower threshold for bone density would catch most cases of osteoporosis and limit \u201cincidentaloporosis\u201d - incorrect osteoporosis diagnoses \u201cdiscovered\u201d while doctors were looking for something else.\nThe researchers, who published their findings in the Annals of Internal Medicine on Monday, compared patients\u2019 CT scans to their dual-energy X-ray absorptiometry (DXA), which is traditionally used to diagnose osteoporosis.\nIn an editorial accompanying the study, however, experts wrote that using CT scans to gauge bone density could lead to some people being incorrectly diagnosed, particularly if people at low risk are tested.\n\u201cWhat we found is that there is pretty good correlation,\u201d said the study\u2019s lead author Dr. Perry Pickhardt, professor of radiology at the University of Wisconsin School of Medicine and Public Health in Madison.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story mentioned that both DXA and CT scans involve radiation, although it would have been helpful to note that the radiation exposure is much higher with CT scans.\nMore importantly, it addressed the risk of \u201cincidentaloporosis\u201d \u2013 or incorrect osteoporosis diagnoses that arise when doctors are looking for something else.\u00a0 We wish, though, that the story had added a line to drive home the point of the potential harm from such overdiagnosis.\n\u00a0", "answer": 1}, {"article": "Taken together, the risk of suicidal thoughts and behavior was 0.43 percent for those on drug therapy and 0.22 percent for those given placebos.\nDrugs for epilepsy, bipolar illness and mood problems double the risks of suicidal thoughts and behavior, and patients taking them should be watched for sudden behavioral changes, drug regulators have said.\nDoctors said Thursday that the increased risk did not outweigh the benefits of the drugs.\nThese medications are primarily used to help epileptics control seizures and to calm the surges in energy and mood that, along with bouts of depression, characterize bipolar disorder.\nThe Food and Drug Administration undertook a combined analysis of 199 clinical trials with 43,892 patients and found 4 suicides and 105 reports of suicidal symptoms among the 27,863 patients who were given the drugs compared to no suicides and 35 reports of suicidal symptoms among the 16,029 patients treated with placebos.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The focus of the story is a potential harm of treatment, namely, an increased risk of suicidal thoughts or behaviors. The story notes the risks are greater for epileptics than for those taking\u00a0 the same medications for psychiatric conditions or for chronic pain. The story does not note other, less serious harms of these drugs, which can include weight gain, mental confusion and an upset stomach. Discussion of other side effects would be useful information if patients are considering the full risks and benefits of taking this class of medication over the long-term. ", "answer": 1}, {"article": "Fibrosis - where persistent inflammation causes scar tissue to form in the liver, but the liver is still able to function normally \n\n4.\nWe currently have to rely on liver biopsy to measure fibrosis at its early stages - by examining a piece of the liver under the microscope.\nIt is the first time an epigenetic signature in blood has been discovered which is diagnostic of the severity of fibrosis for people with Non-alcoholic Fatty Liver Disease (NAFLD).\n\"We know that the presence of even mild fibrosis of the liver predicts a worse long-term outcome for patients with NAFLD and so it's important to be able to detect liver scarring at an early stage.\"\nIn this first stage of research the team developed the blood analysis in 26 patients with NAFLD.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "There\u2019s no discussion of potential harms. How accurate is the new blood test? Is there a risk of false positives or misdiagnosis \u2014 and, if so, how high is that risk? The investigators assembled only a small number of carefully selected patients. Many were excluded if they had other liver diseases as well as complications from alcohol. And\u00a0the as-yet undetermined potential for both false positive and false negative results could certainly undermine its value in reassuring patients.", "answer": 0}, {"article": "CT (computed tomography), sometimes called CAT (computed axial tomography), is performed by computerized machines that scan patients with X-rays to create three-dimensional cross-sectional images of organs and other parts of the body, providing far greater detail than standard single X-rays.\nA child's risk may run as high as one case of cancer for every 500 scans, experts say.\nBecause it would take decades to follow a large number of patients who have undergone CT scans to determine the exact risks posed by the exams, there are no direct data demonstrating the danger.\nThe concern comes from the fact that CT scans expose patients to much more radiation than standard X-rays.\nWhile there are scant hard data about how often CT scans are done needlessly, several experts estimated that perhaps one-third could be eliminated.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does a good job of describing the harms of radiation exposure due to CT scans. Notably, the story comments on how many excess cases of cancer could be explained by the radiation exposure and that some of the risk is easily avoidable: some scans are unnecessary.", "answer": 1}, {"article": "\u201cShe would wake up in the middle of the night with night terrors at a very young age, she stopped napping around 15 months \u2026 any type of change in our schedule could set off an epic tantrum.\u201d\n\nOakes didn\u2019t know it then, but her daughter Mallory was one of more than 10 percent of American children living with attention deficit hyperactivity disorder (ADHD)\n\n\u201cShe was diagnosed in first grade after there were some difficulties in the classroom,\u201d Amy said.\n\u201cWe tried some medication therapies that ended up being really a nightmare for us, and making matters worse.\u201d\n\nMedication is often the first line of defense in conventional medicine for kids with ADD and ADHD, with doctors prescribing everything from stimulants to antipsychotics and even antidepressants to help control the symptoms.\n\u201cIf you get a child who has really strong left brain and delayed right brain, those are kids that may be labeled with attentional problems or behavioral problems or social issues,\u201d Melillo said.\n\u201cThere were times I remember saying to my husband that her behaviors are holding our family hostage because it could be one meltdown a day, it could be five meltdowns a day,\u201d Amy said.\n\u201cShe wasn't able to attend mainstream school anymore and the school that we ended up putting her in was an end-of-the-road school \u2026 in my mind, it was not a place where she belonged,\u201d Amy said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does not discuss any potential harms.", "answer": 0}, {"article": "To compare the effects of linagliptin to glimepiride (the most commonly used sulphonylurea), the researchers conducted a double-blind study over the course of two years.\nThe researchers pointed out that most patients are prescribed a class of drugs called sulphonylureas to supplement metformin.\nResearchers in Germany noted that the new drug, linagliptin (Tradjenta), is intended for use in patients that do not fare well with metformin, the most common first-line drug used to treat the disease.\nOne expert said patients and doctors may still have to balance the superiority of linagliptin against its higher cost in comparison to older drugs.\nNone of the patients had responded to metformin alone.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There was inadequate/incomplete quantification of the harms.", "answer": 1}, {"article": "The U.S. National Institute on Deafness and Other Communication Disorders has more about ear infections in children.\nWEDNESDAY, Dec. 21, 2016 (HealthDay News) -- A shorter period of antibiotic treatment for ear infections in young children does more harm than good, a new study finds.\nWhat's more, the children in the five-day group didn't have a lower risk of antibiotic resistance or of side effects such as diarrhea or diaper rash.\n\"The results of this study clearly show that for treating ear infections in children between 9 and 23 months of age, a five-day course of antibiotic offers no benefit in terms of adverse events or antibiotic resistance,\" Hoberman said.\nThese infections are the most common reason why children are given antibiotics, the University of Pittsburgh researchers noted.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story mentions there were no differences in the rate of antibiotic resistance, diaper rash or diarrhea. This is just enough information to rate satisfactory\u2013but barely.\nBut unfortunately we know those markers would likely be higher in a cohort of kids taking antibiotics, versus those taking nothing (placebo). \u00a0Without a placebo arm in this trial, we have no idea what the rate of adverse effects would have likely been. A stronger story would have pointed this out.", "answer": 1}, {"article": "\"Doing that could be a lot easier than nudging children about going to bed,\" Raine said.\nThe researchers also want to add to this current observational study to establish, through randomized controlled trials, that eating fish can lead to better sleep, better school performance and other real-life, practical outcomes.\nGiven the young age of this study group, Liu and colleagues chose not to analyze the details participants reported about the types of fish consumed, though they plan to do so for work on an older cohort in the future.\nFor the work, a cohort of 541 9- to 11-year-olds in China, 54 percent boys and 46 percent girls, completed a questionnaire about how often they consumed fish in the past month, with options ranging from \"never\" to \"at least once per week.\"\n\"We have found that omega-3 supplements reduce antisocial behavior, so it's not too surprising that fish is behind this.\"\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Current dietary recommendations include warnings about some commonly eaten types of fish that are high in mercury, but this or any other potential drawbacks associated with consuming fish were not mentioned.", "answer": 0}, {"article": "Platelets, the blood cells that promote clotting, contain hundreds of proteins, called growth factors, that are important in repairing injuries.\nFerrell told me not to use nonsteroidal anti-inflammatories, such as ibuprofen, for a week after the injection because the goal is to encourage, not stifle, inflammation.\nThose who seek this treatment must look for a clinician with considerable PRP experience \u2014 someone who does the procedure several times a day, not once or twice a month \u2014 and who has a good success rate, Ferrell says.\nStill, \u201cit has significant cost savings\u201d compared with surgery, Ferrell says.\nBased on my experience with it, I think they are right.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The only mention of potential harms in the story comes in this statement:\u00a0 \u201cThe American Academy of Orthopedic Surgeons \u2014 which says PRP \u2018holds great promise\u2019 \u2014 describes the risk as minimal.\u201d\u00a0 That\u2019s not\u00a0acceptable given that there is no explanation of what those risks might be. Readers are\u00a0left\u00a0clueless when it comes to questions of potential harms.", "answer": 0}, {"article": "WASHINGTON\u2014The Food and Drug Administration questioned the clinical benefit of using GlaxoSmithKline PLC's Avodart to cut the risk of prostate cancer.\n\nAvodart is currently approved to treat benign enlargement of the prostate. The company is seeking FDA approval to market the drug to certain men to reduce the risk of prostate cancer. The drug will be reviewed by an FDA advisory panel on Wednesday along with Merck & Co.'s Proscar, a drug similar to Avodart.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Use of Avodart\u00a0is associated with increased risk of sexual side effects and a small increase in heart failure risk. The story didn\u2019t mention these potential problems.", "answer": 0}, {"article": "Due to diffuse symptoms, pancreatic cancer is usually diagnosed very late in the disease progression.\nA new blood test developed by researchers at Lund University in Sweden, Herlev Hospital, Knight Cancer Center and Immunovia AB, can detect pancreatic cancer in the very earliest stages of the disease.\nThis provides information about the development of tumours long before being visible on CT or detected by ctDNA.\nSince the immune system is the first to respond to threats like complex diseases, such as cancer, autoimmune diseases and infections, the microarray was designed to mirror this early response.\nPancreatic cancer is currently very difficult to detect while it is still resectable.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Harms are not discussed and two types of harms are relevant here. The study \u2014 but not the news release \u2014 mentions a false-positive rate of 6%; that\u2019s the fraction of people erroneously diagnosed with a cancer they don\u2019t have. (Who might then go on to endure the costs and risks involved with subsequent evaluation.)\nThe flip side would be: what\u2019s the false-negative rate? That\u2019s the number of people who are told they\u2019re cancer-free but really aren\u2019t. The potential emotional harm in this case is quite clear.\nThis is important as well because pancreatic cancer is a rare condition. We know that a good screening test works best when the disease has high prevalence in a population, so when dealing with something rare, the 6% leading to harms may mean something very different.", "answer": 0}, {"article": "Ellison says she tried meditation, but her mind kept wandering.\nUntil a large study comes along using this sort of approach, parents and consumers will have to decide for themselves whether neurofeedback is worth the time and effort.\nOn the other hand, Rabiner says, neurofeedback may offer something other treatments can't.\nBut it will take better research to figure out whether neurofeedback can live up to that promise, Rabiner says.\nIn the meantime, he says, the study has shown that it is possible to do neurofeedback research that involves a placebo.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story failed to discuss\u00a0any potential harms of neurofeedback treatment.\u00a0The most prominent of these is\u00a0that patients\u00a0could forego other treatment approaches that have better supporting evidence and are more likely to reduce symptoms.\u00a0There is also some evidence that\u00a0neurofeedback can cause seizures or make\u00a0symptoms\u00a0worse in some individuals with psychological disorders.\u00a0In addition, the need for frequent treatments may necessitate taking a child out of school.", "answer": 0}, {"article": "Adults don\u2019t have much brown fat, but a new study suggests that hormones produced by the heart just might help them make more.\nIf studies show the same thing in humans, the heart hormone may hold the key to an effective weight loss treatment, says researcher Sheila Collins, PhD, of Sanford-Burnham Medical Research Institute in Orlando, Fla.\n\u201cThese hormones are involved in fluid regulation, but we showed in this study that they also play a role in breaking down fat,\u201d she says.\nResearchers found that the hormones, known as cardiac natriuretic peptides, caused regular energy-storing white fat cells to turn into energy-burning brown fat in mice.\nFeb. 6, 2012 -- You may have heard about brown fat -- a unique type of fat that acts like a furnace in the body to burn calories instead of storing them as excess weight.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "We\u2019ll give the benefit of the doubt here because the story does mention the possibility of unintended harms from brown fat-activating treatments. However, we thought it was worth noting \u2014 as the authors of the study did in their paper \u2014 that the hormones that activated brown fat in this study are elevated during heart failure and cancer-related wasting. Thus, any weight loss they produce may be accompanied by important adverse effects.", "answer": 1}, {"article": "EEGs measure brain electrical activity through electrodes attached to the scalp.\n\"If it can eventually be shown that this technique can reliably identify which children will indeed develop autism, then we will have a valuable tool for early detection,\" Ewen said.\nAlso, the study predicted who was at high risk of autism, but it's unknown if those babies actually went on to develop autism, he noted.\nEEGs are also relatively inexpensive, painless and safe, Bosl said.\nA very high-functioning person with autism might not be so different from a so-called 'normal' person who is quirky.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "No harms were quantified. Instead, readers were told that the EEG is \u201cpainless and safe.\u201d The story presses the idea that \u201cearly intervention is extremely important\u201d even though the study did not detect autism in any way that would warrant treatment. What would be the next step for these children? Should they be put into behavioral therapy, put on a restrictive diet, given drugs of some kind? All of these options have potential consequences that could, indeed, prove harmful to the children, especially if they are falsely diagnosed as having autism. And, like most screening tests, there is the additional potential harm of unnecessary worry for some parents, as it is likely that at least some kids will \u2018screen positive\u2019 and then develop normally.\nScreening tests have harms.\u00a0 It is a common journalistic pitfall to overlook this fact.", "answer": 0}, {"article": "Some doctors are raising concerns about a new cancer-treatment device that uses electrical jolts to zap tumors but that hasn't been through a large clinical trial to prove it's safe and effective in people.\n\nThe device, called NanoKnife, is currently being used in about 13 U.S. hospitals including Baptist Health Medical Center in Little Rock, Ark., University of Louisville, and Shands Hospital/University of Florida in Gainesville, Fla. Each machine costs as much as $300,000. Some of the hospitals are aggressively promoting...", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Because of the lack of evidence, it is difficult to quantify the harms. But the story did a nice job of addressing the harms. \"Some side effects have been reported. Because the device uses large electrical bursts, it can trigger fast heartbeats. Four such cases out of about three dozen patients were described in a recent report by Ken Thomson, a radiologist in Melbourne, Australia. AngioDynamics says that these cases have all been treatable and that the company has taken technical steps to minimize such future occurrences. One case reported to the FDA was of a U.S. patient who in July suffered a serious hemothorax, or blood buildup between the chest wall and lungs. The patient had to stay in the hospital for 16 days, and doctors said an artery \"most likely\" was punctured during the operation. AngioDynamics said in the FDA report that such a puncture is a \"possible complication\" of any such operation.\" This is more detail than is provided in most stories, even when there is much more evidence available.", "answer": 1}, {"article": "About the American Urological Association: The 111th Annual Meeting of the American Urological Association takes place May 6 \u2013 10 at the San Diego Convention Center in San Diego, CA.\nFollowing a 13-week efficacy phase, men continued to receive their assigned treatment for up to 52 weeks.\nThroughout a 52-week study period, a total of 315 hypogonadal men were randomized either to LPCN 1021 or T gel (active control).\nThe research will be highlighted by study authors during a special press conference to be moderated by Tobias S. K\u00f6hler, MD, MPH, FACS, AUA spokesperson and associate professor of Surgery at Southern Illinois University on May 8, 2016 at 7:30 a.m. PT in the San Diego Convention Center.\nOf the 315 men, 210 were randomized to LPCN 1021 and 105 were randomized to active control.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The news release does describe adverse effects reported in the study, including that there were no \u201chepatic, cardiac or drug-related serious adverse events.\u201d It lists the percentages of patients in each of the treatment groups who had certain adverse effects, and notes that lipid levels were comparable in the two groups and androgenic measurements showed no significant differences during the study period. However, the news release fails to acknowledge long-term safety concerns, including the FDA\u2019s call last year for manufacturers to conduct a controlled clinical trial to clarify how testosterone might affect cardiac health. The abstract presented at the medical conference (the only available information about the study) states that the total numbers of adverse events was almost the same in both groups (67% in oral group compared with 65% in the topical group) without specifying the statistical significance of that result or the types of adverse effect in these groups. \u00a0The adverse events given only add up to about 10% in both groups.", "answer": 0}, {"article": "Followers of the popular regime eat during an eight-hour window, in this case between 10 a.m. and 6 p.m. And for the 16 hours in between, they consume only calorie-free drinks, such as water.\nCommenting broadly on fast-style diets, James Catterson of the Institute of Healthy Ageing at University College London, who was not involved in the study, previously told Newsweek the jury is still out on fasting diets.\nThe authors noted that the results mirror those from previous studies of other forms of intermittent fasting, including alternate day fasting, where an individual eats normally every other day.\nKrista Varady, one of the study's authors and associate professor of kinesiology and nutrition at the University of Illinois at Chicago's School of Applied Health Sciences, said in a statement that the take-home message from the study is that cutting out certain foods or counting calories aren\u2019t the only effective methods for losing weight.\nThe study's authors acknowledged that their preliminary data offers \"promise for the use of time-restricted feeding as a weight loss technique in obese adults, but longer-term, large-scale randomized controlled trials [are needed].\"\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Fasting for brief periods is pretty safe, although the story could have mentioned risks of dehydration, sleep problems, or headaches that might come from getting too hungry.", "answer": 1}, {"article": "Mammography with ultrasound spotted 78 percent.\nIn today's study of about 2,809 women with dense tissue and other risk factors, mammography alone found only half of the cancers.\nAnd it's an important story, because about half of women under the age of 50 are found to have dense breast tissue when they get their mammograms.\nFortunately, her doctor had an extra tool to screen her for breast cancer - an ultrasound.\nA mammogram had missed her cancer, CBS News medical correspondent Dr. Jon LaPook reports.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story mentioned the potential harms of treatment, which may be an increase in false-positives,\u00a0unnecessary biopsy, and anxiety.\u00a0 False positives may decrease with additional screening, such as an MRI, or when ultrasound is done annually.\u00a0 The high rate of false positives with mammography plus ultrasound meant that only about 1 in 10 women with cancer suspected on combined screening turned out to have cancer when biopsy was done,\u00a0whereas about 1 in 5 women with abnormal mammograms alone actually had cancer. ", "answer": 1}, {"article": "\"After screening a natural compound library, we developed an unbiased look at combinations of nutrients that have a better effect on prostate cancer than existing drugs,\" says corresponding author Stefano Tiziani, assistant professor in the Department of Nutritional Sciences and Dell Pediatric Research Institute at UT Austin.\nThis is a neat solution: blocking the uptake of a nutrient needed by prostate cancer cells with nutrients that are commonly in the human diet.\nNew research from The University of Texas at Austin identifies several natural compounds found in food, including turmeric, apple peels and red grapes, as key ingredients that could thwart the growth of prostate cancer, the most common cancer afflicting U.S. men.\nThese compounds minimize one of the risk factors for cancer, inflammation within the body.\nThe researchers first tested 142 natural compounds on mouse and human cell lines to see which inhibited prostate cancer cell growth when administered alone or in combination with another nutrient.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Plant chemicals are generally considered safe, but there\u2019s potential for toxicity if they\u2019re consumed in combination with certain drugs or at high concentrations. There\u2019s added risk for consumers who buy these substances in the form of dietary supplements, which are not tightly regulated by the FDA.", "answer": 0}, {"article": "\u201cThat\u2019s a simple enough statement, and people are not put off by that,\u201d she said.\n\u201cWe are now trying to see if people can learn, perform and have continuing confidence without the physician reinforcement,\u201d said Robinson.\nEach person in the study was trained on how to find melanoma and attended booster sessions every four months.\nFor now, she said people can go to the American Academy of Dermatology's website to learn the steps - known as the ABCDEs - of finding melanoma (bit.ly/2h9zl0Y).\nThe new results show people can ask friends or relatives to help examine their bodies for suspicious moles, said Robinson.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Having a partner check for melanomas doesn\u2019t have immediate harms, so we\u2019ll rate this N/A. It could be harmful if a person relies too heavily on a friend\u2019s assessment versus a physician\u2019s though.", "answer": 2}, {"article": "Women aged 70 to 75 had the greatest risk reduction, reducing the risk of dying from breast cancer by 84 percent.\nThe study, however, has some limitations, Bernik noted.\nThe routine screening also lowered the chances of being diagnosed with an advanced cancer, she said.\nThe greater risk reduction in women aged 70 to 75, Otto said, is probably a result of the long-term good effects of screening participation in the earlier target age group, 50 to 69, before the upper age limit for screening was extended in the Netherlands from 69 to 75.\nNearly 36 percent of these women had never had a mammogram.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The article refers briefly to \u201covertreatment\u201d but fails to explain this or other potential harms.", "answer": 0}, {"article": "Autistic children are prone to seizures.\nLupron therapy grew from the mercury camp.\nLupron critics said autism parents may not understand the dangers.\nGeier could not be reached for comment despite several attempts by phone.\nThe drug is not approved for children \u2013 except a rare few with premature puberty \u2013 because it can impair bone development crucial to growth, said Dr. Gary Berkovitz, chief of pediatric endocrinology at the University of Miami medical school.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story did a good job dedicating quite a bit of discussion to potential harms from this approach \u2013 both known and unknown. ", "answer": 1}, {"article": "God watches out for fools and little children.\nThose who got the therapy also had significantly more improvement in other measures of symptoms, according to the study that will appear today in the Journal of the American Medical Association.\n\"That's huge,\" said lead author Fran Weaver, a researcher with the Hines VA Hospital in Hines, Ill.\n\nShe said the best drugs provide only one to two hours of added improvement, or \"on time.\"\nNausieda said much of the benefit found in the study could be due to a placebo effect.\nBeyond that, doctors need to do a better job of optimizing drug therapy, he said, noting that there are thousands of potential combinations of drugs that can be used to control symptoms.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story mentions the \"much greater risk of serious adverse side effects\" in the same sentence that delivers the positive results. Placing the \"bad news\" of side effects right alongside the \"good news\" of improvements is a best practice for which this reporter should be commended.\nLater in the story the reporter lists these side effects and provides data on the number, severity and duration of the side effects. The story also mentions the death that resulted from the surgery.\u00a0\nYet the story fails to mention that the study found consistent, if small, loss of cognitive function in the stimulation group. It also fails to mention that the long-term effect of the sugery is unknown, and that this study, lasting just six months, cannot help answer that question.\u00a0 ", "answer": 1}, {"article": "\u201cFar too many cancers are picked up too late, when it is no longer possible to operate and the chances of survival are slim,\u201d he said.\nThe test was most accurate for diagnosing pancreatic, ovarian, liver and gallbladder cancers, correctly finding the diseases in at least four out of five patients.\nResearchers said their results showed promise in the approach of blood screenings for cancer, but noted further \u201cclinical development\u201d was needed.\nProf Nicholas Turner from the Institute of Cancer Research in London described the findings as really exciting and as a possible universal screening tool.\nA blood test for 10 different types of cancers could one day help doctors screen for the disease before patients show symptoms, researchers at the world\u2019s largest gathering of oncologists have said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story includes no mention of what many experts consider to be the most important considerations when it comes balancing the harms vs. benefits of liquid biopsies. These include:", "answer": 0}, {"article": "The procedure, called a prostatic urethral lift, does not improve flow as much as surgery, in which a physician cuts away some of the inside of the prostate to allow better flow. But the lift procedure and recovery are much quicker, with no hospital stay and fewer complications. And patients who get the sutures can always come back for surgery later.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The minimally invasive surgery seems safer than other kinds of surgery, but without any specific details on the potential for harms, we can\u2019t be sure. We are told that most patients experienced more frequent urination after the procedure, but that the improvements\u00a0may take four weeks or so to be seen.", "answer": 0}, {"article": "\u201cFor young people they don\u2019t want to commit themselves to a treatment which they might need to take for the next five to ten years,\u201d he said.\nSeventy-six of the 81 study participants, or 94 percent, completed the trial, Amminger noted, which underscores the safety and tolerability of fish oil.\nThe effect of fish oil capsules, Amminger noted, was similar to that seen in two trials of antipsychotic drugs in at-risk individuals.\n\u201cAt the moment there\u2019s no state-of-the-art guideline (on) how to treat those people.\u201d\n\nPrescribing antipsychotic medications may be helpful, Amminger added, but these medications have serious side effects, and can also be stigmatizing.\nThere are a number of mechanisms through which omega-3s could protect the brain, Amminger said; they are a major component of brain cells.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "While fish oil supplements are generally recognized as safe, the story could have told readers about potential side effects which can be gastrointestinal and include blood clotting problems, particularly for people taking blood thinners.\u00a0 ", "answer": 1}, {"article": "Given in the abdomen, AMG145 reduced low-density lipoprotein (LDL) cholesterol levels among a group of healthy volunteers.\nFormer AHA President Dr. Ralph Sacco said that it is too early to make any predictions about what role, if any, this therapy will have in lowering cholesterol levels, but it could one day fill an important void.\nThe new drug did hit its target, PCSK9, and decreased levels of LDL cholesterol by up to 64 percent.\nMONDAY, Nov. 14, 2011 (HealthDay News) -- Preliminary research suggests that a single injection of a man-made protein might lower levels of \"bad\" cholesterol.\nNow, researchers are testing the new shot in people who have high cholesterol.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story says that researchers reported\u00a0no \u201cserious\u201d side effects with the drug. OK, but\u00a0\u00a0we wish the story had mentioned that this study was really much too small\u00a0to even estimate adverse effects. In the past, other monoclonal antibodies\u00a0have produced rare but serious adverse effects- something that could have provided meaningful context for readers.", "answer": 0}, {"article": "\"They have a lot of promise and are potentially very important,\" said Katherine Hamilton, a headache specialist at Penn Medicine. The drugs, which are injected under the skin, offer hope for patients who have not responded to other treatments, but Hamilton said that what is \"potentially even more clinically relevant is they have a lower side-effect profile\" than other medications commonly used for migraine. She added, though, that it remains to be seen how patients who take them for long periods will fare. As new drugs, their long-term impact is not yet known.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story addressed the major concern with these medications: that it \u201cremains to be seen how patients who take them for long periods will fare. As new drugs, their long-term impact is not yet known.\u201d\nThe story story also reported the new drugs have \u201ca lower side-effect profile\u201d than other medications commonly used for migraine, and mild constipation was the most serious side effect of the drugs in the trials.\nThe story could have mentioned other adverse events. For example, with Emgality, hypersensitivity reactions such as rashes were reported in clinical studies.", "answer": 1}, {"article": "The World Health Organization estimates that more than 300 million people suffer from clinical depression world-wide. But cost, time, stigma, distance to travel, language barriers and other factors prevent many from seeking help.\n\nNow, a growing group of health-care providers are betting that technology\u2014from web-based courses to mobile apps that send prompts via text\u2014can help bridge that gap.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Risks are not broached here. This is an issue for a topic such as this, as one could imagine readers expressing concern about the efficacy of a non-human \u201ctherapist.\u201d The story actually acknowledges that concern in its second paragraph (\u201cIt [the use of technology] might seem surprising, since therapy, more than many other kinds of medicine, is so focused on the relationship between patient and therapist.\u201d But it never digs into the possible debits of wrestling with moderate depression online. We also think the story should have discussed the risk patients being victimized in an open source or relatively open chat room or other online group setting. One important element of psychiatry is privacy and patient confidentiality.", "answer": 0}, {"article": "Rheumatoid arthritis, which is felt throughout the whole body, is caused when a person's immune system attacks his or her own tissues.\nThe findings are published in the Nov. 28 online edition of Arthritis & Rheumatism.\nThe studies included arthritis patients aged 18 or older who had hip or knee replacements.\nThe study team found no differences between the two groups of arthritis patients in rates of follow-up surgery, or 90-day blood clot or death risk.\n\"Joint arthroplasty is successful in relieving the pain and disability caused by hip or knee arthritis,\" study author Dr. Bheeshma Ravi, from the University of Toronto and Women's College Research Institute, said in a journal news release.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Potential harms of joint replacement are the focus of the story, but there is no attempt to put them in perspective for readers.\nThe story does not tell readers how high or low the rates of complications are. It says people with rheumatoid arthritis had higher rates of dislocation and infection after a joint replacement than those with osteoarthritis, but no relative or absolute risk statistics are reported. The story pulls a quote from a news release saying \u201ccomplication rates are low,\u201d but \u201clow\u201d is not defined.", "answer": 0}, {"article": "Newswise \u2014 Bethesda, Md.\nIn some studies, the research team found that statins reduced inflammatory molecules that are typically elevated with liver disease and improved inflammation in the endothelium (cells that line the blood vessels).\nBut in a new review of more than 50 studies, researchers cite reductions in liver inflammation and improvements in other related factors as reasons why statins make good candidates for treating chronic liver disease.\nThe article is published ahead of print in the American Journal of Physiology\u2014Gastrointestinal and Liver Physiology.\nThe researchers acknowledge that statin drugs can contribute to liver damage in some people, but for people with advanced liver disease, \u201c[s]tatins are cost-effective, generally well-tolerated by patients and the benefits of statin treatment in most patients outweigh their potential hepatotoxic risk.\u201d\n\nRead the full article, \u201cRationale for the use of statins in liver disease\u201d published ahead of print in the American Journal of Physiology\u2014Gastrointestinal and Liver Physiology.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The researchers acknowledge that statin drugs can contribute to liver damage in some people, but the statement that \u201cstatins are cost-effective, generally well-tolerated by patients and the benefits of statin treatment in most patients outweigh their potential hepatotoxic risk,\u201d doesn\u2019t seem to adequately address the potential harms.\nPeople who are prescribed statins must undergo liver function tests since this class of drugs can cause rare but serious liver dysfunction. Deciding to give someone with advanced liver disease a statin as a means to help the patient\u2019s liver is unproven and has the potential for real harm.\nWe aren\u2019t provided any context on how significant the damage can be to those with advanced liver disease, or even in otherwise healthy people.", "answer": 0}, {"article": "Lipton directs the Montefiore Headache Center at the Albert Einstein College of Medicine in the Bronx.\nDrugs commonly used in the treatment of severe headaches are generally not considered effective in the aura phase of migraine attacks, and many patients want to treat their migraines without using drugs, neurologist and headache specialist Richard B. Lipton, MD, tells WebMD.\nCompared to patients who got sham treatments, more patients treated with the experimental device, known as single-pulse transcranial magnetic stimulation (sTMS), were pain-free two hours later.\nMarch 3, 2010 -- A handheld device that magnetically zaps pain may be a promising new treatment for patients with a common type of migraine.\n\"Some people don't tolerate the drug treatments very well and others just want to avoid them.\"\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "According to the study, 9 out of 99 (9%) of patients in the sham group reported at least one adverse event compared to 14 out of 102 (14%) in the sTMS group. Even though the authors suggest the adverse events were similar between the groups, the story should have reported this.\u00a0 Furthermore, we have no long-term information about problems associated with magnetic pulses in the brain, nor do we know about long-term effects on the primary endpoint, namely headache. Could they worsen over time? ", "answer": 0}, {"article": "The study comes a month after Gov.\nThey say the test's value is limited because it doesn't identify which plaque are stable and which could rupture and cause a heart attack.\nDr. William Zoghbi, director of Methodist Hospital's Cardiovascular Imaging Institute, said the cancer risk numbers reported in the study are actually fairly low compared to other tests that take X-rays of the chest area, such as a regular CAT scan or coronary angiography.\nThe Texas law will require insurance companies pay $200 of the bill for patients to get the test every five years.\nThe American Heart Association did not endorse the legislation, which Khera estimates could result in millions of Texans being screened.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "\n\n\n\n \nThe potential cancer risk caused by CT screening for signs of heart disease is the point of this story. Also, by highlighting uncertainty about the benefits of the screening and recapping debate over the Texas law mandating coverage of the scans, the story emphasizes the importance of considering potential harms when setting public policy on screening tests. A longer story could have considered other potential harms, including the side effects of treatments prescribed based on screening tests.", "answer": 1}, {"article": "Of those 40 women, 26 had mutations carrying low to moderate risk of breast or ovarian cancer, eight had mutations associated with Lynch syndrome, which increases colon and ovarian cancer risk, and three had high-risk breast cancer genes.\nThough these results indicate that additional genetic screening is clinically useful, some genetic test results will be uncertain, and it can be psychologically difficult for patients to deal with this uncertainty, Ellisen said.\nAnd for many, family testing would be recommended for first-degree relatives, according to the report in JAMA Oncology.\nEven among all appropriate candidates who are sent for genetic testing, only nine percent will test positive for the BRCA mutations, so an additional four percent who have non-BRCA mutations is a significant number, Ellisen said.\n\u201cThere\u2019s a lot of controversy even among experts,\u201d said the senior author of the new study, Dr. Leif W. Ellisen of Massachusetts General Hospital Cancer Center in Boston.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Potential harms, including having uncertain results leading to psychological difficulties, were mentioned in a quote from the lead author, who also discussed the complexity of interpreting the results. The article also quoted him as saying that misinterpretation could potentially lead to \u201ca drastic, unnecessary surgical procedure\u201d.", "answer": 1}, {"article": "After adjusting for non-modifiable stroke risk factors (such as age and family history), researchers found stroke risk among women who breastfed their babies was on average:\n\u2022 19 percent lower in women who had breastfed for up to six months.\nThe Association has strict policies to prevent these relationships from influencing the science content.\n\u2022 Available multimedia including photos and an audio interview are on the right column of the release link - https:/\n\u2022 Story on previous JAHA study (June 21, 2018): Breastfeeding may reduce a mother's heart attack and stroke risk\n\u2022 For updates and new science from JAHA, follow @JAHA_AHA\n\nStatements and conclusions of study authors published in American Heart Association scientific journals are solely those of the study authors and do not necessarily reflect the association's policy or position.\nHowever, because the Women's Health Initiative is large, researchers were able to adjust for many characteristics, and the effects of breastfeeding remained strong, Jacobson said.\nThe WHI was supported by the National Health, Lung, and Blood Institute.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Breastfeeding may be \u201cnatural,\u201d but it\u2019s not effortless. Breastfeeding can be time-consuming and exhausting, and carries risks of dehydration and breast pain. That said, these are not necessarily medical issues that rise to the level of discussion in a news release about an observational study like this one. As such, we\u2019ll rate this criterion as not applicable.", "answer": 2}, {"article": "You've probably heard about it \u2014 maybe you even remember seeing it once \u2014 but you're not really sure what it is or even where to find it.\n\nThe female condom (FC2), or internal condom, is a non-hormonal barrier method of birth control. But instead of going on a penis, it goes in a vagina, which is why it's also sometimes referred to as an internal condom. For more information, BuzzFeed Health spoke with two experts who could demystify this lesser-known contraceptive:\n\n* Dr. Harry Fisch, clinical professor of urology and reproductive medicine at Weill Cornell Medical College, and chief corporate officer of Veru Healthcare, which distributes FC2\n\n* Dr. Lauren Streicher, associate clinical professor of obstetrics and gynecology at Northwestern University\u2019s Feinberg School of Medicine", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There is a good discussion of the drawbacks of condom use, for both male and female condoms.", "answer": 1}, {"article": "Kids with August birthdays are more likely to get an ADHD diagnosis.\nThe participants in the small study ranged in age from 20 to 70 and had suffered from back pain for an average of 7.3 years.\nLed by Daniel C. Cherkin of Group Health Research Institute in Seattle, the experiment involved randomly assigning 342 adults with the condition to meditate, talk with a psychologist or continue with their normal techniques for addressing the pain, such as medication.\nThe study looks at adults with chronic low back pain, one of the leading cause of disabilities in the United States and one reason why more and more people are addicted to painkillers.\nThe study did caution that 30 of the 103, or about one-third, of the participants in the meditation group reported an \"adverse event,\" most often an increase in pain due to yoga.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story notes: \u201cThe study did caution that 30 of the 103, or about one-third, of the participants in the meditation group reported an \u2018adverse event,\u2019 most often an increase in pain due to yoga.\u201d It\u2019s good to see that included. Since the story is effectively comparing MBSR to CBT and conventional treatment, it would also have been worth noting \u201cadverse events\u201d for those groups in the study. According to the study, 10 percent of the CBT group also experienced \u201cadverse events,\u201d and no adverse events were mentioned for the control group.\nDefining \u201cadverse events\u201d would also have been good, since it\u2019s not clear whether they mean momentary pain or a debilitating flare-up of long-term pain. According to the study, the pain\u2013for both MBSR and CBT groups\u2013was \u201cmostly temporary\u201d and no \u201cserious\u201d adverse events were reported. Those things are worth mentioning. (It\u2019s also worth finding out what \u201cmostly\u201d and \u201cserious\u201d mean.)", "answer": 1}]